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1. Clinical importance of identifying viable myocardium
Assessment of myocardial viability in patients with coronary artery disease (CAD) and
left ventricle (LV) dysfunction is of major importance for prognosis (1-3).Patients with this
condition are at high risk for cardiac death and usually have significant limitations in their
lifestyles. It is well known that LV dysfunction is not necessarily an irreversible process.
Dysfunctional but viable myocardium has the potential to recover after restoration of
myocardial blood flow by either coronary arterial bypass grafting (CABG) or percuta-
neous transluminal coronary angioplasty (PTCA), whereas scarred tissue will not recover
(4-7). Patients with CAD and severe dysfunction but viable LV have a poor prognosis
when treated with medical therapy alone (8). In selected patients with sufficient viable
myocardium, coronary revascularization appears to afford a long-term survival benefit
(9,10). Nuclear imaging techniques like positron emission tomography (PET) or single
positron emission computed tomography (SPECT) play a major role in the assessment of
myocardial viability (11-14). Further improvement for the detection of myocardial viability
will be expected, because of new technique development in the nuclear cardiology field,
like attenuation corrected SPECT, dual isotope simultaneous acquisition (DISA) SPECT
and gated FDG PET. Also the combination of multislice computed tomography scanners
with PET opens possibilities of adding coronary calcium scoring and noninvasive coro-
nary angiography to myocardial perfusion imaging and quantification.
In the next paragraphs we describe several conventional and new nuclear techniques, a
radiopharmaceutical overview and pathophysiogical backgrounds of myocardial viability.
2. Pathophysiology of myocardial contractile dysfunction
LV dysfunction may be caused by (1) (repetitive) stunning, (2) widespread hibernation or
by (3) infarcted necrotic myocardium. Myocardial stunning is a condition of prolonged,
postischemic dysfunction of viable tissue that can be salvaged by reperfusion (15). Stun-
ning may occur after acute coronary occlusion followed by thrombolysis, but also after a
period of unstable angina or exercise-induced ischemia. Repetitive stunning is a phe-
nomenon defined as repeated episodes of ischemia inducing reduction in contractility. It
appears that one of the mechanisms responsible for myocardial stunningischemia is an
alteration of contractile proteins resultingin decreased responsiveness of the contractile
machinery to Ca2+, so that the myocardium generates less force (16). In this sense,
myocardial stunning could be viewedas a disturbance of myofilament function.
Hibernation means chronically reduced myocardial perfusion at rest associated with
impairment in contractile function, which can be reversed after revascularization. The
reduction of contractile function associated with hibernation may be a protective
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strates, leading to a new situation of perfusion-contraction matching, which prevents
apoptosis and cell death (17,18). In hibernating myocardium, myocytes are in a stable
non-contractile state. Cell membrane and cellular metabolism remain intact and little or
no evidence of apoptosis is present (19,20). Elsasser et al. biopsied areas of hibernating
myocardium during coronary artery bypass graft (CABG) (21). They found an enlarged
extracellular space with cellular debris, macrophages, fibroblasts and collagen, associ-
ated with basement membrane thickening and increased collagen fibrils and fibroblasts.
There also appears to be an alternation of structural proteins, metabolism to a more fetal
form, disorganization of the cytoskeleton, loss of myofilaments, occurence of large fields
with glycogen, and sarcomeric instability (22). Unclear is if these findings are typical
related to hibernated myocardial tissue or also to other tissue conditions.
The time course of functional recoveryof hibernating myocardium may vary considerably,
and depends on several factors including the duration and severity of myocardial
ischemia, the time and completeness of myocardial revascularisation,and the extent of
ultrastructural alterations within the dysfunctional myocardium (23). There is increasing
evidence that cell death after myocardialischemia and reperfusion may begin as apopto-
sis rather than necrosis (24). The induction of apoptosis and necrosis is regulated by
manyof the same biochemical intermediates, including alterationsin high-energy phos-
phates, intracellular calcium accumulation,and reactive oxygen species. Apoptosis, first
descibed by Kerr and coworkers, is characterized by morphologic changes, including cell
shrinkage and formation of membrane-bound apoptotic bodies (25).In contrast, necrosis
is characterized by cell swelling, depletion of high energy stores,disruption of the cellular
membrane involving fluid and electrolyte alterations and fragmentation of DNA, due to
mechanisms such as ischemia and thrombosis (26).These findings suggest that necro-
sis into scar formation occurs continuously due to myocytes loss and that early revascu-
larization would enhance recovery of function.
Several imaging techniques are based on the detection of viable myocardium in order to
select those patients who will benefit from revascularization. These techniques will be
outlined in the next paragraphs
3. Methods for the detection of myocardial viability 
What is the gold standard for viability studies? The choice of gold standard or reference
technique for viability is still a long debate.There have been many end-points proposed
for viability studies, including preserved cellular metabolism (27), histological examina-
tion of biopsied tissue (28), preserved regional wall contraction by low-dose dobutamine
echography, gated SPECT or magnetic resonance imaging (MRI) (29-32), regional or
global functional recovery (33-36), symptom improvement (37,38) and improved survival
(39,40) (Table 1).From a pathophysiological point of view, biological signals as generated
from PET and SPECT or histological examination provide important insights into viability
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sue indicates preserved viability (41). High 99mTc-annexin V affinity to the cellular wall,
due to phosphatidyl-serine overexpression indicates apoptosis, associated with pro-
grammedcell death (42). Short duration of apoptosis can be reversible, whereas longer
existing apoptosis is mostly an irreversible process and results in depletion of sarcom-
eres and extensive interstitial fibrosis, indicating absent viable myocardium (43).
Regional dysfunctional contractility of the left ventricle, can be transiently reversed by
positive inotropic stimulation. During stimulation with dobutamine infusion (used in MRI,
gated SPECT or echography), systolic wall thickness will increase in viable, but not in
scarred myocardium, because only viable cells are able to response to the inotropic stim-
ulus. Assessment of regional or global functional recovery of the LV after restoration of
blood flow is also relevant because it is directly associated with the definition of stunned
or hibernating myocardium.From a clinical point of view, the improved survival and symp-
toms following revascularization are optimal endpoint of viability studies, because these
are considered as the main goals of revascularization procedures, but this requires a long
follow-up period. Probably, the global improvement of LV function and reduction in end-
systolic and end-diastolic volume (reverse remodeling) after revascularization is an
acceptable alternative, because this is easy to measure and is likely to be associated with
improved prognosis (44).PET is an attractive technique for the assessment of myocardial
viability.This will be outlined in the next paragraph.
3.1 PET
PET imaging differs from conventional radionuclide imaging because it uses radionu-
clides that decay with positron emission. A positron has the same mass as an electron
but has a positive charge. The positron travels a short distance, up to a few millimeters,
interacts with an electron, and the two undergo a mutual annihilation, resulting in the pro-
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Table 1: Outline of different referent methods for the assessment of myocardial viability.
Assessment viability Technique
Cellular function Biopsy
99mTc-annexin V
FDG
11C-acetate
11C-palmitate
99mTc-sestamibi/99mTc-tetrofosmin
201Tl
Regional LV contractility Dobutamine stress MRI
Dobutamine stress echocardiography
Dobutamine stress gated  SPECT
Clinical Cardiac events
Symptoms
LV recovery post-revascularization
BINNENWERK SLART  25-05-2005  13:06  Pagina 17duction of two 511-kev gamma photons, 180° apart from each other. PET imaging con-
sists of detection of these photons in coincidence in a ring detector system. Imaging by
PET leads to high acquisition efficiency, resulting in high-quality images.
The clinical utility of PET imaging to identify viable myocardial tissue was first described
by Tillisch et al.in the middle eighties (45).The accuracy of FDG (with or without an addi-
tional perfusion tracer) imaging for predicting improvement in LV function after revascu-
larization, as reported in several previous studies, is high, with a negative predicting
value ranging from 76% to 90% and a positive predicting value ranging from 82% to
100% (46-51).Therefore, PET is recognized as an accurate technique for the quantifica-
tion of metabolism and perfusion of the myocardium, resulting in high diagnostic accu-
racy for the detection of myocardial viability (52,53).
3.1.1 Metabolic imaging: FDG
Free fatty acids, glucose, and lactate are the major energy sources of the heart (54-56).
Fatty acids play a major role in the metabolism of the non-ischemic heart, whereas glu-
cose becomes the major substrate for the myocardium during ischemic conditions (57-
59).FDG closely resembles glucose and is therefore a suitable tracer to visualize glucose
metabolism.
A prerequisite for FDG imaging of the heart is high myocardial uptake. For most studies
using FDG, glucose loading either by oral glucose administration or by insulin clamp is
essential.Acipimox, a nicotinic acid derivate, may be an alternative to clamping.Acipimox
inhibits peripheral lipolysis and therefore reduces plasma free-fatty acid levels, and, indi-
rectly stimulates cardiac FDG uptake in this way (60). Previous data have shown that
good image quality can be obtained using acipimox (comparable with clamping and
superior to oral glucose load) (61).
The clinical applicability of FDG is based on the effective intracellular trapping after phos-
phorylation of FDG into FDG-6-phosphate. In contrast to glucose-6-phosphate, FDG-6-
phosphate is not a substrate for further metabolism.Therefore, FDG enables detection of
metabolic changes at the cellular level during ischemia. The preserved or increased glu-
cose utilization, and subsequent FDG uptake in hypoperfused and dysfunctional myo-
cardium (flow-metabolism mismatch) is regarded as a metabolic marker of cell survival and
viability, whereas concordant reduction in both blood flow and FDG uptake (matched
defect) is indicative of scar (Figure 1).Thus, FDG PET provides a biological signal on cel-
lular viability, and is considered to be one of the most accurate non-invasive techniques to
identify viable tissue, as supported by a number of studies using PET (62-68).
Image are usually interpreted semi-quantitatively, based on the relative regional uptake
of FDG (69).Absolute quantification of regional myocardial glucose utilization by dynamic
imaging and compartment modeling does not appear to enhance the diagnostic accuracy
of FDG PET to detect viable myocardium, probably because of high variability in glucose
utilization rates in individual patients, even in comparison with a normal database (70).In
general, the relative FDG uptake is considered clinically sufficient for this purpose. PET
studies can be displayed in polarmaps or short and long axes of the left ventricle.
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Under aerobic conditions, the heart uses predominantly fatty acids, but after carbohy-
drate loading, the inhibitory effect of insulin on release of fatty acids from adipocytes
diminishes circulating fatty acids and up-regulates glucose use by the heart. During
myocardial ischemia, fatty acid metabolism is diminished and glucose uptake is
enhanced (71). Normal (relative to flow) or enhanced glucose metabolism serves as the
metabolic signature of ischemic myocardium. Stunned or hibernating myocardium also
demonstrate preserved oxygen use relative to perfusion and function (72).
Because the diminished use of fatty acids is a key metabolic feature of myocardial
ischemia, early interest with PET focused on the use of fatty acids such as 11C-palmitate
(Table 2) (73). However, because of its relatively complicated synthesis, the need for an
on-site cyclotron, and the complex tracer kinetics, this tracer is not currently used for
identification of viable myocardium.
11C-acetate is an another PET tracer for studying myocardial oxidative metabolism and a
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Figure 1: PET polarmaps display. The first polarmap illustrates rest 13N-ammonia perfusion of the
left ventricle. In the mid-inferior wall a relative small defect is visible and becomes lager on the sec-
ond, dypiridamole (DST) stress 13N-ammonia perfusion polarmap, indicating insufficient flow
reserve. 18F-fluorodeoxyglucose (FDG) in the inferior wall is largely preserved on the lowermost
polarmap, indicating ischemia and viability. A minor FDG defect is persisting in the mid-inferior
region, indicating a small infarcted area.
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myocardial tissue. However, this tracer also requires a cyclotron in addition to the assess-
ment of wash-out kinetics, thereby making this tracer somewhat less useful for most centers.
3.1.3 Flow Tracers
The ideal tracer for the assessment of myocardial perfusion would possess the following
properties: distribution in the myocardium in linear proportion to blood flow (without
plateau effect at high flow rates) over the full range of values experienced in health and
disease, efficient myocardial extraction from the blood on the first passage through the
myocardium, stable retention within the myocardium during data acquisition, rapid elimi-
nation allowing rapid repeat studies, good availability, competitive pricing and good imag-
ing characteristics (short half-live, high photon flux, adequate energy, low radiation
burden to the patient). No current tracer possesses all of these properties and comprim-
ises have to be made.
Absolute quantification of myocardial blood flow is feasible using PET and tracer kinetic
models (74,75). In clinical practice, FDG PET is often combined with a flow tracer to
assess myocardial perfusion. Although FDG PET imaging without a flow tracer has suffi-
cient sensitivity and specificity for detecting viable tissue (76), a combination of flow and
metabolism provides more comprehensive information on viability and herein the differ-
entiation between hibernation and stunning (77-79). Stunned myocardium exhibits
slightly reduced or normal perfusion, whereas in hibernating myocardium perfusion is
20 | Chapter 1
Table 2: Single-photon emitting and positron emitting (*) tracers
for cardiac imaging.
Tracer Assessment Uptake mechanism
201Tl Perfusion/viability Na+/K+-ATPase celmembrane pump
99mTc-sestamibi Perfusion (viability) Mitochondrial K+-ATP channel
99mTc-tetrofosmin Perfusion (viability) Mitochondrial K+-ATP channel
15O-water* Perfusion Diffuses freely across cell membrane
13N-ammonia* Perfusion Diffuses freely across cell membrane.The
ammonium form is intracellularly trapped in
glutamine via the enzyme glutamine
synthase
82Rb* Perfusion/viability Na+/K+-ATPase celmembrane pump
18FDG* Glucose consumption Intracellular trapping after phosphorylation of
FDG to FDG-6-phosphate
11C-acetate* Oxidative metabolism/ Converted intracellular to acetyl-CoA and 
perfusion further metabolized in the Krebs cycle of the
mitochondrium to 11CO2
11C-palmitate* Free fatty acid metabolism FFA intracellularly converted to FFA-CoA,
cleavage of carbon fragments of FFA-CoA
during ß-oxidation and further metabolized in
the Krebs cycle of the mitochondrium to
11CO2
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tion, whereas hibernating myocardium may take a longer time to (fully) recover in func-
tion after revascularization (80).
3.1.3.1 13N-ammonia
In the bloodstream, 13N-ammonia consists of neutral ammonia (NH3) in equilibrium with
its charged ammonium (NH4) ion. The neutral NH3 molecule readily diffuses across
plasma and cell membranes. Inside the cell, it re-equilibrates with its ammonium form,
which is trapped in glutamine via the enzyme glutamine synthase (81,82). Despite back
diffusion, the first-pass trapping of 13N ammonia at rest is high, although decreasing with
higher blood flow. 13N-ammonia allows quantification of perfusion both at rest and after
application of vasodilatating agents to assess myocardial perfusion reserve, such as
dipyridamole or adenosine (83,84). With the use of a 2- or 3-compartmental model, sat-
isfactory reproducibility and accuracy can be obtained (85,86).
The suitability of 13N-ammonia as a myocardial flow tracer is established in numerous
studies (87-92). Kitsiou et al. demonstrated that 13N-ammonia retention rather than
absolute myocardial blood flow was a good marker of cellular viability (93). The use of
13N-ammonia is restricted to sites with a cyclotron.
3.1.3.2 15O-Water
Unlike 13N-ammonia, 15O-water diffuses freely across plasma membranes and makes this
tracer a favorite for quantification of myocardial blood flow. In theory, 15O-water is consid-
ered to be an ideal tracer for measurement of myocardial blood flow without plateau effect
at high flow rates (94,95). However, poor contrast between the myocardium and cardiac
blood pool, due to the properties of 15O-water (necessity for subtraction of blood pool
activity), and a very short physical half-life time may cause heterogeneity of flow meas-
urements, as demonstrated by Nitzsche et al (96).
A unique feature of 15O-water PET imaging is that the proportion of the total tissue that is
capable of rapidly exchanging water (water perfusable tissue index, PTI) can be used as
a marker of tissue viability (97,98). Although more work needs to be done before its clin-
ical utility is determined, this technique appears to provide information on tissue viability.
The use of 15O-water is restricted to sites with a cyclotron.
3.1.3.3 Rubidium-82 (82Rb)
82Rb is produced in a commercially available generator by decay from strontium-82
attached to an elution column. 82Rb decays by positron emission with a short half-life of
75 s.Therefore it facilitates the rapid completion of a series of resting and stress myocar-
dial perfusion studies. 82Rb, like 201Thallium (201Tl), is a cation and an analog of potassium.
It is extracted from plasma by myocardial cells via the Na+/K+-ATPase pump. Myocardial
extraction of 82Rb is similar to (201Tl) and slightly less than 13N-ammonia, decreasing dur-
ing hyperemia (99). 82Rb extraction can be altered by severe acidosis, hypoxia, and
ischemia (100). Thus, uptake of 82Rb is a function of both blood flow and of myocardial
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advantages of 82Rb include the high energy of its positron (3.3 MeV) and a rather low
extraction fraction (65%). However, PET imaging with 82Rb has proven to be highly accu-
rate in the detectionand functional assessment of coronary artery stenoses and infarct
size imaging (101,102).
3.2 Gated FDG PET
Compared to echography, MRI, CT, gated SPECT, gated blood pool SPECT, PET sys-
tems also offer the capability to perform an electrocardiograph (ECG)-gated acquisition
andto generate systolic and diastolic images of the heart (103,104).In combination with
myocardial perfusion, gated FDG PET permits a complete LV evaluation, using a single
modality for evaluation of major myocardial parameters, including glucose metabolism,
flow reserve and LV function. Obtaining functional information of the LV requires no extra
scan or tracer injection. Assessment of cardiac function by gated FDG PET without the
need for other clinical modalities will significantly reduce the time and costs of pre-revas-
cularization work-up.While MRI is considered the reference method for the assessment
of LV function, most studies compared gated FDG PET with other techniques like gated
SPECT, left ventriculography, and 2D echocardiography (105-110).
Other PET techniques including gated blood pool PET after red blood-cell labelling with
C15O (111,112) or gated 13N-ammonia (113) also provide information about LV volumes
and function, but give no information about metabolism. Furthermore, gated FDG PET
studies for the prediction of functional recovery after revascularization are currently not
available, using FDG uptake and wall thickening as viability parameters.
3.3 SPECT
Myocardial perfusion scintigraphy (MPS) SPECT is an established imaging technique
that is already an integral part of the managing of coronay artery disease and is included
in a number of professional guidelines. Many studies has assessed the diagnostic accu-
racy of MPS for the detection of coronary artery disease (114-116). In the largest study
of 2,560 patients randomized to each of the three tracers (99mTc-sestamibi, 99mTc-tetro-
fosmin and 201Tl) and using mainly adenosine stress (the ROBUST study, UK based),
overall sensitivity in the subset of patients undergoing angiography was 91% and speci-
ficity 87%, with no significant difference between the three tracers (117). For many
patients with coronary artery disease, the assessment of prognosis, or likelihood of future
cardiac events, is an essential step in choosing between medical management and
revascularization. The power of MPS for predicting future coronary events has been
demonstrated in large number of studies and in many of thousand of patients. It is per-
haps the area of nuclear cardiology where the evidence is most strong (118-120). The
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severity of induced ischemia (121) but other predictors are increased lung uptake of 201Tl
(122), stress-induced ventricular dilatation (123). MPS has incremental prognostic value
even after clinical assessment, exercise electrocardiography, and coronary angiography
(124). In contrast, a normal MPS indicates good clinical outcome with < 0.6% event rate
of major cardiac events yearly as reported in a multicenter registry of 4,728 patients
(125). Further, 99mTc-labeled myocardial perfusion tracers reflect not only flow, but also
myocardial viability (126).
PET imaging is an established technique to distinguish viable from scarred myocardium,
howvever its relative limited availability, dependency of cyclotrons and high costs has lim-
ited the widespread use in clinical practice. PET has several technical advantages over
gamma-technique SPECT such as higher counting sensitivity, higher spatial resolution,
routine use of attenuation correction and absolute quantification of myocardial perfusion
flow and metabolism. However, most of these technical advantages of PET over SPECT
for accurate assessment of myocardial viability are not strongly required, although atten-
uation correction systems might be beneficial (127).To meet the advantages of attenua-
tion correction, some SPECT systems are equipped with attenuation correction systems
at present.Substantial efforts have been made for further improvement of the less expen-
sive and much more widely available SPECT technique for the assessment of viability.
Presently, several traditional and novel tracers for the detection of ischemia and viability
are used with SPECT.
3.3.1 201Thallium
The active uptake of 201Tl by myocardial cells is dependent on myocardial blood flow and
active transport (128). 201Tl is a potassium analog that is actively transported into myo-
cytes by a Na+/K+-ATPase-dependent mechanism. Its uptake thus requires an intact,
functional cellmembrane.Therefore, myocardial 201Tl uptake represents both myocardial
perfusion and cellular viability. It has been shown that delayed imaging 3–4 hours after
stress injection of 201Tl frequently underestimates the presence of viable myocardium as
compared to metabolic imaging with FDG PET (129). Modified 201Tl protocols such as
reinjection technique (130,131) enhanced the detection of viable myocardium, although
viability in myocardium may still be underestimated by 201Tl as compared with FDG PET
(132). Kitsiou et al. showed that stress induced reversible defects are highly predictive of
functional recovery after revascularization (133). Therefore, the use of stress and redis-
tribution imaging protocol is preferred.Images are usually interpreted visually, but relative
quantitation of regional tracer uptake within the dysfunctional myocardium may provide
more objective and accurate results than visual assessment of myocardial viability (134).
3.3.2 99mTc-sestamibi and 99mTc-tetrofosmin
Technetium-99m labeled flow tracers such as 99mTc-sestamibi and 99mTc-tetrofosmin are
lipophilic and positive charged, and now widely available as alternatives to 201Tl. Com-
pared with 201Tl, these 99mTc-labeled agents emit higher energy photons yielding better
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dosage. At high flow rates the detection of CAD is underestimated by 99mTc-labeled flow
tracers (135,136). A more important characteristic of these tracers is that, unlike 201Tl,
they do not show significant redistribution over time, and there have been controversies
regarding the use of 99mTc-labeled agents as a viability tracer (137). However, experi-
mental studies demonstrated that myocardial retention of both 99mTc-sestamibi and 99mTc-
tetrofosmin requires cellular viability (138). Uptake and retention of 99mTc-sestamibi and
99mTc-tetrofosmin is dependent on cell membrane integrity and mitochondrial function
(139). Myocardial ischemia is interfering with mitochondrial K+-ATP channel activation
(140) thereby changing its mitochondrial membrane potential (141), and finally reducing
cellular 99mTc-sestamibi uptake (142). Further, regional 99mTc-sestamibi (143) or 99mTc-
tetrofosmin (144) activity is closely correlated with 201Tl, indicating viability.
Udelson et al.(145) described the utility of 99mTc-sestamibi for the prediction of functional
recovery after revascularization, which was comparable to that of 201Tl in severe CAD
patients. Similar results have been reported for 99mTc-tetrofosmin, a relative newer 99mTc-
labeled flow tracer, whereas  99mTc-tetrofosmin uptake also predicted functional recovery
as did rest injected 201Tl (146).
3.4.1 Methods to enhance the detection of viability: nitrates
Nitrates improve collateral blood flow to hypoperfused myocardial regions as demon-
strated in previous studies using 201Tl imaging (147). Bisi et al (148). proposed that
nitrates might have an role in improving the ability of 99mTc-sestamibi imaging to predict
myocardial viability.Several, more recent studies demontrated that the use of nitrates fur-
ther improves the diagnostic accuracy of viability tests with flow tracers (149,150). Scia-
gra et al. (151) found that nitrate induced changes in 99mTc-sestamibi activity are an
accurate marker of potentially reversible myocardium for regional (152) and global (153)
functional recovery. Furthermore, the prognostic value of nitrate enhanced 99mTc-ses-
tamibi imaging has been validated by the same authors (154).
3.4.2 Attenuation correction 
It is well known that attenuation artifacts may unfavorably affect the diagnostic accuracy
of myocardial perfusion SPECT imaging. The non-uniform attenuation of the emitted
radiation may produce severe artefacts which may result in fixed defects on SPECT
images that could easily be mistaken for myocardial infarction.Common causes of atten-
uation artefacts are associated with breast attenuation in women, and diaphragmatic
attenuation in men.
Attenuation correction using transmission scans may help in distinguishing attenuation
artefacts from myocardial infarction patterns, especially in the posterior, posterolateral
and posteroseptal wall, where misinterpretation is most common.Hendel et al.performed
the first prospective multicenter trial, using a dual-detector camera equipped with a
Gadolinium-153 line source (155). In their study the normalcy rate (n=88), was signifi-
cantly improved (86% vs 96%, respectively), and false positive perfusion images were
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based attenuation correction have become available now (156).Commercialized SPECT
attenuation correction systems measure the nonhomogeneous attenuation distribution
utilizing external collimated radionuclide sources (157) or X-ray CT with hibrid sytems
(158). Attenuation correction may considerably change the appearance of images that
readers have long been used to (Figure 2). In addition to the variability in methods of
attenuation correction, these systems usually also employ different acquisition and
reconstruction protocols, and may or may not also incorporate scatter correction algo-
rithms or depth-dependent resolution correction methods.
3.5 Gated SPECT
The widespread application of 99mTc-labeled myocardial perfusion tracers and data pro-
cessing capacityhave made ECG-gated SPECT imaging part of the clinical routine in
nuclear imaging laboratories (159). The 99mTc-labeled perfusion tracers, permit assess-
ment of regional myocardial wall motion and wall thickening throughout the cardiac cycle,
due to their high count rates and stable myocardial distribution with time.The automatic
quantification of LV volumes, ejection fraction (EF), regional myocardial wall motion and
thickening from gated SPECT is rapid and accurate, with minimal operator interaction,
and is therefore widely used (Figure 3). Gated SPECT is also valuable in its ability to
enhance artifact identification by differentiating scarred tissue from attenuation artifacts,
because these artifacts reveal normal wall motion and thickening. DePuey and Rozanski
demonstrated that false-positive perfusion studies could be reduced from 14% to 3% by
incorporating regional wall motion data in the interpretation of perfusion imaging (160).
The combination of gating and attuenation correction provide the highest diagnostic
accuracy and should be considered complementary (161). Gated SPECT imaging has
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  Figure 2: Improve-
ment generated by
attenuation correction
(AC). Lower row shows
myocard perfusion rest
vertical long axis slices
without correction,
showing a marked
inferior defect origi-
nally judged to be an
infarction. Upper row
shows corresponding
images after AC, now
correctly normal.
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suspected CAD (162).Travin et al. demonstrated in a group of 3207 patients that abnor-
mal gated SPECT wall motion score was associated with an annual event rate of 6.1%
compared with 1.6% for a normal score, and an abnormal left ventricular ejection fraction
was associated with an event rate of 7.4% compared with 1.8% for normal patients (163).
Dobutamine stress gated SPECT using 99mTc-labeled perfusion tracer provides informa-
tion on both perfusion and contractile reserve in a single study as recently documented
by Yoshinaga et al., who compared the accuracy of low-dose dobutamine stress gated
myocardial SPECT with the accuracy of dobutamine stress echocardiography in identify-
ing viable myocardium in patients with previous myocardial infarction (164). Because
SPECT is more objective and reproducible than echo-cardiography, gated SPECT with
pharmacological intervention may become an indispensable diagnostic tool for viability
testing.
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Figure 3: Polarmap display of gated SPECT. Perfusion of the end-diastolic and end-systolic phase
is automatical quantified (upper row polarmaps). Wall motion (mm) and wall thickening (%) is also
automatical quantified (middle row). The end-diastolic and end-systolic phase of the left ventricle
(LV) is displayed in the lower row, showing endocard and epicard contours. End-diastolic, end-sys-
tolic and LV ejection fraction is calculated automatically and displayed on the right side. The short
and long axes with the detection contours are displayed in the vertical row on the left side on the
overview.
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Substantial effort has been invested in the development of SPECT using extra-high 
energy collimators, which may permit larger scale clinical use of FDG imaging (165-
167). Several clinical studies have shown that FDG SPECT offers diagnostic information
similar to PET, and it compares favorably with other imaging modalities, including rest
redistribution (168), stress-reinjection 201Tl imaging (169), or low dose dobutamine echo-
cardiography (170). Despite the difference in resolution of both systems FDG SPECT
shows a good agreement (94%) with FDG PET (171). As with PET studies, metabolic
activity measured by FDG SPECT is generally interpreted in combination with a flow
tracer. For this purpose, a dual-isotope simultaneous acquisition (DISA) SPECT protocol
with FDG and 99mTc-perfusion tracer is attractive because it enables assessment of
myocardial glucose utilization and perfusion in a single study (Figure 4) (172-174). DISA
SPECT shortens the duration of procedure, with the advantage of an identical geometric
registration of the different isotope images. Direct comparison of the perfusion tracers
99mTc-sestamibi/FDG DISA SPECT and 13N-ammonia PET are scarce.Only Matsunari et
al. published a small study about the concordance and discordance of 99mTc-sesta-
mibi/FDG DISA SPECT and 13N-ammonia/FDG PET in 10 patients with CAD, by using
the difference between the perfusion tracer and FDG of both techniques (175). They
found a good overall concordance between the activity distribution of FDG and flow trac-
ers of both techniques. Different FDG-perfusion patterns can be observed in the left ven-
tricle with contractile dysfunction (Table 3).
ECG-gated FDG SPECT or DISA SPECT is additional technique to assess LV function
(176). Thereby DISA SPECT has the potential to assess myocardial glucose utilization,
perfusion, and LV function in a single study. Despite these potential advantages, DISA
SPECT imaging has not been compared directly with PET imaging for the prediction of
LV recovery in patients with LV dysfunction.
3.7 SPECT-CT and PET-CT
The introduction of combination of CT scans into SPECT and PET systems is a recent
development.In oncology combined SPECT and CT or PET and CT in a single combined
unit become the preferred approach for SPECT and PET approach for imaging. For car-
diological purposes CT could be used for attenuation correction, calcium score, func-
tional LV assessment and visualization of coronary arteries and accompanying stenoses.
On the other hand, CT attenuation correction is more susceptible to artifacts produced by
metallic implants or pacemakers, than pin source-produced attenuation maps. Other
potential beneficials of SPECT-CT and PET-CT systems in cardiac imaging are:the scout
CT scan can, in a few seconds to check the proper positioning of the patient.A very short
scanning time for the CT attenuation map may under-sample the position of the heart and
diaphragm, due to cardiac contraction, and respiratory movement.The transmission scan
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the average position of the heart during the emission scan at rest and again during
stress.
Another potential application of the single combined unit is the possibility of obtaining
coronary calcium scores at the same imaging session as the SPECT or PET scan, which
is feasible with an 8- or 16-slice multidetector CT scanner.The clinical value of coronary
calcium scoring is at this time still an open question in clinical practice and their interac-
tion and significance needs to be explored (177,178).
An intriguing possibility is the potential value of CT coronary angiography performed
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Table 3: N = normal;   = decreased;    = severely decreased;   = increased
contraction perfusion FDG uptake Recovery after revasularization
Normal myocardium N N N
Repetive stunning   NN  tot   +
Hibernation    N tot   +
Transmural scar          –
Non-transmural scar     –/+
Figure 4: Short-axis view of a dual isotope simultaneous acquisition (DISA) SPECT image.The first
row demostrates row is shows a large perfusion defect in the apex, mid-anterior, septal and inferior
wall after (dypiridamole) stress 99mTc-sestamibi. The simultaneous performed FDG study on the
second row shows adequate uptake in these regions, indicating ischemia or preserved viability.
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(MSCT) scans have been found to have sufficient temporal resolution to image, with
intravenous contrast, coronary arteries with a diameter or 1.5 mm or greater, with a initial
reported sensitivity for 50% or greater coronary lesions of 86% to 92%, a specificity of
93% to 99%, and accuracy of 93% compared with invasive coronary angiography (179).
Electron beam CT (EBCT) and MSCT show similarly high levels of accuracy for deter-
mining and ruling out significant coronary artery stenoses (180).MSCT is capable of pro-
viding good image quality in more coronary segments than EBCT because of its better
contrast to noise ratio and higher spatial resolution. Motion artefacts seen at heart rates
of > 75 beats/min and a higher radiation exposure are the main limitations of MSCT
(181).
There are limitations in visualizing lesions in the smallest distal vessels, and in the pres-
ence of heavy calcifications.The latter limitation can be overcome with the aid of the PET
or SPECT perfusion results.
It is conceivable that patients with known or suspected disease could be studied with
sequential stress-rest perfusion imaging and CT angiography and ventriculography,
allowing acquisitions of superimposed images of both coronary anatomy, perfusion, wall
motion, and viability.This complete set of spatially mapped information could add preci-
sion and ease to decision-making for interventions in multivessel disease intervention
planning, or in patients with physiologically abnormal perfusion but anatomically normal
coronary arteries.This proposition still needs to be evaluated in clinical studies, because
the experience of PET-CT or SPECT-CT is scarce at present.
Outline of the thesis
In the present thesis we evaluated the value of (a) attenuation corrected myocardial per-
fusion scintigraphy, (b) DISA SPECT and (c) gated FDG PET for the assessment of
myocardial viability and LV function in patients with coronary artery disease.
SECTION II evaluates the value of attenuation correction in myocardial perfusion and via-
bility detection.The first aim of this work was to determine, as described in chapter 2:(a)
the yield of attenuation correction with regard to sensitivity and specificity, and (b) to
determine the influence of 1 year ’s clinical experience of routinely applied attenuation
correction on the interpretation of myocardial perfusion scintigraphy are analyzed. In
chapter 3 the impact of attenuation correction on the assessment of viability with resting
99mTc-tetrofosmin SPECT is reported. Both non-corrected images and corrected images
were compared with the viable segments on FDG SPECT  imaging that served as the ref-
erence method.
SECTION III evaluates the value of DISA SPECT for the detection of myocardial viability.
In chapter 4, the first main goal of that study was to analyse the quality of the 99mTc-ses-
tamibi images of DISA SPECT.Therefore, 99mTc-sestamibi images of single and dual iso-
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investigate whether signs of myocardial viability could be detected with FDG SPECT in
irreversible perfusion defects present on previous rest-stress 99mTc-sestamibi.In chapter
5, a head-to-head comparison between 99mTc-sestamibi/FDG DISA SPECT and 13N-
ammonia/FDG PET of normal and dysfunctional LV segments was performed using both
visual and quantitative analysis.In chapter 6, the diagnostic performance between 99mTc-
sestamibi/FDG DISA SPECT and 13N-ammonia/FDG PET was compared for the predic-
tion of regional function, global LV function and LV remodelling in 47 patients with chronic
ischemic LV dysfunction undergoing revascularization. MRI was used to assess LV func-
tion before and after revascularization.
Section IV evaluates the value of gated FDG PET for the assessment of LV function and
viability. In chapter 7, the value of gated FDG PET for the prediction of LV recovery was
analyzed, by using MRI as an independent reference method for the assessment of LV
function before and after revascularization.In chapter 8, the accuracy of gated FDG PET
for the assessment of LV function, LV volumes and regional wall motion was evaluated in
38 patients with chronic coronary artery disease and depressed LVEF in comparison with
the reference method MRI. Chapter 9 contains the summary, including future perspec-
tives and conclusions. Chapter 10 contains the summary, including future perspectives
and conclusions in Dutch.
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Aim: To  determine the yield of attenuation correction in myocardial perfusion imaging
(MPI), before and after a 1-year experience period.
Methods: In 48 consecutive patients referred for MPI, both non-corrected (NC) and
attenuation corrected (AC) images were analyzed by 3 independent readers shortly after
implementation of AC. The same images were re-analyzed one year later, after having
obtained experience in AC on a routine basis in >500 patients with clinical feedback.
Results were compared with gold standards for ischemia and infarction based on coro-
nary angiography, follow-up, ultrasound and gated blood pool imaging.
Results: Sensitivity and specificity for detection of coronary artery disease were 95%
and 45% respectively for NC images, and 77% and 70% for AC images at first readings.
After one year of AC experience, NC sensitivity/specificity was 100%/61%, and AC
results were 89%/92%.
Conclusion: Attenuation correction improves the performance of MPI interpretation.
With attenuation correction, specificity is increased and sensitivity is similar as compared
with non-corrected images. However, attenuation correction requires experience and is
associated with a learning curve.
Keywords: myocardial perfusion imaging, 99mTc-sestamibi, attenuation correction, learn-
ing curve.
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Although single-photon emission computed tomography (SPECT) using tracers such as
99mTc-sestamibi, 99mTc-tetrofosmin or thallium-201 is an accurate, noninvasive diagnostic
method for the detection of coronary artery disease (CAD), attenuation artefacts reduce
the specificity of this technique (1,2).The non-uniform attenuation of the emitted radiation
may produce severe artefacts which may result in fixed defects on SPECT images that
could easily be mistaken for myocardial infarction. Common causes of attenuation arte-
facts are associated with breast attenuation in women, and diaphragmatic attenuation in
men (2-4). Attenuation correction using transmission scans may help in distinguishing
attenuation artefacts from myocardial infarction patterns, especially in the posterior, pos-
terolateral and posteroseptal wall, where misinterpretation is most common (5,6).
Recently, several methods for transmission scan based attenuation correction (AC) have
become available (4). Some authors have reported considerable improvements in the
accuracy, but others found no improvement or even decreasing accuracy (4, 6-12).Atten-
uation correction may considerably change the appearance of images that readers have
long been used to. For this reason centers that obtained attenuation correction, discon-
tinue using it after a short period. In addition to the variability in methods of attenuation
correction, these systems usually also employ different acquisition and reconstruction
protocols, and may or may not also incorporate scatter correction algorithms or depth-
dependent resolution correction methods.These factors contribute to confusion as to the
real clinical impact (13).
Apart from the variations in systems and methods, it is likely that a significant learning
effect exists in interpretation of AC images.The impact of this learning effect may even be
greater than the differences between various systems and methods. In this study we
report our experience with attenuation correction using a multiple-line array of gadolin-
ium-153 (153Gd) rods.The aims of this study were (a) to determine the yield of attenuation
correction with regard to sensitivity and specificity, and (b) to determine the influence of
1 year’s clinical experience of routinely applied attenuation correction on the interpreta-
tion of myocardial perfusion scintigraphy. For this purpose three independent readers
evaluated 48 studies shortly after implementation of the attenuation correction system
and blindly re-analyzed the same studies again after obtaining this experience.
Materials and methods
Forty-eight consecutive patients suspected of coronary artery disease or referred for risk
stratification analysis (35 male, 13 female, mean age 58 ± 13 (SD), range 27 - 87 years)
were included. These patients were referred between May and July 2000 for routine
myocardial perfusion SPECT imaging.Twenty-one patients of this group had a history of
myocardial infarction (Table 1).
Six-hundred MBq of 99mTc-sestamibi was injected at rest and the next day after dipyri-
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tion using a double headed gammacamera (Siemens E.Cam) equipped with low-energy
high-resolution collimators. The camera heads were in perpendicular position. Other
acquisition parameters were: 32 steps rotation, 20 sec per step, 128 x 128 matrix size,
rotation from the 45° right anterior oblique to the 135° left posterior oblique position with
the patient laying supine.The attenuation correction system consists of an array of 153Gd
external line sources incorporated in retractable ‘wings’on the camera, and is called ‘pro-
file attenuation correction’.These wings form a 180° degree arc opposite to the perpen-
dicular camera heads. A shutter opens and closes the external sources. In this study
simultaneous emission and transmission images were obtained, using a 20% window
over the 99mTc-photopeak and a 20% window over the 153Gd photopeak. No scatter cor-
rection was performed. Non-corrected (NC) emission scans were reconstructed after fil-
tered-back-projection using a Butterworth 0.30/6 filter. Attenuation corrected images
were reconstructed from the emission and transmission images using iterative recon-
struction (Wallace) methods on Siemens ICON computers (version 8.5). The manufac-
turer considers these methods standard and dedicated to this application. All data were
reorientated in order to produce short-axis (SA), horizontal long-axis (HLA) and vertical
long-axis (VLA) sections. Both an uncorrected printout and an attenuation corrected
printout was obtained.
NC and AC myocardial perfusion images of individual patients were analyzed together by
three independent nuclear medicine physicians, blinded for the clinical pretest likelihood
of coronary artery disease, final diagnosis or each other’s results. Differences in the
interpretation of a study as normal or abnormal or differences confined to individual seg-
ments were resolved by a fourth experienced reader in a blind manner.The NC and AC
perfusion images were scored into 3 categories (0 = normal, 1 = ischemia, 2 = infarction)
using a 9-segment polar map (basal and distal anterior, lateral, inferior and septal walls,
and one for the apex). Images were read according to the standard procedure in our
department, meaning that non-severe irreversible defects on NC images could be attrib-
uted to attenuation correction and scored as normal, based on the experience of the
reader. To correlate results with vessel territories, anterior, septal and apical segments
were assigned to the left anterior descending artery (LAD), lateral segments to the left
circumflex artery (RCX), and inferior segments to the right coronary artery (RCA).
The first reading took place shortly after the implementation of the AC system, and the
exact same reading and scoring system was applied by the same three readers one year
later.In the intervening period the readers had obtained experience in > 500 MPI patients
undergoing routinely evaluation for clinical purposes with and without AC, incorporating
feedback from clinicians. These MPI routine studies were always evaluated in coopera-
tion with experienced cardiologists. Available CAG and clinical information were com-
pared to the NC and AC MPI results. In cases of discordance between CAG and the MPI
results, other techniques were available to detect or exclude CAD, like positron emission
tomography (PET).
The results of the 3 readers were pooled, and average values are presented.A reduction
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dard for the presence of ischemia. However, coronary angiography was available in only
26 of the patients; in the remaining 22, the likelihood of coronary artery disease was
assessed on the basis of follow-up data recorded over 1 year. For assessment of myo-
cardial infarction, we relied on the patient’s history, e.g. ECG changes clearly suggestive
of myocardial infarction accompanied by an increase in myocardium-specific enzymes or
the presence of wall motion disorders such as akinesia or dyskinesia on ultrasound or
blood pool imaging (information of one type ot the other was available in all patients). At
the time of attenuation correction acquisition, gated SPECT was not available. Both NC
and AC images were compared with the gold standard for each segment, before and
after the 1-year experience period. From these data sensitivities and specificities per
patient for the overall detection of coronary artery disease, for detection of ischemia only
and for detection of infarction only were calculated.
Statistical analysis
Data were expressed as mean ± SD. McNemar’s test with Yate’s correction was used to
determine the differences in sensitivity and specificity for paired data samples. A P value
of <0.05 was considered significant.
Results
Gold standard
Thirteen patients were diagnosed with ischemia in one or more segments, all based on
coronary angiography. Nine had single-vessel disease and four had two-vessel disease.
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Table 1. Demographic data
No.
Patients 48
Male 35
Female 13
Mean age (yrs) 58 ± 13
CAD* 26
Infarction only 13
Infarction and ischemia 8
Ischemia only 5
CAG 26
1-vessel disease 9
2-vessel disease 4
3-vessel disease 0
* Assessed by coronary angiography (CAG), MUGA, ultrasound or X-ray ventriculography
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in 13, and on unremarkable follow-up combined with low clinical likelihood of coronary
disease (14). In 21 patients, a previous infarction was confirmed by MUGA, ultrasound,
X-ray ventriculography or combinations thereof. In the others, combinations of these
available tests ruled out unknown infarctions.In total 26 patients had coronary artery dis-
ease, with a mean of 1.7 abnormal segments (Table 1).
Initial assessments
A total of 432 segments in 48 patients were evaluated and compared with the gold stan-
dard. On average 1.9 segments per patient were scored as abnormal with the NC study.
Sensitivity for the detection of CAD was 95% for the NC images, at a specificity of 45%.
For the AC images sensitivity was 77% (not significantly different from NC, P = 0.13) at a
specificity of 70% (P = 0.13). Mean accuracy with an average difference between the 3
readers of the NC and AC studies was 68% (average difference 1.3%) and 73% (average
difference 3.6%). Considering only the detection of ischemia, NC sensitivity was 72%
and specificity 80%.Using the attenuation corrected images these figures were 30% and
87% (sensitivity and specificity NC vs AC; P =0.24 and 0.37, respectively). Considering
only the detection of infarctions, NC subgroup sensitivity and specificity were 86% and
62% respectively, while for AC studies the sensitivity and specificity were 79% and 80%
respectively (sensitivity and specificity NC vs AC; P =NS and 0.045 respectively).
Assessments after one year
Analyzing the same patient data after 1 year of experience with attenuation correction,
the sensitivity of NC for the detection of CAD on the patient level was now 100% (P = NS
vs initial reading), and the specificity had improved to 61% for the NC readings (P <
0.001).The sensitivity of the AC images for CAD was 89%; it had improved with the initial
readings, but not significantly (P = 0.71). Specificity of AC MPI was 92%, showing a sig-
nificant improvement compared with the initial assessments (P = 0.023, Table 2). Mean
accuracy of the NC and AC studies was 83% (average difference between the 3 readers
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Table 2. Sensitivity and specificity in detection of CAD in 38 patients without and after 1 year of
attenuation correction experience.
Approach Sensitivity (%) Specificity (%)
Initial assessment
NC 95 45
AC 77 70
P = 0.13 P = 0.13
After 1 year’s experience
NC 100 61
AC 89 92
P = 0.71* P = 0.023*
* Initial AC reading vs AC reading after 1 year’s experience 
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Considering only the detection of ischemia, the sensitivity of NC studies was 68% and the
specificity, 83%. For the AC studies, these values were 48% and 94% respectively.
Considering only the detection of infarctions, the sensitivity and specificity of NC studies
were 93% and 71% respectively, while sensitivity and specificity of AC studies were 97%
and 97% respectively (sensitivity and specificity of NC vs AC; both P = NS). Re-analyz-
ing NC studies after 1 year changed the final diagnosis in 16% of the patients. Re-ana-
lyzing AC studies after 1 year’s experience AC changed the final diagnosis in 15% of the
patients.
Discussion
At time of the first reading, shortly after the implementation of attenuation correction sys-
tem, we found that attenuation correction led to an increase in specificity for the detection
of CAD as compared with NC studies; the difference was not, however, statistically sig-
nificant.The sensitivity of the AC images tended to be lower than that of the NC images,
leading to a mixed positive/negative yield. However, after 1 year of experience, the sen-
sitivity of the AC studies had increased to approach the level previously achieved with NC
image interpretation, though the improvement was not significant. Specificity in CAD
detection with AC images had also increased and was significant better compared with
the specificity of AC images 1 year earlier. The specificity of NC images for detection of
CAD had similarly increased significantly compared with the initial NC reading.
The overall results of attenuation correction therefore appear to be beneficial, and per-
formance in interpretation of MPI is improved (Figure 1). However, this study demon-
strates that this improvement requires experience and is associated with a learning
curve. In addition, we found that also the NC reading performance, and especially differ-
entiation of attenuation artefacts from infarction, improved after using attenuation correc-
tion for 1 year, suggesting that performance in general increases with this new feature.
While our data, in agreement with many other reports, mainly showed improvements in
specificity as result of attenuation correction, others have also reported increased sensi-
tivities (4,7,8,10,12). Usually in these studies, sensitivity for overall detection of CAD is
given, thereby aggregating the detection of infarcted areas with the more important
detection of ischemia. In our setting, we apparently read our images with high sensitivity,
at lower specificity. Therefore, it may not be surprising that especially specificity in-
creased after we implemented the attenuation correction system. All centers have their
own ‘set-point’ in the trade-off between sensitive or specific reading of MPI, and it thus
seems logical that in some centers sensitivity may increase by attenuation correction. It
should be noted that in other studies, scatter correction and motion correction also
assisted in the detection of artificial fixed defects (6,7).
We found not only that attenuation correction resulted in no overall improvement in sen-
sitivity, but also that it yielded considerably worse sensitivity in (small) subgroup of pa-
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myocardial infarctions, on the other hand, sensitivity was similar for NC and AC imaging,
at considerable better specificity.Therefore, some caution is advised in basing a diagno-
sis of ischemia solely on AC images, while a diagnosis of infarction appears to be more
reliable using AC. Although combined reading of AC and NC studies is complex, in our
opinion the NC and AC images should be used in conjunction at present. As the feature
of AC is truly additional, the conjunct reading poses no problems.
Our study is too small to draw conclusions on the performance of AC for each of the three
vessel territories. Other limitations of this study include the retrospective nature and
associated problems such as verification bias (for instance there was lack of accurate
confirmation of infarcted myocardial tissue with 18F-fluorodeoxyglucose (FDG)). Also
gated SPECT for evaluation of wall motion and wall thickening was not available in our
center at the time of MPI acquisition. However, we believe that the relatively high fre-
quency of coronary angiography in this study and the availability of clinical follow-up data
probably minimized the likelihood of errors in this study.
Despite the improvement in MPI interpretation that is offered by attenuation correction,
further advances in the AC method would be welcome. Especially the increase in subdi-
aphragmatic activity induced by attenuation correction may interfere with assessment of
the inferior wall.This problem may be reduced by better reconstruction methods.It is also
conceivable in the near future, better tracers with less gastrointestinal activity will become
available, leading to reduced subdiaphragmatic activity (99mTc-tetrofosmin has already
represented an advance in this direction). It is also to be noted that in general, the qual-
ity of the attenuation correction appears to be related to the quality of the transmission
map (  map). In a recent report by O’Connor et al. (15), the best attenuation correction
was found using computed tomography (CT) for transmission imaging. The high photon
flux produced by CT generates better correction than the lower flux methods incorporat-
ing radioactive sources, such as the array of 153Gd rods used in this study.This approach
might also decrease costs in the long run, as replacement of 153Gd rods is not longer be
necessary. In addition, improved methods for scatter compensation, motion correction
and collimator resolution modelling will also contribute to better diagnostic performance
(7,16).
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Figure 1. Improvement generated by AC. Lower
row shows MPI rest vertical long axis slices with-
out correction, showing a marked inferior defect
originally judged to be an infarction. Upper row
shows corresponding images after AC, now cor-
rectly normal.
BINNENWERK SLART  25-05-2005  13:06  Pagina 52Conclusion
In this study attenuation correction resulted in an increase in the specificity of myocardial
perfusion scintigraphy at similar sensitivity as compared with non-corrected images.
However, the method requires experience and is associated with a learning curve. From
this and other studies it slowly becomes clear that attenuation correction should be part
of the standard myocardial perfusion imaging method, as recently stated by the American
Society of Nuclear Cardiology (17).With future technical improvements, and given appro-
priate experience with this method, attenuation correction might further improve myocar-
dial perfusion imaging, which will ultimately translate into a beneficial clinical effect.
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Figure 2. Deteriorating effect of AC. MPI transversal slices in a patient with ischemia inferior show-
ing modest reversibility in the inferior wall on non-corrected images (A). The corresponding AC
images (B) were read as normal by all observers.
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The aim of this study was to evaluate the value of attenuation correction (AC) of 99mTc-
tetrofosmin single photon emission computed tomography (SPECT) imaging for the
detection of myocardial viability.
Methods: A head-to-head comparison between resting 99mTc-tetrofosmin SPECT and
18F-fluorodeoxyglucose (FDG) SPECT was performed. Both the non-corrected (NC) and
AC 99mTc-tetrofosmin SPECT images were compared with the FDG images that served
as the reference for viability. Consecutive patients (n=33) with chronic coronary artery
disease and left ventricular dysfunction were included. Segmental 99mTc-tetrofosmin and
FDG data were displayed in polar maps (17-segment model) and the segments were
normalized to peak activity using the 4D-MSPECT software program.Segments with nor-
malized FDG activity greater than 50% were considered viable.A similar cutoff to assess
viability was used for the NC and AC 99mTc-tetrofosmin images.Regional contractile func-
tion was determined from the gated 99mTc-tetrofosmin images and scored as normokine-
sia, hypokinesia or akinesia/dyskinesia.
Results: Of all segments, 482 (85%) were viable on FDG SPECT. Of these, 427 (89%)
were classified as viable with NC 99mTc-tetrofosmin.Thus 55 (11%) were underestimated
with NC 99mTc-tetrofosmin SPECT; these segments were mainly located in the inferior
and inferoseptal regions. AC changed 39 segments (70%) of the underestimated seg-
ments into viable. By the use of attenuation correction, the agreement between 99mTc-
tetrofosmin and FDG imaging improved from 84% to 90%. Similar observations were
made when the analysis was restricted to the dysfunctional segments.
Conclusion: The addition of attenuation correction to 99mTc-tetrofosmin SPECT signifi-
cantly improved detection of myocardial viability in patients with chronic artery disease,
although minimal underestimation of viability remained as compared with FDG SPECT
imaging.
Keywords: attenuation correction, 99mTc-tetrofosmin, 18F-fluorodeoxyglucose, single pho-
ton emission computed tomography, myocardial viability.
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Myocardial viability assessment is an important clinical issue in patients with coronary
artery disease (CAD) and left ventricular (LV) dysfunction. Patients with viable
myocardium have been demonstrated to benefit from revascularization, with an improve-
ment in LV function and a favourable prognosis after revascularization (1-3).
Various techniques have been proposed for the detection of viable myocardium, includ-
ing nuclear imaging with 18F-fluorodeoxyglucose (FDG), thallium-201 and technetium-
99m (99mTc) labeled agents (4-10). In addition, other imaging modalities have been used
for the assessment of viability, including magnetic resonance imaging and dobutamine
stress or contrast echocardiography (11-13).
For clinical use, 99mTc-labeled agents may be preferred (4,14,15). The feasibility of 99mTc-
sestamibi and 99mTc-tetrofosmin imaging to assess viability has been demonstrated (4,14).
Still, as compared with FDG imaging, the 99mTc-labeled agents appear to underestimate the
presence of residual viable myocardium, in particular in severely dysfunctional regions
(5,7,16-18). This underestimation of viability may partially be ascribed to attenuation arte-
facts, scatter and partial volume effects (19-22).In particular, the non-uniform attenuation of
the emitted radiation of 99mTc-labeled tracers may produce severe artefacts, resulting in
defects on single photon emission computed tomography (SPECT) imaging, leading to
underestimation of viability (22-24). Attenuation correction (AC) by the use of transmission
scans may help in distinguishing attenuation artefacts from myocardial infarction patterns,
especially in the posterior wall, where misinterpretation is most common (21,25). Recently,
several methods for transmission scan-based attenuation correction have become avail-
able, and clinical results have shown its utility to improve the detection of CAD (23,26).Data
on the added value of attenuation correction in viability assessment are scarce (27). In this
study we report the impact of attenuation correction on assessment of viability with resting
99mTc-tetrofosmin SPECT. Both non-corrected (NC) images and corrected images were
compared with the viable segments on FDG imaging that served as the reference method.
Material and methods
Patients
This study included 33 consecutive patients with chronic CAD and LV dysfunction (23
men, mean age 63 ± 11 years [range 37-80]).Of these, 22 (66%) had a history of myocar-
dial infarction and 19 (57%) had undergone previous revascularization (both > 3 months
before the study).
The mean number of stenosed coronary arteries on angiography was 1.6 ± 1.0
The mean LV ejection fraction (LVEF) in the study population was 41 ± 13 %.Ten patients
had diabetes mellitus type 2. All patients underwent a resting gated SPECT 99mTc-tetro-
fosmin and a resting FDG SPECT in random order. None of the patients had cardiac
events or therapeutic interventions during the study.
Attenuation-corrected 99mTc-tetrofosmin SPECT versus FDG SPECT | 57
BINNENWERK SLART  25-05-2005  13:06  Pagina 57Resting 99mTc-tetrofosmin SPECT: Data acquisition, Analysis and Viability Criteria 
At rest, 600 MBq 99mTc-tetrofosmin was injected. SPECT images, including gated images
in 16 frames with an R-R interval of ± 10%, were acquired 1 hr after tracer administration
using a dual-headed gamma camera (Siemens E.Cam, Siemens Medical Systems, Hoff-
man Estates, Ill, USA) equipped with low-energy high-resolution collimators. This system
has a spatial resolution of 7.4 mm full-width at half maximum (FWHM).The camera heads
were in perpendicular position (90° opposed). Other acquisition parameters were: 32
steps, 20 s per step, 128 matrix size, zoom 1.0 and rotation from 45° right anterior oblique
to 135° left posterior oblique position with the patient in the supine position.The AC system
consisted of an array of 153Gd external line sources incorporated in retractable “wings” on
the camera. This system is called Profile Attenuation Correction (Siemens Medical Sys-
tems). These wings form a 180° arc opposite the perpendicular camera heads. A shutter
opens and closes the external sources. In this study simultaneous emission and transmis-
sion images were obtained, using a 20% window over the 99mTc-photopeak and a 20%
window over the 153Gd-photopeak.No scatter correction was performed.After filtered back-
projection reconstruction, NC emission slices were two-dimensionally filtered using a But-
terworth filter with cutoff frequency of 0.30 cycles/pixelof Nyquist frequency and order 6.
AC images were reconstructed from the emission and transmission images using iterative
reconstruction (Wallis and Miller (28)) methods on Siemens ICON computers (version 8.5).
All data from the 99mTc-tetrofosmin SPECT studies were reorientated in short-axis, hori-
zontal and vertical long-axis sections.Data were analyzed and displayed in a 17-segment
polar map (as recently proposed (29)), using the 4D-MSPECT program, a commercially
available gated cardiac software package (developed by the University of Michigan Med-
ical Center, Ann Arbor, MI, USA) (30).
Average counts per segment were obtained from the 17 segments and the measured
counts were normalized to the segment with the highest average counts.NC and AC seg-
ments were regarded as viable when the normalized activity was greater than 50%
(99mTc-tetrofosmin > 50%), and non-viable when activity was 50% or lower (99mTc-tetro-
fosmin ≤ 50%) (31).
The quantitative 4D-MSPECT analysis program was also used for assessing LV volumes,
LVEF and regional wall motion.The 4D-MSPECT model uses a cylindric-spheric coordi-
nate system, with cylindric coordinates to sample from the basal to the distal wall and
spheric coordinates to sample the apex. Weighted spline and thresholding techniques
were used to refine surface estimates. Fitted to a Gaussian function, wall position and
wall thickness were estimated. LV wall motion was classified visually in 3 categories (0 =
normal 1, = hypokinesia, 2 = akinesia/dyskinesia) by use of the 17-segment model.
FDG SPECT: Data acquisition, Analysis and Viability Criteria
FDG SPECT acquisition was performed on a separate day. Patients received a glucose-
enriched breakfast.Acipimox (a nicotinic acid derivative, 500 mg) was administered orally
to lower the circulating free fatty acids.To prevent side effects of acipimox (eg.skin rash),
250 mg of aspirin was administered orally 5 minutes before acipimox intake. Guided by
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(32).
Ninety minutes after acipimox administration, 200 MBq FDG was injected at rest. Sixty
minutes thereafter, data acquistion was started. A Siemens MultiSPECT dual-headed
gamma camera with extra-high energy (EHE) collimators (Siemens) was used, with only
one head activated during acquisition set at an energy window of 511 keV (± 15%).This
system has a spatial resolution of 12.3 mm full width at half maximum. Sixty-four projec-
tions were acquired over a circular orbit of 180° (45° right anterior oblique to 45° left pos-
terior oblique; 30 s per angle). The total acquisition time was 35 min. The planar FDG
images were corrected for the decay of 18F during data acquisition. Short-axis, vertical -
and horizontal long-axis images of FDG were reconstructed using filtered back projection
with a Butterworth filter (Nf 0.5, order 6). Further analysis of data was performed using
the 4D-MSPECT program, similarly to the 99mTc-tetrofosmin data and displayed in polar
maps (17-segment model). Average counts per segment were obtained from the 17 seg-
ments and the measured counts were normalized to the segment with the highest aver-
age counts.Segments were considered as non-viable, when the normalized FDG activity
was ≤ 50% and as viable when the activity was > 50%.
Comparison between 99mTc-tetrofosmin and FDG SPECT
A head-to-head comparison for each corresponding segment was performed between
99mTc-tetrofosmin and FDG in all segments. In addition, the comparison was repeated in
the dysfunctional segments, since viability is mainly important in dysfunctional
myocardium. The normalized activities were compared and agreement between the 2
techniques (for assessment of viability and scar tissue) was determined.
Statistical analysis
Data were expressed as mean ± SD.
The agreement for viability detection using 99mTc-tetrofosmin and FDG was assessed by
the use of weighted K-statistics. K-values of < 0.4, of 0.4 - 0.75, and of > 0.75 were con-
sidered to present poor, fair to good, and excellent agreement respectively, on the basis
of the Fleiss classification (33). McNemar and Chi square tests were used to evaluate
concordance/discordance and agreement/differences between NC 99mTc-tetrofosmin and
AC 99mTc-tetrofosmin respectively. A P value <0.05 was considered significant.
Results
All segments
Of all 561 segments, 482 (85%) segments were viable on FDG SPECT (FDG >50%); the
mean activity was 74 ± 12% (range 51% to 98%).
Of these, 427 (89%) were classified as viable when NC 99mTc-tetrofosmin images were
used (Figure 1).The mean activity was 73 ± 13 (range 51 to 98%).The agreement on a
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tistic of 0.41 (95% confidence interval (CI) 0.27-0.54, P <0.0001).
Of the 482 FDG viable segments, 55 (11%) were underestimated with NC 99mTc-tetrofos-
min (Figure 1). Underestimation with NC 99mTc-tetrofosmin was mainly localized in the
inferior and inferoseptal regions (see Table 1).
Of the 482 FDG viable segments, 466 (97%) were classified as viable when AC 99mTc-
tetrofosmin images were used, reducing the number of underestimated segments by 70%
(from 55 to 16, Figure 1). The mean AC 99mTc-tetrofosmin activity was 75 ± 11% (range
51% to 98%). The total agreement on a segmental basis between AC 99mTc-tetrofosmin
and FDG SPECT was 90%, with a K-statistic of 0.48 (95% CI 0.31-0.64, P <0.0001).
Of the total of 55 underestimated NC 99mTc-tetrofosmin segments, 70% were correctly
reclassified as viable segments after AC, in particular in the inferior and inferoseptal
regions (Figure 2).
Segments with contractile dysfunction
Of all 222 dysfunctional segments, 164 (73%) segments were viable on FDG SPECT and
the mean activity was 71 ± 11% (range 51 to 97%).
Of these 164 segments, 134 (81%) were classified as viable when NC 99mTc-tetrofosmin
images were used (Figure 3). The mean activity was 70 ± 12% (range 51 to 98%). The
total agreement on a segmental basis between NC 99mTc-tetrofosmin and FDG SPECT
was 77%, with a K-statistic of 0.43 (95% CI 0.27-0.59, P <0.0001).Of the 164 FDG viable
segments, 30 (18%) were underestimated with NC 99mTc-tetrofosmin. Underestimation
with NC 99mTc-tetrofosmin was mainly localized in the inferior, inferolateral and inferosep-
tal regions (see Table 2). Of the 164 FDG viable segments, 159 (97%) were classified as
60 | Chapter 3
Figure 1. Bar graph showing the assessment for viability of NC 99mTc-tetrofosmin (89%) and AC
99mTc-tetrofosmin (97%) out of 482 FDG SPECT viable segments.
NC = non-corrected; AC = attenuation-corrected;TF =rest 99mTc-tetrofosmin.
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fosmin activity was 73 ± 11% (range 51 to 98%).The total agreement on segmental basis
between AC 99mTc-tetrofosmin and FDG SPECT was 83%, with a K-statistic of 0.51 (95%
CI 0.32-0.69, P <0.0001).
Of the 30 underestimated NC 99mTc-tetrofosmin segments, 25 (83%) were correctly
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Figure 2. Bar graph showing the added value of attenuation correction for assessment of viability
according to the different regions. The largest underestimation is observed in the inferoseptal (is)
and inferior (inf) regions, and attenuation correction corrects the most in these regions.
Ant: anterior wall; as: anteroseptal; il: inferolateral; al: anterolateral; apx: apex.
NC = non-corrected; AC = attenuation-corrected.
Table 1. Detection of viability with NC and AC 99mTc-tetrofosmin in the 7 main regions of all viable
segments 
FDG-viable segments  No. of segments (%)
(No.) underestimated
NC AC
ANT (86) 6 (7%) 1 (1%)
AS (78) 11 (14%) 11 (14%)
IS (52) 12 (23%) 1 (2%)
INF (84) 16 (19%) 1 (1%)
IL (63) 5 (8%) 1 (2%)
AL (95) 3 (3%) 1 (1%)
Apex (24) 2 (8%) 0 (0%)
Total (482) 55 (11%) 16 (3%)
Viability detection in the inferior and inferoseptal regions was especially less underestimated after
attenuation correction. ANT, anterior wall; AS, anteroseptal; IS, inferoseptal; INF, inferior; IL, infero-
lateral; AL, anterolateral; NC = non-corrected; AC = attenuation-corrected.
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ticular in the inferior, inferoseptal and inferolateral regions (Figures 4 and 5).
Discussion
99mTc-labeled tracers to assess myocardial viability
99mTc-labeled tracers including 99mTc-tetrofosmin and 99mTc-sestamibi are lipophilic
myocardial perfusion tracers that have been used extensively over the past decade.It has
been shown that the uptake and retention of these 99mTc-labeled agents is associated
with mitochondria function and may reflect cellular viability (34).
Various comparative studies between 99mTc-sestamibi SPECT and other viability tech-
niques have been performed (9,17,35,36). Kaltoft et al. evaluated 50 patients with 99mTc-
sestamibi SPECT to assess viability, and the results were compared with FDG PET (17).
Considering FDG PET as the gold standard, 99mTc-sestamibi SPECT had a sensitivity of
87% with a specificity of 82% for the detection of viable myocardium (17).Additional stud-
ies have used 99mTc-sestamibi to predict improvement of function after revascularization.
When the 10 available 99mTc-sestamibi studies (with 207 patients) were pooled, a sensi-
tivity and specificity of 87% and 71%, respectively, were obtained for the prediction of
improvement of regional LV function after revascularization (37). Less experience has
been obtained with 99mTc-tetrofosmin SPECT. Both 99mTc-labeled tracers have been
demonstrated to yield comparable image quality, and provided comparable accuracy for
the detection of coronary artery disease (8,14,38,39).Few studies have used 99mTc-tetro-
fosmin SPECT for the assessment of viability. Matsunari et al. performed a head-to-head
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Figure 3. Bar graph showing the assessment for viability of NC 99mTc-tetrofosmin (81%) and AC
99mTc-tetrofosmin (97%) out of 164 dysfunctional but FDG SPECT viable segments.
NC = non-corrected; AC = attenuation-corrected;TF =rest 99mTc-tetrofosmin.
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sidering FDG PET as the gold standard, they demonstrated a diagnostic accuracy of
80% for the detection of viable myocardium.
99mTc-tetrofosmin, attenuation correction and FDG SPECT
Despite the good results with the 99mTc-labeled tracers, several studies demonstrated
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Figure 4. Bar graph showing the added value of attenuation correction for assessment of viability
according to the different regions of dysfunctional segments. The largest underestimation is
observed in the inferoseptal (is), inferior (inf) and inferolateral (il) regions, and attenuation correction
corrects the most in these regions.
Ant: anterior wall; as: anteroseptal; al: anterolateral; apx: apex.
NC = non-corrected; AC = attenuation-corrected.
Table 2. Detection of viability with NC and AC TF in the 7 main regions of all viable, but dysfunc-
tional segments.
FDG viable NC underestimated AC underestimated
segments: n per region: n (%) per region: n (%)
ANT (n=25) 4 (16%) 3 (12%)
AS (n=29) 4 (13%) 2 (7%)
IS (n=20) 5 (25%) 0 (0%)
INF (n=40) 11 (27%) 0 (0%)
IL (n=21) 3 (14%) 0 (0%)
AL (n=13) 1 (8%) 0 (0%)
Apex (n=16) 2 (12%) 0 (0%)
Total (n=164) 30 (18%) 5 (3%)
Viability detection in the inferior (INF), inferolateral (IL) and inferoseptal (IS) regions was less under-
estimated after AC. ANT: anterior wall; AS: anteroseptal; AL: anterolateral. NC = non-corrected; AC
= attenuation-corrected.
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(5,17,18,40,41).Altehoefer et al.compared 99mTc-sestamibi and FDG PET in 111 patients
and demonstrated FDG uptake in 23% of the defects on 99mTc-sestamibi SPECT (40).
Matsunari et al. reported a comparable underestimation of viability by 99mTc-tetrosfosmin
SPECT as compared with FDG PET: 20% of the FDG PET viable segments was consid-
ered nonviable on 99mTc-tetrofosmin SPECT (27). In our study, with a head-to-head com-
parison between 99mTc-tetrofosmin SPECT and FDG imaging, 11% of the FDG viable
segments were considered nonviable by 99mTc-tetrofosmin SPECT. Underestimation of
64 | Chapter 3
Figure 5.
A. Non-corrected (NC) and attenuation corrected (AC) rest 99mTc-tetrofosmin (TF) images divided
in short-axis (SA), horizontal (HLA) and vertical long axis (VLA) slices from the apex to the base
of the left ventricle.The NC rest 99mTc-tetrofosmin study improved from an activity   50% to an
activity > 50% after AC in the apex, septal and inferior wall, suggesting viable myocardial tissue.
B. FDG SPECT divided in SA-axis, HLA-axis and VLA-axis of the left ventricle in the same patient.
FDG activity > 50% confirmed the presence of viable myocardial tissue in the corresponding
apex, septal and inferior wall.
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tracer properties of 99mTc-labeled tracers and FDG, but is also related to attenuation arte-
facts as observed with 99mTc-tetrofosmin SPECT (27,42,43).Soufer et al.already pointed
out that underestimation of viability by 99mTc-sestamibi was predominantly observed in
the inferior and septal regions, where attenuation artefacts are likely to occur (41). Also,
in the present study, the majority (51%) of the underestimated segments was located in
the inferior and septal regions (Table 1).
More recently, the use of AC has been introduced, and various studies have demon-
strated the value of AC and 99mTc-sestamibi imaging to detect CAD (20,23,26,44).
Indeed, attenuation correction using transmission scans can help in distinguishing atten-
uation artefacts from myocardial infarction patterns, in particular in the inferior, posterior
and septal regions (21,25). Thus far, 1 study has systematically compared NC and AC
99mTc-tetrofosmin for the assessment of viability. In a direct comparison with FDG PET,
the authors demonstrated an improvement for assessing viability when AC was used
(27). In particular, the defect extent on 99mTc-tetrofosmin SPECT decreased significantly
from 19.8 ± 15.2% on the NC images to 9.7% ± 12.6% on the AC images (P =0.01).More-
over, the percentage of dysfunctional segments classified nonviable by 99mTc-tetrofosmin
SPECT that were viable on FDG PET decreased from 24.5% on the NC images to 13.7%
on the AC images, thus a reduction of 44% in underestimation of viability when AC was
applied to the 99mTc-tetrofosmin SPECT images.In our study, a similar reduction in under-
estimated segments was shown when AC was applied to the 99mTc-tetrofosmin SPECT
images.The number of 99mTc-tetrofosmin nonviable but FDG viable segments decreased
from 11% to 3% when AC was used.A similar reduction (from 18% to 3%) was observed
when the analysis was restricted to the dysfunctional segments only. In addition, the
largest reduction in underestimated segments was observed in the inferior and septal
regions (Table 2).
Still, despite AC, some underestimation of myocardial viability remained as observed by
Matsunari et al. (27) and confirmed in our study.
Limitations
The major limitation of the study is the lack of assessment of outcome after revascular-
ization. Whether AC will result in an improved prediction of recovery of function post-
revascularization remains to be demonstrated. In addition, larger patient populations
need to be studied to confirm the added value of AC for assessment of viability with 99mTc-
tetrofosmin SPECT.
Although the spatial resolution of FDG SPECT is lower as compared with FDG PET, the
detection of viability with NC and AC 99mTc-tetrofosmin SPECT was still significant differ-
ent.Using a PET technique may have resulted in higher differences between NC and AC
99mTc-tetrofosmin SPECT for the detection of myocardial viability. Attenuation-correction
was not performed for the FDG SPECT studies, but the quality of FDG SPECT images
will be less hampered by attenuation due to the high photon energy of 18F. Matsunari et
al. used attenuation-corrected static FDG PET images performed on a dedicated PET
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small differences were noticed in myocardial activity distribution between FDG SPECT
and FDG PET (45).
Left ventricular function in the subjects was relatively modestly depressed (LVEF: 41 ±
13%) probably based on relatively high prevalence of viable segments.The difference in
detection of viability between NC and AC 99mTc-tetrofosmin SPECT may also be higher in
patients with more severely depressed LV function, in whom more extensive and severe
perfusion defects might be identified.
Conclusion
The addition of attenuation correction to 99mTc-tetrofosmin SPECT significantly improved
detection of myocardial viability in patients with chronic CAD, although minimal underes-
timation of viability remained as compared with FDG SPECT imaging.
Acknowledgement
We gratefully acknowledge J. ter Veen for technical assistance.
66 | Chapter 3
BINNENWERK SLART  25-05-2005  13:06  Pagina 66Reference List
1. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC et al. Value of metabolic
imaging with positron emission tomography for evaluating prognosis in patients with coronary
artery disease and left ventricular dysfunction. Am J Cardiol. 1994; 73(8):527-533.
2. Rahimtoola SH.The hibernating myocardium. Am Heart J. 1989; 117(1):211-221.
3. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M et al. Reversibility 
of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;
314(14):884-888.
4. Acampa W, Cuocolo A, Petretta M, Bruno A, Castellani M, Finzi A et al.Tetrofosmin imaging in
the detection of myocardial viability in patients with previous myocardial infarction: comparison
with sestamibi and Tl-201 scintigraphy. J Nucl Cardiol. 2002; 9(1):33-40.
5. Altehoefer C, vom-Dahl J, Biedermann M, Uebis R, Beilin I, Sheehan F et al. Significance of
defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: compari-
son with fluorine-18-FDG PET. J Nucl Med. 1994; 35(4):569-574.
6. Bax JJ, Cornel JH, Visser FC, Fioretti PM, Van Lingen A, Reijs AE et al. Prediction of recovery
of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglu-
cose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardio-
graphy. J Am Coll Cardiol. 1996; 28(3):558-564.
7. Dilsizian V, Arrighi JA, Diodati JG, Quyyumi AA, Alavi K, Bacharach SL et al. Myocardial viabil-
ity in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thal-
lium reinjection and [18F]fluorodeoxyglucose. Circulation. 1994; 89(2):578-587.
8. Kapur A, Latus KA, Davies G, Dhawan RT, Eastick S, Jarritt PH et al. A comparison of three
radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl
Med Mol Imaging. 2002; 29(12):1608-1616.
9. Kauffman GJ, Boyne TS, Watson DD, Smith WH, Beller GA. Comparison of rest thallium-201
imaging and rest technetium-99m sestamibi imaging for assessment of myocardial viability in
patients with coronary artery disease and severe left ventricular dysfunction.J Am Coll Cardiol.
1996; 27(7):1592-1597.
10. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T et al.Myocardial viability assess-
ment with technetium-99m-tetrofosmin and thallium-201 reinjection in coronary artery disease.
J Nucl Med. 1995; 36(11):1961-1967.
11. Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de Vivie ER et al.Predictive value of low
dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose
positron emission tomography for recovery of regional left ventricular function after successful
revascularization. J Am Coll Cardiol. 1996; 28(1):60-69.
12. Kuijpers D, Ho KY, van Dijkman PR, Vliegenthart R, Oudkerk M. Dobutamine cardiovascular
magnetic resonance for the detection of myocardial ischemia with the use of myocardial tag-
ging. Circulation. 2003; 107(12):1592-1597.
13. Iliceto S, Galiuto L, Marchese A, Cavallari D, Colonna P, Biasco G et al. Analysis of microvas-
cular integrity, contractile reserve, and myocardial viability after acute myocardial infarction by
dobutamine echocardiography and myocardial contrast echocardiography.Am J Cardiol. 1996;
77(7):441-445.
14. Acampa W, Cuocolo A, Sullo P, Varrone A, Nicolai E, Pace L et al. Direct comparison of tech-
netium 99m-sestamibi and technetium 99m-tetrofosmin cardiac single photon emission com-
puted tomography in patients with coronary artery disease.J Nucl Cardiol. 1998; 5(3):265-274.
15. Freeman I, Grunwald AM, Hoory S, Bodenheimer MM. Effect of coronary occlusion and
myocardial viability on myocardial activity of technetium-99m-sestamibi. J Nucl Med. 1991;
32(2):292-298.
Attenuation-corrected 99mTc-tetrofosmin SPECT versus FDG SPECT | 67
BINNENWERK SLART  25-05-2005  13:06  Pagina 6716. Burt RW, Perkins OW, Oppenheim BE, Schauwecker DS, Stein L, Wellman HN et al. Direct
comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for
detection of myocardial viability. J Nucl Med. 1995; 36(2):176-179.
17. Kaltoft A, Bottcher M, Sand NP, Flo C, Nielsen TT, Rehling M. 99mTc-Sestamibi SPECT is a
useful technique for viability detection:results of a comparison with NH3/FDG PET.Scand Car-
diovasc J. 2001; 35(4):245-251.
18. Sawada SG, Allman KC, Muzik O, Beanlands RS, Wolfe E-RJ, Gross M et al.Positron emission
tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll
Cardiol. 1994; 23(1):92-98.
19. DePuey EG.How to detect and avoid myocardial perfusion SPECT artifacts.J Nucl Med. 1994;
35(4):699-702.
20. Hendel RC, Berman DS, Cullom SJ, Follansbee W, Heller GV, Kiat H et al. Multicenter clinical
trial to evaluate the efficacy of correction for photon attenuation and scatter in SPECT myocar-
dial perfusion imaging. Circulation. 1999; 99(21):2742-2749.
21. Kjaer A, Cortsen A, Rahbek B, Hasseldam H, Hesse B. Attenuation and scatter correction in
myocardial SPET:improved diagnostic accuracy in patients with suspected coronary artery dis-
ease. Eur J Nucl Med Mol Imaging. 2002; 29(11):1438-1442.
22. Miles J, Cullom SJ, Case JA. An introduction to attenuation correction. J Nucl Cardiol. 1999;
6(4):449-457.
23. Corbett JR, Ficaro EP. Clinical review of attenuation-corrected cardiac SPECT. J Nucl Cardiol.
1999; 6(1 Pt 1):54-68.
24. DePuey EG, Garcia EV.Optimal specificity of thallium-201 SPECT through recognition of imag-
ing artifacts. J Nucl Med. 1989; 30(4):441-449.
25. Gallowitsch HJ, Sykora J, Mikosch P, Kresnik E, Unterweger O, Molnar M et al.Attenuation-cor-
rected thallium-201 single-photon emission tomography using a gadolinium-153 moving line
source: clinical value and the impact of attenuation correction on the extent and severity of per-
fusion abnormalities. Eur J Nucl Med. 1998; 25(3):220-228.
26. O’connor MK, Kemp B, Anstett F, Christian P, Ficaro EP, Frey E et al. A multicenter evaluation
of commercial attenuation compensation techniques in cardiac SPECT using phantom models.
J Nucl Cardiol. 2002; 9(4):361-376.
27. Matsunari I, Boning G, Ziegler SI, Nekolla SG, Stollfuss JC, Kosa I et al. Attenuation-corrected
99mTc-tetrofosmin single-photon emission computed tomography in the detection of viable
myocardium: comparison with positron emission tomography using 18F-fluorodeoxyglucose. J
Am Coll Cardiol. 1998; 32(4):927-935.
28. Wallis JW, Miller TR. Rapidly converging iterative reconstruction algorithms in single-photon
emission computed tomography. J Nucl Med. 1993; 34(10):1793-1800.
29. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al. Standardized
myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement
for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical
Cardiology of the American Heart Association. J Nucl Cardiol. 2002; 9(2):240-245.
30. Ficaro EP, Kritzman JN, Corbett JR.Development and clinical validation of normal Tc-99m ses-
tamibi database:comparison of 3D-MSPECT to Cequal [abstract].[abstract].J Nucl Med. 1999;
40(suppl)(125P).
31. Maes AF, Borgers M, Flameng W, Nuyts JL, van de Werf F, Ausma JJ et al. Assessment of
myocardial viability in chronic coronary artery disease using technetium-99m sestamibi
SPECT. Correlation with histologic and positron emission tomographic studies and functional
follow-up. J Am Coll Cardiol. 1997; 29(1):62-68.
68 | Chapter 3
BINNENWERK SLART  25-05-2005  13:06  Pagina 6832. Schinkel AF, Bax JJ, Valkema R, Elhendy A, van Domburg RT, Vourvouri EC et al. Effect of dia-
betes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocar-
dial viability. J Nucl Med. 2003; 44(6):877-883.
33. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. ed. New York, NY: Wiley;
1981:212-236.
34. Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium-tetrofosmin. I:
Uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol.
1995; 2(4):317-326.
35. Lee VS, Resnick D, Tiu SS, Sanger JJ, Nazzaro CA, Israel GM et al. MR imaging evaluation of
myocardial viability in the setting of equivocal SPECT results with (99m)Tc sestamibi. Radiol-
ogy. 2004; 230(1):191-197.
36. Marzullo P, Parodi O, Sambuceti G, Reisenhofer B, Gimelli A, Giorgetti A et al. Myocardial via-
bility: nuclear medicine versus stress echocardiography. Echocardiography. 1995; 12(3):291-
302.
37. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM.Accuracy of currently available
techniques for prediction of functional recovery after revascularization in patients with left ven-
tricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am
Coll Cardiol. 1997; 30(6):1451-1460.
38. Flamen P, Bossuyt A, Franken PR.Technetium-99m-tetrofosmin in dipyridamole-stress myocar-
dial SPECT imaging: intraindividual comparison with technetium-99m-sestamibi. J Nucl Med.
1995; 36(11):2009-2015.
39. Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J et al.Prognostic value of
normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multi-
center registry of 4,728 patients. J Nucl Med. 2003; 44(2):134-139.
40. Altehoefer C, Kaiser HJ, Dorr R, Feinendegen C, Beilin I, Uebis R et al. Fluorine-18 deoxyglu-
cose PET for assessment of viable myocardium in perfusion defects in 99mTc-MIBI SPET: a
comparative study in patients with coronary artery disease. Eur J Nucl Med. 1992; 19(5):334-
342.
41. Soufer R, Dey HM, Ng CK, Zaret BL. Comparison of sestamibi single-photon emission com-
puted tomography with positron emission tomography for estimating left ventricular myocardial
viability. Am J Cardiol. 1995; 75(17):1214-1219.
42. Banzo I, Pena FJ, Allende RH, Quirce R, Carril JM.Prospective clinical comparison of non-cor-
rected and attenuation- and scatter-corrected myocardial perfusion SPECT in patients with
suspicion of coronary artery disease. Nucl Med Commun. 2003; 24(9):995-1002.
43. Kluge R, Sattler B, Seese A, Knapp WH. Attenuation correction by simultaneous emission-
transmission myocardial single-photon emission tomography using a technetium-99m-labelled
radiotracer: impact on diagnostic accuracy. Eur J Nucl Med. 1997; 24(9):1107-1114.
44. Slart RH, Que TH, Van Veldhuisen DJ, Poot L, Blanksma PK, Piers DA et al. Effect of attenua-
tion correction on the interpretation of (99m)Tc-sestamibi myocardial perfusion scintigraphy:
the impact of 1 year’s experience. Eur J Nucl Med Mol Imaging. 2003; 30(11):1505-1509.
45. Matsunari I, Kanayama S, Yoneyama T, Matsudaira M, Nakajima K, Taki J et al. Myocardial dis-
tribution of (18)F-FDG and (99m)Tc-sestamibi on dual-isotope simultaneous acquisition SPET
compared with PET. Eur J Nucl Med Mol Imaging. 2002; 29(10):1357-1364.
Attenuation-corrected 99mTc-tetrofosmin SPECT versus FDG SPECT | 69
BINNENWERK SLART  25-05-2005  13:06  Pagina 69SECTION III
DISA SPECT for the detection of
myocardial viability
BINNENWERK SLART  25-05-2005  13:06  Pagina 71Chapter 4
Comparison of 99mTc-sestamibi-18F-
fluorodeoxyglucose dual isotope
simultaneous acquisition and rest-stress
99mTc-sestamibi SPECT for the assessment
of myocardial viability
Jaep de Boer1, Riemer H.J.A. Slart1, Paul K. Blanksma2, Antoon T.M.Willemsen1, 
Pieter L. Jager1, Anne M.J. Paans1, Willem Vaalburg1, D. Albertus Piers1.
Departments of Nuclear Medicine and Molecular Imaging1, Cardiology2, 
University Medical Center Groningen, The Netherlands.
Nucl Med Commun 2003 Mar;24(3):251-7.
BINNENWERK SLART  25-05-2005  13:06  Pagina 73Abstract
Background: Dual isotope simultaneous acquisition (DISA) SPECT offers the advan-
tage of obtaining information on myocardial perfusion using 99mTc-sestamibi and metab-
olism using 18F-fluorodeoxyglucose (FDG) in a single study. The prerequisite is that the
99mTc-sestamibi images are not degraded by scattered 511 keV photons or poor count
statistics due to a lower efficiency of the extra high energy collimator (EHE). Therefore,
we compared the registered 99mTc-sestamibi uptake and image quality of a DISA SPECT
and single isotope SPECT acquisition. Furthermore we investigated whether DISA
SPECT yields additional information for the assessment of myocardial viability in com-
parison with rest-stress 99mTc-sestamibi.
Methods: 19 patients with known coronary artery disease and irreversible perfusion
defects on previous rest-stress MIBI test studies were studied. After oral glucose loading
and simultaneous injection of 600 MBq 99mTc-sestamibi and 185 MBq FDG at rest, DISA
SPECT was performed using energy windows of 140 ± 15%, 170 ± 20% and 511 ± 15%
keV. Planar 140 keV images were corrected for scatter by subtraction using the 170 keV
window. The single and dual isotope 99mTc-sestamibi images were both displayed in a
polar map with 128 segments normalized to maximum counts. FDG and 99mTc-sestamibi
images were visually scored for a perfusion-metabolism mismatch pattern using 9
regions per heart.
Results: There was an excellent correlation (r =0.93, P <0.0001) of the 99mTc-sestamibi
uptake as detected in the single and dual isotope acquisition.The average difference of
the dual and single isotope 99mTc-sestamibi uptake was -1.2% (NS from zero) and the
coefficient of variation of the difference was 8.7%
Of the 79 regions with irreversible perfusion defects on prior rest-stress 99mTc-sestamibi,
6 regions in 5 patients (7.6%, P <0.0034)  showed a perfusion-metabolism mismatch pat-
tern.
Conclusion: We conclude that in DISA SPECT acquisition does not affect the quality of
the 99mTc-sestamibi images. Furthermore 99mTc-sestamibi-FDG DISA SPECT may show
viability in a small but significant number of regions with irreversible perfusion defects on
rest-stress 99mTc-sestamibi.
Keywords: Dual Isotope Simultaneous Acquisition, SPECT, 99mTc-sestamibi,  18F-fluo-
rodeoxyglucose, myocardial viability
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In patients with coronary artery disease and poor left ventricular function identification of
viable myocardium is needed prior to revascularization.When viable tissue is revascularized,
left ventricular function and ejection fraction improve significantly (1,2), the frequency of car-
diac events is reduced and life expectancy is increased (3,4). For routine practice dobuta-
mine-echocardiography and nuclear imaging techniques can be used for the assessment of
myocardial viability. 201Tl-rest-redistribution scintigraphy shows intact myocardial membrane
function (5,6). Intact myocardial glucose metabolism can be shown by 18F-fluorodeoxyglu-
cose (FDG) imaging (2,3,7) and intact myocardial mitochondrial uptake is demonstrated by
99mTc-sestamibi scintigraphy (8,9).While scintigraphy with single photon emission computed
tomography (SPECT) tracers 201Tl- and 99mTc-sestamibi are used routinely mostly, FDG
positron emission tomography (PET) has emerged as the most sensitive and specific tech-
nique (10). FDG is transportable due to its relatively long half-life (110 min) and, as a result
of the limited availability of PET cameras, acquisition with SPECT using extra high energy
(EHE) collimators (511 keV) is considered as a clinically useful alternative (11-14). In addi-
tion, SPECT dual isotope simultaneous acquisition (DISA) using a 140 keV and a 511 keV
window has the advantage that information on myocardial perfusion with 99mTc-sestamibi
and metabolism with FDG can be obtained at the same time (14,15).This results in a fast,
patient-friendly protocol and identically oriented metabolism and perfusion images.However,
the prerequisite is that the 99mTc-sestamibi images are not degraded by scatter of 511 keV
photons and poor count statistics due to the lower efficiency of the EHE collimator.
The first main goal of our study was to evaluate the quality of the 99mTc-sestamibi images
of the DISA SPECT acquisition. Therefore we compared quantitatively and qualitatively
the 99mTc-sestamibi images of a single and dual isotope acquisition.
From other comparative studies, it is known that 99mTc-sestamibi tends to underestimate
myocardial viability in comparison with FDG PET (8,9,16-18).Therefore, our second goal
was to investigate whether signs of myocardial viability could be detected with FDG
SPECT in irreversible perfusion defects present on previous rest-stress 99mTc-sestamibi.
Materials and methods
Patients
We  studied 19 patients with known coronary artery disease and no signs of stress
induced ischemia (i.e. only irreversible perfusion defects) on prior rest-stress 99mTc-ses-
tamibi. Patients with diabetes mellitus were excluded. Patients were studied because of
chest pain, congestive heart failure, ventricular fibrillation or recent infarction.The median
delay between the rest-stress 99mTc-sestamibi and DISA SPECT studies was 27 days
(range 1-63 days). No cardiac events occurred between the studies. Patient characteris-
tics are summarized in Table 1. All patients gave informed consent. The study was
approved by the Local Medical Ethics Committee.
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Patients were studied after an overnight fast and refrained from caffeine and theophylline.
Using a two day protocol and a single-headed gamma camera (Siemens Orbiter) with a
low-energy high-resolution collimator (Siemens) 99mTc-sestamibi images were acquired
one hour after intravenous injection of 600 MBq 99mTc-sestamibi at rest and at peak exer-
cise (8 patients) or 4 minutes after intravenous dipyridamole (0.56 mg/kg body weight in 4
min) infusion (11 patients). Chocolate and coffee were given after the injection to promote
liver clearance of 99mTc-sestamibi.With the patient in supine position, 64 projections were
acquired in a circular orbit of 180° (45° right anterior oblique (RAO) to 45° left posterior
oblique (LPO)); 20 s each angle, energy peak at 140 keV ± 15%. Images were recon-
structed using filtered backprojection with a Butterworth filter (Nf 0.5, order 6) and reori-
ented along the short axis, vertical long axis and horizontal long axis of the heart.
DISA SPECT imaging
Patients were instructed to have a glucose rich breakfast and were given a 75 g oral glu-
cose load 45 min prior to the simultaneous injection of 600 MBq 99mTc-sestamibi and 185
MBq FDG at rest.After the injection a chocolate bar and coffee were given to enhance the
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Table 1. Demographic and clinical characteristics of 19 patients.
Characteristic Value
Sex (male/female) 17/2
Age: years 62 (range 38-75)
Previous myocardial infarction 14
Prior revascularization:
CABG 8
PTCA 3
Symptoms:
Angina 15
Congestive heart failure 5
Ventricular fibrillation 2
Angiographic findings:
Single vessel disease 7
Double vessel disease 5
Triple vessel disease 3
Unavailable 4
Ejection fraction:
>50% 8
30-50% 7
<30% 3
Not available 1
CABG: coronary artery bypass graft; PTCA: percutaneous transluminal coronary angioplasty.
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started. A Siemens Multispect double-headed gamma camera with EHE collimators
(Siemens) was used, with one head activated during acquisition. In this way, image quali-
ties of the double-headed camera were not favoured relative to the images of the single-
headed gamma camera. Three energy windows were set at 140 ± 15%, 170 ± 20% and
511 ± 15% keV.Sixty-four projections were acquired over a circular orbit of 180° (45° RAO
to 45° LPO;30 s per angle).The total acquisition time was 35 min.Planar 140 keV images
were corrected for scatter by subtraction of the 170 keV images using a convolution based
correction method (19). The planar FDG images were corrected for decay of 18F during
acquisition. Short axis, vertical long axis and horizontal long axis images of 99mTc-ses-
tamibi and FDG were reconstructed using identical axes and filtered backprojection with a
Butterworth filter (Nf 0.5, order 6 for both the FDG and 99mTc-sestamibi study). In this way,
identically oriented FDG and 99mTc-sestamibi images were obtained from DISA SPECT.
Comparison of detected uptake of 99mTc-sestamibi in single versus dual isotope
acquisition 
Both studies were analysed quantitatively en qualitatively. Visual analysis and quantita-
tive analysis was done separately. It was assumed that the orientation of the separately
acquired single and dual isotope 99mTc-sestamibi scans was comparable after reorienta-
tion. Eight short axis slices were analyzed, starting at the apex. First, for each slice, the
epi- and endocardial contours were determined automatically as described previously
(20).Each slice was divided into 16 equiangular segments between the two contours.For
each segment the mean activity was calculated resulting in a total of 128 activity values
per study.These values were normalized and expressed as percentage of the maximum
of each image. Least-squares linear regression analysis and the method of Bland and
Altman (21) were used to evaluate the segmental 99mTc-sestamibi uptake of the single
isotope acquisition versus the dual isotope acquisition.
Viability assessment
Short and long axis images of the rest-stress 99mTc-sestamibi images and DISA SPECT
images, viewed on a computer screen, were read by four experienced readers in con-
sensus. A nine-region heart model was used.One region was assigned to the apex.The
anterior, septal, inferior and lateral walls were divided into a distal and basal region.The
regions of the rest-stress 99mTc-sestamibi studies were classified into two categories: 1)
normal perfusion: normal stress 99mTc-sestamibi uptake or a mildly irreversibly reduced
99mTc-sestamibi uptake such as seen in cases of attenuation; 2) irreversible perfusion
defect: moderate to severe irreversibly reduced uptake of 99mTc-sestamibi, indicative of
scar tissue. Reversible perfusion defects were not found due to the inclusion criteria.
The regions of the DISA SPECT studies regions were classified into three categories: 1)
normal perfusion and metabolism: intact 99mTc-sestamibi and FDG uptake; 2) perfusion-
metabolism mismatch defect:a moderately to severely reduced 99mTc-sestamibi uptake in
combination with an intact or relatively increased FDG uptake representing viable
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uptake of both 99mTc-sestamibi and FDG indicative of scar tissue.The results of viability
assessment were tested for significance using the Wilcoxon test for paired data. P <0.05
was considered significant.
Results
Comparison of detected uptake of 99mTc-sestamibi of single versus dual isotope
acquisition 
In a total of 2432 segments, the 99mTc-sestamibi activity of the dual and single isotope
acquisition correlated well (r =0.93, P <0.0001) (Figure 1A).Visual inspection showed no
noticeable difference in quality of the rest 99mTc-sestamibi and DISA SPECT 99mTc-ses-
tamibi studies (Figure 2).The average difference of the dual and single isotope 99mTc-ses-
tamibi uptake was -1.2% (NS from zero) and the coefficient of variation of the difference
was 8.7% (Figure 1B). Minor deviations were seen in the apical and basal slices of the
heart due to partial volume effect and patient misalignment inherent to the separate
acquisitions of the resting single isotope 99mTc-sestamibi and the DISA SPECT studies.
Viability assessment
Rest-stress  99mTc-sestamibi showed irreversible perfusion defects in 79 of 171 regions
obtained from the 19 patients. Of these 79 regions 73 regions showed a match defect with
DISA SPECT which is statistically significantly less (P =0.034) than the 79 defects from the
rest-stress  99mTc-sestamibi. With DISA SPECT 6 of the 79 (7.6%) irreversible 99mTc-ses-
tamibi regions showed a perfusion-metabolism mismatch pattern indicating myocardial via-
bility. These 6 regions were obtained in 5 patients. In 3 patients viability was found in the
inferior wall, in 2 patients in the lateral wall and in one patient in the basal anterior wall (Fig-
ure 2).
Discussion
This study shows that after correction dual isotope 99mTc-sestamibi images are not
degraded by scatter of the 511 keV photons in comparison with the separately acquired
single isotope 99mTc-sestamibi images. In addition 7.6% (6/79) of the regions with irre-
versible perfusion defects on rest-stress 99mTc-sestamibi were viable with DISA SPECT
as demonstrated by a perfusion metabolism mismatch pattern.
Dual isotope SPECT imaging
Myocardial FDG imaging with SPECT is a useful alternative in the absence of PET tech-
nology (11-14). In addition dual isotope simultaneous acquisition allows simultaneous
imaging of either rest (22) or stress (14) perfusion with 99mTc-sestamibi and metabolism
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nuclear medicine department. These practical points advocate the use of cardiac FDG
imaging with DISA SPECT (23). Despite the increasing clinical application of DISA
SPECT, only a small number of clinical studies have been performed to evaluate the qual-
ity of the 99mTc-sestamibi images of the DISA SPECT acquisition (15,22). A comparable
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Figure 1
A. Correlation of normalized single isotope 99mTc-sestamibi uptake (x-axis) and normalized dual
isotope 99mTc-sestamibi (y-axis). MIBI = 99mTc-sestamibi
B. Bland and Altman plot. Normalized mean single isotope 99mTc-sestamibi uptake (x-axis) against
the difference between the dual versus normalized single isotope 99mTc-sestamibi uptake (y-
axis). MIBI = 99mTc-sestamibi
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BINNENWERK SLART  25-05-2005  13:06  Pagina 79study with 99mTc-tetrofosmin-FDG was performed by Fukuchi et al. (24), which showed a
good correlation between single-rest 99mTc-tetrofosmin and 99mTc-tetrofosmin images
obtained from a scatter corrected DISA SPECT 99mTc-tetrofosmin-FDG study.
Although theoretically 99mTc-sestamibi images could be degraded by scattered 511 keV
photons and poor count statistics due to the EHE collimator, our results showed no dif-
ference between the normalized dual and single isotope 99mTc-sestamibi uptake.The effi-
ciency ratio in count detecting of our EHE collimator compared to the LEHR collimator in
the 140 keV window is about 30%.Visual inspection showed no noticeable difference in
quality of the rest 99mTc-sestamibi and DISA SPECT 99mTc-sestamibi studies.The results
in our patients are in accordance with other comparable studies (15,22,24), and a car-
diac-phantom study (22). Scatter distribution in the technetium window can become sig-
nificant in physiologically unlikely situations of a fourfold increase of metabolism in
combination with a twofold reduced perfusion (22).
In all patients, the FDG scans were interpretable. However, in some patients image qual-
ity was suboptimal due to a heterogeneous FDG uptake.This has also been reported by
others (25,26). Image quality can be increased with an euglycemic hyperinsulinemic
clamp or the use of acipimox in order to lower the circulating free fatty acids and increase
the blood insulin concentration.This results in a more homogeneous myocardial glucose
and FDG uptake (25,27).
FDG as a viability tracer
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Figure 2. Example of a
patient with an irre-
versible perfusion
defect in the infero-lat-
eral with rest-stress
99mTc-sestamibi and a
perfusion-metabolism
mismatch in this area
with MIBI/FDG DISA
SPECT.
Left row: short axis.
Middle row: horizontal
long axis. Right row:
vertical long axis. MIBI
= 99mTc-sestamibi
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bly of SPECT acquisition of FDG with extra high energy collimators has been described
(11,28) and improvement of ventricular wall motion after revascularization could be
detected with a sensitivity and specificity of 84% and 86%, respectively (25). The FDG
uptake of SPECT and PET were highly concordant in three studies (12,13,29). Although
in these studies patients were not revascularized, it is to be expected that acquisition with
SPECT may replace PET for routine purposes.
We also found a small (7.6%) but significant increase in the number of viable regions with
FDG SPECT in comparison with rest-stress 99mTc-sestamibi. This is in accordance with
the general finding that 99mTc-sestamibi has a sensitivity somewhat lower than FDG for
detection of myocardial viability.
99mTc-sestamibi as a viability tracer
The application of 99mTc-labeled perfusion agents for the assessment of myocardial via-
bility has been debated. While some publications (30-32) indicate that 99mTc-sestamibi
SPECT can be used, other comparative studies report that 99mTc-sestamibi SPECT
underestimates myocardial viability in comparison with 201Tl (16,33) and FDG PET imag-
ing (8,16-18,34). Myocardial perfusion defects are usually larger with 99mTc-sestamibi
than with 13N-ammonia PET (17). However, Siebelink (35) et al. demonstrated no differ-
ence in patient outcome and cardiac event free survival between management based on
13N-ammonia/FDG PET and stress/rest 99mTc-sestamibi SPECT imaging.
In only in a small percentage (7.6%) of the irreversible perfusion defects a perfusion
metabolism mismatch consistent with myocardial viability was found. This may have 2
causes. In the first place this might be due to a selection bias since we excluded patients
with reversible perfusion defects. This suggests that we might have excluded patients
with viable myocardium, which also indicates that 99mTc-sestamibi might be a rather good
viability tracer in the majority of patients.However, our results also indicate that FDG may
give additional information in a selected group of patients that have already undergone a
rest-stress 99mTc-sestamibi study. Secondly, because we were not able to analyse wall
motion in all the patients it is possible that regions with wall motion abnormalities but
normal perfusion, which, by definition, were scored as normal in our study were in fact
dysfunctional (due to stunning) but viable myocardium.
Limitations
In this study we compared two scintigraphic techniques. Most patients were not revascu-
larized and also no systematic data on wall motion abnormalities were obtained from all
patients. Therefore, the detection of myocardial viability, i.e. improvement of local wall
motion after revascularization, could not be determined.
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This study shows that, without loss of image quality rest 99mTc-sestamibi images can be
acquired simultaneously with FDG using DISA SPECT. Therefore, dual isotope acquisi-
tion with FDG and 99mTc-sestamibi may become a clinically applicable routine method for
the assessment myocardial viability.Furthermore, signs of viability were found with 99mTc-
sestamibi-FDG DISA SPECT in a small, but significant number (7.6%) of regions with
irreversible perfusion defects on rest-stress 99mTc-sestamibi.
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Aim: Dual isotope simultaneous acquisition (DISA) SPECT is an attractive technique as
it permits assessment of both myocardial glucose metabolism and perfusion within in a
single session, but few data on its accuracy for assessment of viability are available as
yet. In the present study, DISA SPECT was compared with PET for the detection of
myocardial viability in normal and dysfunctional left ventricle (LV) myocardium.
Methods: Fifty-eight patients with chronic coronary artery disease and LV dysfunction
(LV ejection fraction 33 ± 12%) were studied. Patients underwent a 1-day dipyridamole
stress 99mTc-sestamibi/FDG DISA SPECT and 13N-ammonia/FDG PET protocol.Within 1
week, resting MRI was performed to assess contractile function.Comparison of PET and
SPECT data was performed using both visual and quantitative analysis.
Results: The correlation of normalized activities of the flow tracers 99mTc-sestamibi and
13N-ammonia was good, (r = 0.82; P < 0.001).The correlation between both FDG studies
was also good (r = 0.83; P < 0.001).The agreement for the assessment of viability for all
segments between DISA SPECT and PET was 82%, with a  -statistic of 0.59 (95% CI
0.53 - 0.64), without a significant difference; in dysfunctional segments only, the agree-
ment was 82%, with a  -statistic of 0.63 (95% CI 0.56 - 0.70), without a significant differ-
ence.When the DISA SPECT data were analyzed visually, the agreement between DISA
SPECT and PET was 83%, with a  -statistic of 0.58 (95% CI 0.52 - 0.63), without a sig-
nificant difference. Moreover, there was no significant difference between visual and
quantitative DISA SPECT analysis for the detection of viability.
Conclusion: This study shows an overall good agreement between 99mTc-sestamibi/
FDG DISA SPECT and PET for the assessment of myocardial viability in patients with
severe LV dysfunction. Quantitative or visual analysis of the SPECT data did not influ-
ence the agreement with PET, suggesting that visual assessment may be sufficient for
clinical purposes.
Keywords: myocardial viability, acipimox, FDG, DISA SPECT, PET.
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The assessment of myocardial viability has become an important aspect of the diagnos-
tic and prognostic work up of patients with coronary artery disease (CAD) and left ven-
tricular (LV) dysfunction. Patients with viable myocardium have been demonstrated to
benefit from revascularization, with an improvement in LV function and a favourable prog-
nosis after revascularization (1-4).
Positron emission tomography (PET) imaging using fluorine –18 fluorodeoxyglucose
(FDG) combined with a flow tracer such as nitrogen-13 ammonia (13N-ammonia) is an
accurate non-invasive diagnostic technique to distinguish viable myocardium from scar
tissue in patients with chronic coronary artery disease (4,5). However, the clinical use of
the technique is still limited owing to the restricted availability of PET equipment.To meet
the increasing demand, substantial effort has been invested in the development of single
photon emission computed tomography (SPECT) using extra-high energy collimators,
which may permit larger scale clinical use of FDG imaging (6-8). Another advantage of
SPECT with FDG is the possibility of dual-isotope simultaneous acquisition (DISA) in
which  99mTc-labeled myocardial perfusion agent and FDG can be imaged in a single
acquisition session. Besides the time saving effect of DISA, the simultaneous acquisition
also guarantees identical geometric registration of the patient for both sets of images.To
date, only two small patient studies have described the agreement in tracer distribution
between DISA SPECT and PET (7,9). In order to meet the clinical demand of viability
studies, the DISA SPECT protocol needs further adaptation to simplify the procedure, to
ensure high patient throughput. In particular, visual analysis of data may be preferred
over quantitative analysis, but currently no study has addressed this topic. Moreover, the
metabolic circumstances during FDG imaging are important and imaging following acip-
imox (Nedios®, Byk, The Netherlands), a nicotinic acid derivative, has been proposed as
the most simple approach, even in patients with diabetes mellitus (10-12).However, FDG
SPECT imaging following acipimox has also not been compared directly with PET imag-
ing. We performed a head-to-head comparison between DISA SPECT and PET using
both visual and quantitative analysis with patient preparation using acipimox, to study the
degree of agreement between these methods.
Materials and methods
Patients
Fifty-eight patients with chronic CAD and LV dysfunction were included (46 men, mean
age 65 ± 9 years, range 41-83). Thirty-eight patients (65%) had a history of myocardial
infarction (>3 months ago) and 17 patients (29%) had undergone previous revascular-
ization (>3 months before the study).The mean LV ejection fraction (LVEF) in the patient
group was 33 ± 12% and LVEF data was obtained with previous clinical multigated equi-
librium radionuclide angiography (ERNA) or gated SPECT (< 3 months before the study).
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glycemics and/or insulin.
Patients with unstable angina and/or heart failure requiring hospitalization were exclu-
ded. None of the patients had cardiac events or therapeutic interventions during the
study. All subjects signed an informed consent form based on the guidelines of the insti-
tutional ethics committee prior to participation in the study.
The PET and DISA acquisitions were performed on the same day, starting with PET
(schematic outline, see Figure 1). One minute after 13N-ammonia injection, 600 MBq of
99mTc-sestamibi was injected intravenously with the purpose for DISA acquisition later.
The DISA acquisition was performed later during the day, using the same FDG as
injected shortly before the PET images.Perfusion was studied during dipyridamole stress
to analyse viability in segments with chronic and/or reduced flow reserve; using this pro-
tocol, discrimination between stress-induced ischemia and viability (with resting hypop-
erfusion) is not possible, but for clinical purposes both represent jeopardized myocardium
which need to be revascularized.
Positron emission tomography
All anti-anginal medication and caffeine containing beverages were withdrawn at least 24
hr prior to the PET studies. Patients were prepared with a glucose-enriched breakfast.
Ninety minutes prior to FDG injection acipimox (500) mg was administered orally to lower
the circulating free fatty acids (11).To prevent side effects of acipimox (eg.skin rash), 250
mg of aspirin was administered orally 5 minutes before acipimox intake. Guided by the
plasma glucose levels, patients received additional insulin as previously described (12).
PET acquisition was performed on an ECAT-951/31 PET system (Siemens/CTI, Knox-
ville, TN, USA) imaging 31 planes over a total axial length of 10.8 cm.Following the trans-
mission scan (68Ge/68Ga rod sources), dipyridamole infusion (0.56 mg/kg/body weight in
6 minutes) was started.The dynamic acquisition procedure was started immediately after
injection of 400 MBq of 13N-ammonia, 6 minutes after start of dipyridamole infusion, and
continued for 15 minutes.After completion of the 13N-ammonia data acquisition, 400 MBq
of FDG was injected intravenously, followed by the PET dynamic acquisition procedure.
The total FDG PET acquisition time was 40 minutes, with the last 20 minutes acquired in
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Figure 1. Schematic outline of DISA SPECT and PET protocol.
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10 kcps (true coincidents).All gated FDG PET scans were obtained in phased mode, that
is, the length of each gate was optimized for the current RR-interval.The RR-interval was
allowed to vary by ± 10%.Data were corrected for attenuation with the transmission scan
and were reconstructed using filtered back-projection (Hann filter: 0.5 pixels/cycle).
After manual reorientation, 12 short-axis images of FDG and 13N-ammonia were
obtained with a plane thickness from 7 to 9 mm at an in-plane resolution of approximately
7 mm. Myocardial tissue was corrected for spillover of activity from the blood pool in the
LV  myocardium. For equal comparison of PET versus DISA, the dynamic PET studies
were transformed into static studies, as proposed by the clinical guidelines for interpreta-
tion and reporting (13). Frames of gated FDG PET were summed and used for further
data analysis. Similarly, the frames of the last 8 minutes of the 13N-ammonia acquisition
were summed and used for further analysis.
DISA SPECT
DISA SPECT acquisition was performed on the same day, 1 hr after completion of the
PET scan. In the 1-hour waiting time, patients received chocolate and coffee to enhance
hepatic clearance of 99mTc-sestamibi.A Siemens MultiSPECT dual-headed gamma cam-
era with extra-high energy (EHE) collimators (Siemens) was used, with only one head
activated during acquisition (360 degrees had no better results) (14,15).The resolution of
the EHE collimator is 10.4 mm full-width at half-maximum (FWHM) for 18F and 9.2 mm for
99mTc at 10 cm distance from the collimator face.Three energy windows were set at 140
(± 15%), 170 (± 20%) and 511 keV (± 15%). Sixty-four projections were acquired over a
circular orbit of 180° (45° RAO to 45° LPO;30 s per angle).The total acquisition time was
30 min. Planar 140 keV images were corrected for scatter by subtraction of the 170 keV
images using a convolution-based correction method (14,15). The planar FDG images
were corrected for the decay of 18F during acquisition. Short-, vertical -, and horizontal
long-axis images of FDG were reconstructed using filtered back projection with a Butter-
worth filter (Nyquist frequency 0.5, order 6 for both the FDG and 99mTc-sestamibi study).
In this way identically oriented FDG and 99mTc-sestamibi images were obtained from the
DISA SPECT acquisition.
Data analysis and viability criteria for PET and DISA SPECT
All data from the PET and DISA SPECT studies were re-orientated to short-axis, hori-
zontal and vertical long-axis sections. Data of FDG, 13N-ammonia and 99mTc-sestamibi
were analysed quantitatively and displayed in a 17-segment polar map as recently pro-
posed (16), using the 4D-MSPECT program, a commercially available cardiac software
package (developed by the University of Michigan Medical Center, Ann Arbor, MI, USA)
(17). Average counts per segment were obtained from the 17 segments and the meas-
ured counts were normalized to the segment with the highest average counts.
For both PET and DISA segments were considered to be viable when the perfusion activ-
ity was  75% or perfusion activity was  75% but FDG activity  10% than the perfusion
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(i.e. reduced resting flow with increased FDG uptake), but also (since dipyridamole per-
fusion was used) by (post-ischemic) stunning or stress-induced ischemia.
Segments were considered non-viable, when the normalized activity was  75% and the
difference in activities between the perfusion tracer and FDG was  10%. Segments were
subdivided in non-transmural scar tissue when the normalized perfusion activity was 
>25% and  75% with a FDG - perfusion tracer difference  10%. Segments were con-
sidered as transmural scar tissue when the normalized perfusion activity was  25% with
a FDG - perfusion tracer difference  10%.
For DISA SPECT, segmental 99mTc-sestamibi and FDG uptake were also scored visually
by two experienced observers in agreement using a 4-grade scoring system: 1 = normal
tracer uptake (activity 75-100%), 2 = moderately reduced tracer uptake (activity 50-75%),
3 = severely reduced tracer uptake (activity 25-50%) 4 = absent tracer uptake (activity 
 25%). Segments were considered viable when the perfusion tracer score was 1 or
when the FDG uptake grade score was higher than the 99mTc-sestamibi uptake score
(perfusion - FDG mismatch). Segments were considered as non-transmural scar tissue
when a perfusion defect (score 2 or 3) exhibited concordantly reduced FDG uptake (mild
to moderate match pattern). Segments were considered transmural scar tissue when a
perfusion defect (score 4) exhibited concordantly reduced FDG uptake (severe match
pattern).PET was used as the reference method for verification of all DISA SPECT data.
MRI to assess contractile function
Images were acquired on a 1.5 Tesla MRI system (Vision, Siemens Medical Systems,
Erlangen, Germany) equipped with high performance gradients (maximum gradient
strength = 40 mT/m; maximum slew rate = 200 mT/m/ms).Patients were examined in the
supine position using a flexible body array coil for signal reception.
Scout images depicting the myocardium were acquired in the coronal and sagital imag-
ing planes using a 2-D FLASH ECG-triggered sequence (one slice per heartbeat; TR =
40 – 100 ms, TE = 6 ms, flip angle = 58°, field of view (FOV) = 300 – 350 mm, slice thick-
ness = 8 mm) after which the short-axis plane was determined.The short-axis plane was
defined perpendicular to the LV long-axis from the center of the mitral annulus to the
apex.Slices were acquired at 8 to10 LV base to apex short-axis locations during repeated
breath-holds (± 15 seconds).Images were reconstructed using 2D-Fourier reconstruction
with in-plane matrix of 128 x 256 (reconstructed voxel size = 17.6 mm3).The TR were var-
ied depending on the R-R interval of the patient and the number of cardiac phases to be
imaged.A Sparc workstation (Sun Microsystems, Mountain View, CA, USA) was used for
further analysis of data. LV volumes were calculated from the MR images using previ-
ously validated automated software (MR Analytical Software System [MASS], Leiden,
The Netherlands) (18). The window width and window level settings were determined
automatically by scaling to the maximum grey scale. For the assessment of regional wall
motions, MRI images were visually interpreted by a single, experienced observer blinded
to the PET results. A 17-segment model was used and each segment was assigned a
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sia, 3 = akinesia, 4 = aneurysm pattern.
Statistical analysis
All results were expressed as mean ± SD.The comparison of segmental tracer uptake for
PET and DISA SPECT was evaluated by linear regression and correlation analysis
(Pearson correlation coefficient). The degree of agreement between segmental tracer
uptake in the same segments in PET and DISA studies was tested by Bland-Altman
analysis (19). Limits of agreement were calculated using the mean of the differences ±
SD.Agreement for viability in normal and dysfunctional segments was assessed from 2 x
2 and 3 x 3 tables using weighted kappa statistics. Kappa values of  0.4, between 0.4
and 0.75, and >0.75 were considered to represent poor, fair to good, and excellent agree-
ment, respectively, based on the Fleiss classification (20).The kappa values are reported
with their 95% confidence intervals (95% CI) and their SEs. McNemar test was used to
analyse concordancy in segments between DISA SPECT and PET. Statistical signifi-
cance was defined as P  0.05.
Results
Of 986 segments, 24 (2%) segments were excluded from further analysis because of
interfering overprojection of infra-diaphagmatical activity or misalignment of the left ven-
tricle in the field of view in the PET camera.Accordingly, 962 segments were used for fur-
ther analysis.
DISA SPECT versus PET, normalized tracer activities.
Linear regression revealed a high correlation between the normalized activity of the per-
fusion tracers 99mTc-sestamibi and 13N-ammonia (r =0.82; y =0.89x + 4.0; P  0.001).The
highest correlation was in the distal anterior segment (r =0.92; P  0.001), the lowest in
the basal inferior septal segment, although still significant (r =0.58; P  0.001).
Bland-Altman analysis revealed a difference of higher mean activity ratio of 13N-ammonia
versus 99mTc-sestamibi of 3.1 ± 10.7, but without a significant trend and within limits of 24
to -18%, (95% CI: 3.1 - 3.8, see Figure 2A). There was no tendency toward greater dif-
ferences at different mean uptake values.
The correlation between both FDG studies was also high (r =0.83; y =0.95 – 0.24;
P  0.001). The highest correlation between both studies was in the distal anterior seg-
ment (r =0.90; P  0.001), the lowest in the basal inferior septal segment, although still
significant (r =0.56; P  0.001). Bland-Altman analysis revealed a difference of higher
mean activity ratio of FDG PET versus FDG DISA SPECT of 3.6 ± 9.6, but without a sig-
nificant trend and within limits of 22 to -15% (CI: 3.6 - 4.2, see Figure 2B).
There was also no tendency toward greater differences at different mean uptake values.
DISA SPECT and PET agreement & myocardial viability | 91
BINNENWERK SLART  25-05-2005  13:06  Pagina 91DISA SPECT versus PET: quantitative assessment of viability in all segments
The agreement for tissue characterization in the 962 segments between DISA SPECT
and PET was 82%, with a  -statistic of 0.59 (95% CI 0.53 - 0.64;SE 0.027;see Figure 3).
There was no significant difference between DISA SPECT and PET in the detection of
viability in these segments (P = NS). Most discordant segments for the detection of via-
bility with DISA SPECT in comparison to PET were located in the basal anterior wall (25
of 51 (49%) segments), whereas the least false positive or false negative segments were
observed in the mid-inferior wall (3 of 58 (5%) segments).
DISA SPECT versus PET: quantitative assessment of viability in dysfunctional
myocardium
On MRI, 457 (47%) segments showed normal wall motion, whereas 505 (53%) segments
revealed abnormal wall motion. In particular, 368 segments were hypokinetic, 121 aki-
netic and 16 dyskinetic.
The agreement for the detection viability between DISA SPECT and PET in all 505 dys-
functional segments was 82%, with a  -statistic of 0.63 (95% CI 0.56 - 0.70; SE 0.034).
There was no significant difference between DISA and PET in the detection of viability in
segments (P = NS).
When the non-viable segments were divided into non-transmural and transmural scars,
the agreement was 79%, with a  -statistic of 0.62 (95% CI 0.53 - 0.70; SE 0.045; see
Table 1). According to PET, 239 (65%) of 368 hypokinetic segments were classified as
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plots illustrating the
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between 99mTc-ses-
tamibi versus 
13N-ammonia (A) and
FDG DISA SPECT
(FDGD) versus FDG
PET (FDGP) (B).
A
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dyskinetic segments, the agreement between PET and DISA SPECT was 83% (with 66
segments classified as viable on PET and 61 on DISA SPECT).
Visual analysis of DISA SPECT versus PET: assessment of viability in all
segments
The agreement for tissue characterization in the 962 segments between visual analysis
of DISA SPECT and quantitative PET was 83%, with a  -statistic of 0.58 (95% CI 0.52 -
0.63; SE 0.029; see Table 2).There was no significant difference between DISA SPECT
and PET in the detection of viability in these segments (P = NS).
Visual analysis of DISA SPECT: assessment of viability in dysfunctional
myocardium.
The agreement for the detection of viability between visual analysis of DISA SPECT and
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Figure 3. Short-axis series of a corresponding DISA SPECT and PET study. Of note, both series
(PET and DISA SPECT) show reduced myocardial perfusion with preserved FDG uptake in the infe-
rior wall, indicating viable tissue.
Table 1. Agreement for the detection of viable, non-transmural (NTM) and transmural (TM) dys-
functional segments of DISA SPECT vs PET (n = 505 segments).
PET viable PET NTM PET TM
DISA viable 245 31 0
DISA NTM 59 154 3
DISA TM 1 8 4
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0.83; SE 0.028).
When the visual and quantitative SPECT data were compared directly, there was no sig-
nificant difference between the visual and quantitative DISA SPECT analysis in the
detection of viability in all segments (P = NS).The agreement for the detection viability in
all 505 dysfunctional segments between visual and quantitative analysis DISA SPECT
was 86%, with a  -statistic of 0.72 (95% CI 0.65 - 0.77; SE 0.031).
Discussion
The most important finding of this study was a good agreement between DISA SPECT
and PET for the assessment of viability for all or dysfunctional segments, without a sig-
nificant discordance. In addition, visually or quantitatively analyzed DISA SPECT data
compared equally with the PET data.These observations suggest that DISA SPECT pro-
vides adequate information on myocardial viability and visual analysis of data may be suf-
ficient for clinical purposes.
Comparison to previous studies
The normalized regional acitivity of 99mTc-sestamibi correlated well with 13N-ammonia, as
was the case for the normalized FDG SPECT and PET activities. These findings are in
line with previous studies: Srinivasan et al. analyzed the correlation between FDG DISA
SPECT and FDG PET in 28 patients with CAD and found an overall good agreement
(94%) and correlation (r = 0.81, slope = 0.79), with a mean difference of 9.6% between
both techniques (21). Also the study of Fukuchi et al. resulted in comparable FDG find-
ings in 18 patients with CAD, using 99mTc-tetrofosmin/ FDG DISA SPECT in comparison
to PET (r = 0.86,  -statistic of 0.67) (7). Direct comparison of the perfusion tracers 99mTc-
sestamibi/ FDG DISA SPECT and 13N-ammonia PET are scarce.The only such study to
have been publicated was a small investigation by Matsunari et al., who analyzed the
concordance and discordance of 99mTc-sestamibi/FDG DISA SPECT and 13N-ammonia/
FDG PET in ten patients with CAD on the basis on the difference between the perfusion
tracer and FDG with the two techniques (9).
Similar to the agreement in perfusion values, we also found a very good overall  agree-
ment using PET or DISA for the assessment of myocardial viability, both in segments with
normal wall motion and in dysfunctional segments. In dysfunctional myocardium in par-
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Table 2. Agreement PET and visual analysis DISA SPECT (V-DISA) for the detection of in all viable
and non-viable segments (n = 962 segments).
PET viable PET non-viable
V-DISA viable 667 44
V-DISA non-viable 36 215
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ered for revascularization (3,22,23).The agreement in dysfunctional segments was 82%
when quantitative DISA SPECT was compared with PET and also 82% when visually
analyzed DISA SPECT was compared with PET.These observations are in line with pre-
vious studies comparing FDG PET and SPECT in the same patients.The available stud-
ies are summarized in detail in Table 3. This summary indicates also that the direct
comparisons between PET and SPECT are still limited (n= 6, with 131 patients). This
pool will be enlarged by the addition of our data, which also focus on other important
issues not addressed previously.
A first difference between published studies and the current one is that the majority of
these studies (5 out of 6) did not perform DISA SPECT, but rather performed sequential
perfusion and FDG SPECT imaging.Currently, state-of-the-art FDG imaging with SPECT
may utilize dual-isotope imaging and simultaneous acquisition, as used in the current
study.DISA SPECT offers important advantages, including shorter imaging time and per-
fect alignment between perfusion and FDG images.
A second difference is that 3 out of 6 studies were not performed in patients with severe
LV dysfunction, although these are the patients who need viability assessment in order to
justify the enhanced risk of revascularization (24-27). For this reason, only patients with
a LVEF   35% were included in the current study, and the findings indicate that FDG
SPECT also compares well to PET in this subset of patients.
A third difference is that the majority of the available studies performed visual or quanti-
tative analysis of the data, whereas both quantitative and visual analysis were performed
in the present study.Furthermore, the metabolic conditions during which FDG imaging is
performed are important. This is the first study that reports on FDG imaging with both
SPECT and PET after administration of acipimox, which is the most simple and patient-
friendly approach and ensures good image quality in virtually all patients, even in those
with diabetes if whom insulin is co-administered (12).
Finally, the imaging protocol used in the present study was not used previously (Table 3),
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Table 3: Head-to-head comparison between FDG SPECT or DISA SPECT and FDG PET for the
evaluation of myocardial viability (131 patients, 6 studies)
Author (ref) Patients Imaging Metabolic  Perfusion Data LVEF(%) Agreement(%)
(n) approach circumstances tracer analysis or Kappa ( )
Burt (34) 20 sequential oral glucose load 201Tl at rest Visual NA 93
Martin (35) 9 sequential oral glucose load MIBI or 201Tl at rest Visual NA 100
Bax (36) 20 sequential clamp 201Tl at rest Quant 39±16 76
Chen (37) 36 sequential oral glucose load 82Rb stress & rest Quant NA 90
Srinivasan (21) 28 sequential oral glucose load 201Tl stress & rest Quant 33±15 94
Fukuchi (7) 18 DISA oral glucose load 99mTc-tetrof. at rest Quant 35±9   = 0.67
Present study 58 DISA Acipimox MIBI stress Quant 33±12 82
Ref = reference; LVEF = left ventricular ejection fraction; DISA; dual isotope simultaneous acquisi-
tion; MIBI = 99mTc-sestamibi; 99mTc-tetrof = 99mTc-tetrofosmin; Quant = quantitative; NA = not avail-
able.
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resting perfusion images no longer allows discrimination between repetitively stunned
myocardium (with normal resting perfusion) and hibernating myocardium (with reduced
resting perfusion), this information is mainly of interest for research purposes.Other stud-
ies have demonstrated that resting perfusion was near normal in chronic dysfunctional
myocardium (28,29).Vanoverscheldeet al. observed similar levels of perfusion with PET
in regions with normal contraction and regions with chronic dysfunction (29). These
authorsshowed that instead of resting flow, flow reserve was reducedin dysfunctional but
viable myocardium (29). Based on their observations, Vanoverschelde and co-workers
suggested that repeated ischemic attacks may result in chronic dysfunction, with flow
remaining normal or mildly reduced, a condition referred to as repetitive stunning (30).
The current DISA SPECT study, however aimed at providing a simple protocol for detec-
tion of viability of hibernating myocardium and dysfunctional myocardium based on
reduced flow reserve.
In the present study, most segments that yielded discordant results for assessment of via-
bility were located in the basal anterior wall; the precise reason for that finding is unclear.
Considering the difference in photon energies between 18F and 99mTc, one would anticipate
the most discrepancies in the inferior and septal regions, which are the regions most sus-
ceptible to attenuation. The present data, however, suggest that attenuation does not
markedly influence the identification of viable myocardium using DISA SPECT. Most
importantly, no specific over- or underestimation of viability by SPECT was observed.
Furthermore, 65% of the hypokinetic segments were classified as viable on PET, as com-
pared to 58% on DISA SPECT (agreement 79%). In hypokinetic segments more viability
would be presumed. However, many dysfunctional segments showed severe hypokine-
sia, probably due to the presence of non-viable myocardial tissue. This may explain the
high percentage of severe hypokinetic, but non-viable segments. The observation is in
line with previous studies (31).
Clinical implications
The protocol described for DISA SPECT is a simple approach, and may allow high
patient throughput, in order to meet the increasing demand for viability studies with the
exponentially increasing number of patients presenting with ischemic cardiomyopathy
(32). In particular, the use of acipimox may further simplify the procedure and still ensure
good image quality.
One open issue was the analysis of data. Quantitative analysis is considered the most
accurate form of analyzing the data, although for routine clinical purposes visual analysis
may be preferred.To date, a systematic comparison of visual and quantitative analysis of
FDG SPECT data is not available. The findings in the current study indicate that both
analyses compared equally to FDG PET suggesting that visual analysis may be sufficient
in the clinical setting.
All analyses of data were performed with 4D-MSPECT.Besides extensive analysis of the
perfusion and FDG data, this program does also allow assessment of function when data
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LV  dysfunction who need viability testing, since LVEF, LV volumes and regional wall
motion may then be determined in one imaging session.
Study limitations
The major limitation of the study is the lack of assessment of outcome after revascular-
ization. A direct comparison between DISA SPECT and PET against the gold standard
i.e.improvement of wall motion after revascularization is needed before definitive conclu-
sions can be drawn.
Another, technical limitation hampering the current direct comparison of DISA SPECT
and PET is that the SPECT data were not corrected for attenuation. Attenuation correc-
tion may improve the accuracy for detection of myocardial viability (33). Additional stud-
ies specifically addressing the issue of (correction for) attenuation are needed. Also the
delay of FDG injection and DISA SPECT acquisition may possibly influence the quality of
the DISA SPECT images.To overcome the problems of radiation decay patients were in-
jected with 400 MBq FDG instead of the usual dose of 200 MBq in our hospital.
Conclusion
This study shows good overall agreement between 99mTc-sestamibi/FDG DISA SPECT
and PET for the assessment of myocardial viability in patients with severe LV dysfunction.
Agreement with PET was similar with quantitative or visual analysis of the SPECT data,
suggesting that visual assessment may be sufficient for clinical purposes. The use of
acipimox simplifies the DISA SPECT procedure and still ensures reliable assessment of
myocardial viability with FDG.
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Background: FDG PET is an important modality for myocardial viability assessment in
patients with left ventricular (LV) dysfunction. Dual isotope simultaneous acquisition
(DISA) SPECT may be an alternative to PET.The aim of this study was to compare the
diagnostic performance of PET and DISA SPECT for the prediction of regional function,
global LV function and LV remodelling in patients with LV dysfunction undergoing revas-
cularization.
Methods and Results: Patients (n=47) with chronic coronary artery disease and LV dys-
function underwent DISA SPECT (with 99mTc-sestamibi and FDG) and PET (with 13N-
ammonia and FDG) on the same day.ROC analysis was applied to determine the optimal
cutoff values in viability assessment. Segmental and global functional recovery as deter-
mined by serial MRI serving as the reference method for viability.
Of 264 revascularized dysfunctional segments, 143 (54%) recovered in function.For pre-
diction of improvement in regional LV function, PET and DISA SPECT had similar sensi-
tivity (90% vs 89%, (P = NS)) and specificity (86% vs 86%, (P = NS)). For prediction of
improvement in global LV function, sensitivity was 83% for DISA SPECT and 86% for
PET (P = NS), at specificity of 100% for both. Reverse LV remodeling occurred in viable
patients after revascularization, whereas nonviable patients showed further LV dilatation
after revascularization. Sensitivity and specificity for the prediction of LV reverse remod-
eling were similar for DISA SPECT and PET.
Conclusion: In patients undergoing revascularisation, DISA SPECT and PET predict the
improvement in regional LV function, global LV function and LV remodeling equally well.
Key Words: myocardial viability, prediction, functional LV recovery, DISA SPECT, PET
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The assessment of myocardial viability has become an important aspect of the diagnos-
tic and prognostic work-up of patients with coronary artery disease (CAD) and left ven-
tricular (LV) dysfunction. Patients with viable myocardium benefit from revascularization,
in terms of an improved LV function and a favourable long-term prognosis after revascu-
larization (1,2).
Positron emission tomography (PET) imaging using fluoride –18 fluorodeoxyglucose
(FDG) combined with a flow tracer (e.g. 13N-ammonia) is an accurate non-invasive diag-
nostic technique to distinguish viable myocardium from scar tissue in patients with
chronic coronary artery disease (2,3). However, for routine clinical use this PET tech-
nique is less available, more expensive and time consuming compared to (single photon
emission computed tomography) SPECT. For the production of the required perfusion
tracers such as 13N-ammonia or 15O-water, a cyclotron is necessary.Generator-produced
Rubidium-82 chloride (82Rb) can be used as an alternative perfusion PET tracer, but is
relatively expensive, especially when infrequently used.
To  meet the increasing demand for viability studies (4), substantial effort has been
invested in the development of (SPECT) methods. Using extra-high energy collimators,
FDG imaging is possible, and this may permit clinical use of FDG imaging on a large
scale (5-7). Another advantage of SPECT is the possibility of dual-isotope simultaneous
acquisition (DISA) in which a 99mTc-labeled myocardial perfusion agent and FDG can be
performed in a single session. DISA SPECT allows for shorter duration of procedures,
and guaranties an identical geometric registration of the different isotope images.Despite
these potential advantages, DISA SPECT imaging has not been validated in a direct
head-to-head comparison with PET imaging in patients with LV dysfunction, using opti-
mal reference methods. Therefore, the aim of this study was to prospectively study the
diagnostic performance of DISA SPECT and PET in the prediction of LV improvement
after revascularization in the same group of patients with chronic ischemic LV dysfunc-
tion, using magnetic resonance imaging (MRI) before and after revascularision as the ref-
erence method, and coronary angiography for quality control. As the optimal cut-off
points in viability assessment in DISA SPECT and PET imaging are unclear, we first per-
formed receiver operating characteristics (ROC) analysis on DISA SPECT and PET data,
and used the results in the final viability assessments. Finally, we evaluated the relation
between patient characteristics and the prediction of LV improvement after revascular-
ization.
Materials and methods
Patients
Between April 2000 and July 2003, we included 47 consecutive patients with chronic
CAD and LV dysfunction (41 men, mean age 65 ± 9 years, range 41 to 82) referred for
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north of the Netherlands.Thirty-four patients (72%) had a history of myocardial infarction
(>3 months ago) and 14 patients (29%) had undergone previous revascularization (>3
months before the study).The mean LV ejection fraction (LVEF) in the patient group was
33 ± 12% at rest, estimated from equilibrium radionuclide angiography (ERNA) or gated
myocardial perfusion SPECT.The patients had on average 2.4 ± 0.8 stenosed coronary
arteries on coronary angiography.Ten patients had diabetes mellitus, that was well-regu-
lated by combinations of oral hypoglycemics and insulin in all cases, as this is required
for optimal FDG uptake and image quality. Patients with unstable angina or heart failure
requiring hospitalization were excluded. None of the patients had cardiac events during
the study and the 6-months follow-up period.
The study procedures are outlined in Figure 1.
PET and DISA SPECT acquisition were per-
formed on the same day. Assessment of con-
tractile function by MRI was performed within
one week after DISA SPECT/PET and was
repeated 6 months after revascularization. All
surgeons and cardiologists were blinded to the
PET and DISA SPECT results. Coronary an-
giography was repeated 6 months after revas-
cularization to exclude re-occlusion of the
revascularized coronary arteries or bypass
grafts.The study protocol was approved by the
Medical Ethics committee of our institution and
all patients gave written informed consent. To
improve the quality of reporting the diagnostic
accuracy of this study, the Standards for
Reporting of Diagnostic Accuracy (STARD)
stategy was used (8).
Positron emission tomography
All anti-anginal medication and caffeine containing beverages were withdrawn at least 24
hours prior to the PET and SPECT studies. The PET and DISA SPECT protocol is out-
lined in Figure 2. Patients used a glucose-enriched breakfast. Ninety minutes prior to
FDG injection, 500 mg acipimox (Nedios, Byk, The Netherlands), was administered orally
to lower circulating free fatty acids (9).To prevent side-effects of acipimox (eg. skin rash),
250 mg of aspirin was administered orally 5 minutes before acipimox intake. Guided by
the plasma glucose levels, 4 patients received additional insulin as previously described
(10). In short, in patients with a plasma glucose level >9 mmol/L at baseline, 6 units of
insulin were administered subcutaneously. When plasma glucose levels remained >9
mmol/L, additional insulin was administered.
We used an ECAT-951/31 PET scanner (Siemens/CTI, Knoxville, TN, USA), that acquires
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procedures. CAG: coronary angiography.
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68Ge/68Ga rod sources), 0.56 mg/kg/body dipyridamole was infused in 6 minutes. Two
minutes after the end of the dipyridamole infusion, 400 MBq of 13N-ammonia was
injected. Dynamic data of 13N-ammonia were then acquired over 15 minutes. After com-
pletion of the 13N-ammonia data acquisition, 400 MBq of FDG was injected intravenously,
followed by a PET dynamic acquisition procedure. The total FDG PET acquisition time
was 40 minutes, with the last 20 minutes acquired in gated mode with 16 frames per car-
diac cycle.The length of each gate was based on the current RR-interval.The RR-interval
was allowed to vary by ± 10%. Data were corrected for attenuation using the transmission
scan and were reconstructed using filtered back-projection (Hann filter: 0.5 pixels/cycle).
After manual reorientation, 12 short-axis images of FDG and 13N-ammonia were
obtained with a plane thickness of 7 mm at an in-plane resolution of approximately 7 mm.
Myocardial tissue activity was corrected for spillover of activity from the LV cavity. For
equal comparison of PET versus DISA SPECT, the frames of the last 8 minutes of the
13N-ammonia acquisition were summed and used for further analysis. Similarly, all 16
frames of gated FDG PET were summed and used for further data analysis.
DISA SPECT
DISA SPECT acquisition was performed on the same day as the PET scan, 1 hour after
the completion of the PET study (Figure 2). A Siemens MultiSPECT dual-headed gamma
camera (Siemens Medical Systems, Hoffman Estates, IL, USA) with extra-high energy
(EHE) collimators was used. EHE collimators are needed to permit imaging of the high
energy (511 KeV) photons. The resolution of the EHE collimator is 10.4 mm full-width at
half maximum (FWHM) for 18F and 9.2 mm for 99mTc at 10 cm distance from the collimator
face.Three energy windows were set at 140 (± 15%), 170 (± 20%) and 511 keV (±15%).
Sixty-four projections were acquired over a circular orbit of 180° (from the 45° RAO to the
45° LPO position with 30 s per angle).The total acquisition time was 30 minutes.
Planar 140 keV images were corrected for scatter by subtraction of the 170 keV images
using a convolution-based correction method (11,12).The planar FDG images were cor-
rected for the decay of 18F during acquisition, because the relative short half-life time of
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and short-axis images of 99mTc-sestamibi and FDG were reconstructed using identical
axes and filtered back projection with a Butterworth filter (Nyquist frequency 0.5, order 6
for both the FDG and 99mTc-sestamibi study). In this way identically oriented FDG and
99mTc-sestamibi images were obtained from the DISA SPECT acquisition.
Coronary angiography
Repeat coronary angiography was applied by a femoral approach using the standard
Judkins technique and performed by a cardiologist blinded to all study data.After the pro-
cedure, a trained observer interpretated all angiographic findings independently.A signif-
icant re-stenosis or new stenosis was defined as >70% stenosis (percent luminal
diameter narrowing).
MRI to assess contractile function
Images were acquired on a 1.5 Tesla MRI system (Vision, Siemens Medical Systems,
Erlangen, Germany) equipped with high performance gradients (maximum gradient
strength = 40 mT/m; maximum slew rate = 200 mT/m/ms).Patients were examined in the
supine position using a flexible body array coil for signal reception. Scout images depict-
ing the myocardium were acquired in the coronal and sagital imaging planes using a 2-D
FLASH ECG-triggered sequence (one slice per heartbeat;TR = 40 – 100 ms, TE = 6 ms,
flip angle = 58°, field of view (FOV) = 300 – 350 mm, slice thickness = 8 mm) after which
the short-axis plane was determined.The short-axis plane was defined perpendicular to
the LV long-axis from the center of the mitral annulus to the apex.Slices were acquired at
8 to10 LV base to apex short-axis locations during repeated breath-holds (± 15 seconds).
Images were reconstructed using 2D-Fourier reconstruction with in-plane matrix of 128 x
256 (reconstructed voxel size = 17.6 mm3). The TR was varied depending on the R-R
interval of the patient and the number of cardiac phases to be imaged.
For analysis of data we used a Sun Sparc workstation (Sun Microsystems, Mountain
View, CA, USA).Global LV function, i.e.LVEF, and LV volumes were derived from the MR
images using previously validated automated software (MR Analytical Software System
[MASS], Leiden, The Netherlands) (13). An improvement in LVEF ≥ 5% after revascular-
ization was clinically considered significant (14). Reverse remodeling (reduction of LV
end-diastolic and end-systolic volumes) of 10% in LVEDV and LVESV after revascular-
ization was clinically considered significant (15).
Assessment of regional wall motion was performed visually by an experienced observer
blinded to the clinical data and PET results. Baseline and follow-up MRI studies were
interpreted in random order. A 17-segment model was used and each segment was
assigned a wall motion score using a 4-point scoring system (1 = normal wall motion, 2
= hypokinesia, 3 = akinesia, 4 = dyskinesia). An improvement in regional wall motion
post-revascularization by 1 grade or more was considered significant. Of note, a change
from dyskinetic to akinetic was not considered to represent improvement in function, but
a mechanical phenomenon (16).
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Data from FDG PET and FDG SPECT, 13N-ammonia PET and 99mTc-sestamibi SPECT
were analysed quantitatively and displayed in a 17-segment polar map as recently pro-
posed (17), using the 4D-MSPECT program, a commercially (Siemens Medical Systems,
Hoffman Estates, Ill) available cardiac software package (18). Average counts per seg-
ment were obtained from the 17 segments and the measured counts were normalized to
the segment with the highest average counts.
In general, segments are considered viable when FDG uptake is higher than perfusion
tracer uptake (called a perfusion-metabolism mismatch). As the optimal decision level of
this difference is not well described in the literature, ROC curve analysis was used both
for PET and DISA SPECT to determine the optimal cutoff value for this difference in
tracer uptake of FDG and perfusion, using recovery of function on MRI as the gold stan-
dard for viability (19,20). The output of ROC analysis is a area-under-the curve value
between 0 and 1.The performance of a diagnostic test can be generally classified using
this ROC AUC value, as follows: 0.90-1 = excellent, 0.80-0.90 = good. 0.70-0.80 = fair,
0.60-0.70 = poor, 0.50-0.60 = test without value.
Statistical analysis
Regional function
Descriptive results were expressed as mean ± SD.Patient data were compared using the
Student t test for (un)paired data when appropriate. Fisher’s exact test was used for cat-
egorical data. Sensitivity and specificity for the prediction of improvement of regional
function were subsequently determined. McNemar’s test was used to compare the sen-
sitivity and specificity to predict improvement in regional function post-revascularization
between DISA SPECT and PET.
Global function 
Multivariate and univariate logistic regression analysis was performed to determine
which variables best predicted improvement in LVEF after revascularization.The relation
between the number of dysfunctional and viable (or non-viable) segments and the
change in LVEF after revascularization was determined by linear regression analysis.
Another ROC curve analysis was performed to determine the optimal number of
dysfunctional but viable segments on PET and DISA SPECT, allowing discrimination be-
tween patients with and without improvement in LVEF (≥5%) (14). Sensitivity and spe-
cificity for the prediction of improvement in global LV function (LVEF) were subsequently
determined. Sensitivity and specificity were also calculated to predict LV reverse remod-
elling (defined as a reduction by 10% or more in LV volumes).McNemar test was used to
compare the sensitivity and specificity between DISA SPECT and PET to predict
improvement in LVEF and LV reverse remodelling after revascularization. A P-value 
< 0.05 was considered significant.
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Forty-seven patients underwent revascularization, in particular 27 patients underwent
CABG and 20 patients underwent PTCA (mean number of target vessels per patient: 2.1
± 1).The procedures were uncomplicated. Repeat coronary angiography (to assess ves-
sel- or graft-patency) was performed in 33 patients demonstrating that 4 bypass grafts
were occluded and 5 lesions after PTCA showed re-stenosis.The remaining patients who
did not undergo repeat coronary angiography did not have recurrent symptoms after
revascularization.
Of all 799 myocardial segments in the 47 patients, 18 (2%) segments were excluded from
further analysis because of technical reasons. Another 38 (4%) segments allocated to
the vessels/grafts with a re-stenosis or occlusion were also excluded.
Data analysis was based on the remaining 743 segments.Of these, 421 (57%) segments
had contractile dysfunction. Out of these 421 dysfunctional segments, 264 segments
belonged to the distribution area of revascularized vessels. These 264 segments were
used for the final analysis.Of these 264 revascularized segments, 174 (66%) were hypo-
kinetic and 90 (34%) were a- or dyskinetic before revascularisation.
PET and DISA SPECT viability criterion assessment.
Using ROC analysis, a difference of 7% in relative segmental uptake was identified as the
optimal difference between metabolism and perfusion (FDG uptake and 13N-ammonia
uptake) on PET, with an AUC
value of 0.89 ± 0.02, considered
very good – excellent. For DISA
SPECT, this difference was 9%
for FDG uptake and 99mTc-ses-
tamibi uptake with an AUC value
of 0.90 ± 0.02, considered excel-
lent.The difference between PET
and DISA SPECT was not signif-
icant (Figure 3).
Accuracy of PET vs DISA
SPECT for the prediction of
regional recovery
Of all 264 dysfunctional seg-
ments, 143 (54%) recovered in
function on the follow-up MRI
performed 6 months after revas-
cularization (Figure 4). Of these
143 recovered segments, 130
(90%) segments were classified
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Figure 3. ROC curves for PET and DISA SPECT for the
prediction of myocardial viability as defined by the differ-
ence between FDG and the perfusion tracer. The area
under the curve (AUC) for PET of 0.89 ± 0.02 and for DISA
SPECT is 0.90 ± 0.02 (P = NS).
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incorrectly identified as viable by PET (P for difference <0.05).Therefore PET had a sen-
sitivity for the prediction of viability and subsequent functional recovery of 90% at a speci-
ficity of 86%.
Viability on DISA SPECT was present in 128 (89%) segments with functional recovery,
as compared to only 17 (14%) of the segments without functional recovery (P <0.05).
Accordingly, the sensitivity for the prediction of functional recovery of DISA SPECT was
89% at a specificity of 86%. This performance of DISA SPECT and PET in the viability
assessment and functional recovery prediction was not different (P =NS).
Sensitivity and specificity were also assessed for hypokinetic and a-/dyskinetic segments
separately. Of the 174 hypokinetic segments, 108 (62%) showed recovery of function
after revascularization.The sensitivity and specificity of PET imaging were 90% and 86%,
whereas the sensitivity and specificity of DISA SPECT were 87% and 85%. Of the 90 a-
/dyskinetic segments, 35 (38%) recovered in function after revascularization.The sensi-
tivity and specificity of PET were 89% and 84% respectively and for DISA SPECT 87%
and 83%.There was no significant difference between DISA SPECT and PET for the pre-
diction of recovery.
Effect of revascularization on global LV function
The mean LVEF in the whole group of 47 patients improved from 33 ± 12% to 40 ± 14%
(P < 0.001).
A strong direct linear relation was found between the number of viable segments on both
PET and DISA SPECT and the magnitude of improvement in LVEF, suggesting that the
extent of viability determined the magnitude of improvement in LVEF after revasculariza-
tion (P <0.001) (Figure 5a and b). Similarly, a (weaker) inverse relation was observed
between the number of non-viable segments on PET and DISA SPECT and the magni-
tude of improvement in LVEF (y = -1.6 + 11.4, r = 0.45, P < 0.005;y = -1.3 + 10.9, r = 0.39,
P < 0.005, respectively).
In individual LVEF assessment,
we  found a clinically significant
improvement in LVEF (≥ 5%) in
27 (57%) patients.The character-
istics of the patients with and
without improvement in LVEF are
summarized in Table 1.Univariate
analysis (including age, gender,
previous myocardial infarction,
NYHA class, LVEF, number of
stenosed vessels, previous
CABG/PTCA, diabetes, number
of viable/nonviable segments on
PET and DISA SPECT) indicated
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Recovery
of function
n=12 (8%)
Non-recovery
of function
n=145 (92%)
Non-revascularized
n=157
Recovery
of function
n=143 (54%)
Non-recovery
of function
n=121 (46%)
Revascularized
n=264
Dysfunctional segments
n=421
All segments
n=743
Figure 4. Recovery of dysfunctional segments after
revascularization
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the only predictors of improvement in LVEF after revascularization. Multivariate analysis
showed that the number of viable segments was the strongest predictor for improvement
in LVEF.
ROC analysis was used to assess the number of viable segments detected on PET and
DISA SPECT and improvement of LVEF (  5%) after revascularization.The optimal cut-
off level for a correct prediction of LVEF improvement was   2 viable segments for PET
and DISA SPECT with an excellent accuracy (AUC 0.97 ± 0.02 and 0.96 ± 0.02 respec-
tively, P = NS) (Figure 6).At this optimal cutoff level, sensitivity and specificity for the pre-
diction of improvement in global LVEF for PET were 86% and 100% respectively, and for
DISA SPECT 83% and 100%, respectively.This prediction performance of PET and DISA
SPECT were similar (P = NS).
Effect of revascularization on LV remodeling.
After revascularization, the LVEDV and LVESV in patients with more than 2 viable revas-
cularized segments estimated from PET (n = 31) and DISA SPECT (n = 30) decreased
significantly (Table 2). Inversely, LVEDV and LVESV worsened significantly in patients
considered non viable (who had < 2 viable revascularized segments) according to PET
(n=16) and DISA SPECT (n=17) (Table 2).
The sensitivity and specificity of PET for the prediction of reverse remodeling of ≥ 10%
(mL) in LVEDV was 95% and 65%, respectively, whereas the sensitivity and specificity of
DISA SPECT was 95% and 69%, respectively (P = NS).The sensitivity and specificity of
PET for the prediction of reverse modeling of ≥ 10 % (mL) in LVESV was 96% and 79%,
respectively, whereas the sensitivity and specificity of DISA SPECT was 99% and 84%,
respectively (P= NS).
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Figure 5. Scatterplots showing the relation between number of viable segments on PET (A) and
DISA SPECT (B) and the change in LVEF after revascularization.
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FDG PET is considered the technique of choice for assessment of myocardial viability,
and subsequent prediction of recovery of function post-revascularization. Head-to-head
comparative studies between FDG imaging with PET and SPECT in patients undergoing
revascularization have not been reported thusfar. The most important findings of this
study can be summarized as follows.First, ROC curve analysis identified the optimal cut-
off values for perfusion-FDG mismatches. For PET, a 7% difference between FDG activ-
ity and 13N-ammonia activity was optimal and yielded a sensitivity and specificity of 90%
and 86% to predict improvement of regional function. For SPECT, a 9% difference
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Figure 6. ROC curves for PET and DISA
SPECT showing both the optimal cutoff
level of 2 dysfunctional but viable seg-
ments (≥ 2) yielding highest sensitivity
and specificity to predict LVEF improve-
ment of ≥ 5% on patient basis.The area
under the curve (AUC) for PET of 0.97 ±
0.02 and for DISA SPECT is 0.96 ± 0.02
(P = NS).
Table 1. Characteristics of patients with and without improvement in LVEF after revascularization.
Pts with improved  Pts without improved P-value
LVEF (n = 27) LVEF (n = 20)
Age (yrs) 62 ± 9 68 ± 9 <0.05
Gender (M/F) 22/5 19/1 NS
Previous infarction 18 (66%) 16 (80%) NS
NYHA class 2.8 ± 0.9 2.9 ± 0.9 NS
Diabetes 5 5 NS
Previous PTCA/CABG 10 4 NS
Nr stenosed vessels 2.6 ± 0.6 2.3 ± 1.1 NS
LVEF (%) 32 ± 12 33 ± 10 NS
LVEDV (mL) 145 ± 50 149 ± 74 NS
LVESV (mL) 98 ± 46  113 ± 82 NS
Nr.viable segs on SPECT 4.1 ± 2.2 1.8 ± 1.8 <0.001
Nr non-viable segs on SPECT 2.1 ± 2.3 3.0 ± 2.6 NS
Nr viable segs on PET 4.3 ± 2.1 1.8 ± 1.6 <0.001
Nr non-viable segs on PET 1.8 ± 2.2 3.0 ± 2.4 NS
CABG: coronary artery bypass grafting; LVEF: left ventricular ejection fraction;
NYHA: New York Heart Association; PTCA: percutaneous transluminal coronary angioplasty;
Segs: segments.
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89% and 86% (both NS versus PET). Second, for prediction of improvement in LVEF the
sensitivities and specificities were good both for PET (86% and 100%) and for SPECT
(83% and 100%, NS versus PET). Finally, for prediction of LV reverse remodeling the
sensitivity and specificity were good for PET and SPECT, without significant differences.
These results indicate that SPECT and PET have identical value in the evaluation of
myocardial viability and prediction of functional recovery.
Comparison of modalities in previous studies: SPECT versus PET
The high spatial resolution, high-count-density images and the possibility for attenuation
correction of PET, allows accurate assessment of regional uptake using FDG and 13N-
ammonia irrespective of weight or body habitus of patients.The poorer spatial resolution
of SPECT, the lower sensitivity and the lack of attenuation correction in most cases may
cause some discordance between SPECT and PET images (21,22).The clinical feasibil-
ity of imaging positron emitters such as FDG with EHE collimators SPECT techniques
has been reported previously (23,24). Few studies have focused on the comparison of
FDG SPECT and FDG PET, but showed a good agreement in the assessment of viabil-
ity (25-29). The most detailed comparison was performed by the National Institutes of
Health group (29). The investigators studied 28 patients with CAD and a mean LVEF of
33 ± 15%.These patients underwent both FDG SPECT and FDG PET after oral glucose
loading with the addition of intravenous insulin if needed. Regional LV function was eval-
uated with gated SPECT or ERNA.When a 50% FDG uptake threshold was used to dis-
112 | Chapter 6
Table 2. Ongoing remodeling or reverse remodeling of the left ventricle in viable patients (≥ 2 revas-
cularized myocardial segments) or non viable patients (< 2 viable revascularized segments).
Non viable patients
LVEDV LVEDV mean P LVESV LVESV mean P
Pre Post difference Pre Post difference
PET 
non viable 152±64 169±80 +17±36 <0.05 103±54 118±68 +15±31 <0.05
DISA
non viable 154±62 169±77 +15±35 <0.05 105±53 119±66 +14±31 <0.05
Viable patients
LVEDV LVEDV mean P LVESV LVESV mean P
Pre Post difference Pre Post difference
PET 
viable 145±58 122±63 -23±27 <0.002 102±59 76±59 -26±19 <0.001
DISA
viable 146±57 123±62 -23±27 <0.002 101±59 75±59 -26±19 <0.001
LVEDV: left ventricular end-diastolic volume (mL); LVESV: left ventricular end-systolic volume (mL).
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information, yielding an agreement of 94%. Direct comparisons between DISA SPECT
and PET are scarce (6). Fukuchi et al. (6) demonstrated an excellent relation between
segmental FDG activities, measured with PET or DISA SPECT.
However, none of the previous studies compared PET and DISA SPECT in patients
undergoing revascularization.
The imaging protocol used in the present study was not used previously, namely perfu-
sion was assessed during pharmacological stress. Although omission of the resting per-
fusion images no longer allows discrimination between repetitively stunned myocardium
(with normal resting perfusion) and hibernating myocardium (with reduced resting perfu-
sion), this information is mainly of interest for research purposes. Other studies have
demonstrated that resting perfusion was near normal in chronic dysfunctional myo-
cardium (31).Vanoverscheldeet al. (31) observed almost similar levels of perfusion with
PET in regions with normal contraction and regions with chronic dysfunction. These
authorsshowed that instead of resting flow, flow reserve was reducedin dysfunctional but
viable myocardium (31). Based on their observations, Vanoverschelde and co-workers
suggested that repeated ischemic attacks may result in chronic dysfunction, with flow
remaining normal or mildly reduced—a condition referred to as repetitive stunning (32).
The current DISA SPECT study however aims at providing a simple protocol for detection
of viability of hibernating myocardium and dysfunctional myocardium based on reduced
flow reserve.
DISA SPECT for the prediction of LV recovery: comparison with previous studies
In the current study, PET and DISA SPECT were compared directly in patients undergo-
ing revascularization.First, the criteria for a mismatch were defined by ROC curve analy-
sis.ROC analysis indicated that a 7% increase in FDG activity over 13N-ammonia activity
was optimal and yielded a sensitivity and specificity of 90% and 86% to predict improve-
ment of regional function.These results are in line with the literature; pooling of 12 FDG
PET studies yielded a sensitivity of 88% with a specificity of 73% (33) .
For DISA SPECT, a mismatch was defined by a 9% increase in FDG activity over 99mTc-
sestamibi activity.This resulted in a sensitivity of 89% and a specificity of 86% with no sig-
nificant difference from PET. Few SPECT studies have addressed the prediction of
functional improvement after revascularization (34-37).All previous studies used sequen-
tial perfusion and FDG SPECT imaging, with thallium-201 as perfusion tracer. Bax et al.
evaluated 55 patients with chronic CAD and depressed LV function (mean LVEF 39 ±
14%) with resting thallium-201 SPECT and FDG SPECT prior to revascularization and
demonstrated a sensitivity of 84% and a specificity of 86% (35).The results of the current
study are in line with these previous observations.The main advantage of DISA SPECT
in comparison to PET or sequential thallium-201 and FDG SPECT acquisition is the per-
fect alignment between perfusion and FDG data.
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From a clinical point of view, improvement in LVEF is more important than improvement
in regional LV function prediction (38-40). Accurate identification of patients who may
improve in LVEF is important, since LVEF is an important prognostic parameter (41). In
the present study, 27 patients (57%) showed improvement in LVEF (≥ 5%) after revascu-
larization.In line with previous studies, the number of viable segments on PET and DISA
SPECT were linearly related to the improvement in LVEF post-revascularization. More-
over, patients with 2 or more viable segments in either PET or SPECT had a high likeli-
hood of functional recovery after revascularization. In particular, for PET the sensitivity
and specificity were 86% and 100%, and for DISA SPECT these values were 83% and
100% (NS versus PET). Besides the presence of viability, the extent of scar tissue was
also important for improvement of function post-revascularization; the number of nonvi-
able segments was inversely related to the improvement in LVEF post-revascularization.
Similar results were presented recently by Beanlands et al. using FDG PET (42). How-
ever, multivariate analysis in the current study demonstrated the superiority of viability
(over scar tissue) for the prediction of improvement in LVEF.
Another clinically relevant issue is the relation between LV remodeling and viability. The
data in the current study support the hypothesis that patients with viable myocardium do
not only benefit from revascularization because of improvement in LVEF, but also by pre-
vention of ongoing remodeling or even reverse LV remodeling after revascularization.
Large trials have demonstrated the prognostic value of reverse remodeling for long-term
outcome (43,44). In these trials, patients with viable myocardium showed a significant
reduction in LVEDV and LVESV after revascularization. At least as important, patients
with nonviable myocardium showed ongoing LV remodeling, with a significant increase in
both LVEDV and LVESV after revascularization. These results indicate that revascular-
ization per se, does not stop the remodeling process, and emphasize the value of viable
myocardium for outcome after revascularization.
Limitations
Some limitations of this study need attention. First, repeated cardiac catheterization was
not performed in all patients; however, none of the patients without repeated catheteriza-
tion had recurrent symptoms. Second, functional follow-up was performed at 6 months
after revascularization; this period may be too short to fully appreciate recovery of func-
tion;previous work demonstrated that recovery of function may occur up to one year after
revascularization (45). Third, not all dysfunctional segments were revascularized mainly
for technical reasons, but this affects the predictive accuracy of PET and DISA SPECT
equally.
Conclusion
The current findings clearly establish the use of FDG imaging with SPECT. In this head-
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ization, both techniques yielded a similar accuracy for the prediction of improvement in
regional and global LV function. Also, both techniques were equally good in predicting
reverse LV remodeling after revascularization in patients with viable myocardium.There-
fore, this study provides convincing evidence that DISA SPECT is equivalent to PET, and
serves as a good alternative to PET for the assessment of myocardial viability in patients
considered for revascularization.
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Background: Gated FDG PET is an attractive technique for detection of viability as its
permits assessment of both myocardial glucose metabolism and wall contraction within
one study.In this study the value of FDG uptake and wall thickening is analyzed by gated
FDG PET for the prediction of recovery of regional and global left ventricle function in
patients with coronary artery disease after revascularization.
Methods: Thirty-eight patients with chronic coronary artery disease and left ventricular
dysfunction were included. Patients underwent a gated FDG PET protocol and an addi-
tional MRI within 1 week to assess regional wall motion and global ventricular function.
MRI and coronary angiography were repeated 6 months after revascularization.
Results: Of all 213 revacularized dysfunctional segments, 133 (62%) exhibited recovery
of function on the follow-up MRI. Receiver operating characteristic (ROC) curve analysis
calculated a cutoff level of ≥50% FDG uptake yielded the highest sensitivity and speci-
ficity (93% and 85%, respectively) on gated FDG PET for prediction of LV recovery after
revascularization. Using wall thickening (WT) as a predictor of functional LV recovery,
ROC analysis showed ≥10% as the most optimal cut off level for the highest sensitivity
and specificity (89% and 78%, respectively). The number of viable segments with FDG
uptake and WT were the strongest predictors for the improvement in LVEF after revascu-
larization.Reverse LV remodeling occurred in viable patients, whereas nonviable patients
showed further LV dilatation after revascularization. Specificity for the prediction of LV
reverse remodeling were similar for FDG uptake and WT, although sensitivity was higher
using FDG ≥50% uptake criterion.
Conclusion: The observations in the present study provide further support for the use of
FDG PET to predict outcome after revascularization. Segments with ≥50% FDG uptake
or ≥10% WT have a high likelihood to improve in function post-revascularization.Patients
with ≥3 viable segments according to these criteria have a high likelihood to improve in
LVEF and will not suffer ongoing LV dilatation. Preserved (≥50%) FDG uptake is slightly
superior to preserved (≥10%) WT to predict outcome.
Keywords: myocardial viability, gated FDG PET, wall thickening, functional LV recovery.
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The assessment of myocardial viability has become an important aspect of the diagnos-
tic and prognostic work up of patients with coronary artery disease and left ventricular
(LV) dysfunction. Patients with viable myocardium have been demonstrated to benefit
from revascularization, with an improvement in LV function and a favourable prognosis
after revascularization (1-4).
Positron emission tomography (PET) imaging using fluorine –18 fluorodeoxyglucose
(FDG) combined with a flow tracer (eg, 13N-ammonia) is an accurate non-invasive diag-
nostic technique to distinguish viable myocardium from scar tissue in patients with
chronic coronary artery disease (4,5). However, recent studies have suggested that
regional FDG uptake alone is also predictive of improvement of function, and may be
more practical than combination with a flow tracer study in the clinical setting. Even from
a single tracer study, more information can be derived than uptake alone. In particular,
wall thickening (WT) on gated acquisitions could be used as markers of viability. There-
fore, the aim of this study was to evaluate both FDG uptake and WT from a single gated
FDG PET study, as predictors of functional recovery after revascularization. In addition,
we analyzed the optimal cutoff values in FDG uptake and WT in the present study.
Materials and methods
Patients
Thirty-eight consecutive patients with chronic coro-
nary artery disease and LV dysfunction (33 men,
mean age 65 ± 8 years, range 41 to 80) referred for
revascularization were included. Twenty-eight pa-
tients (73%) had a history of myocardial infarction
(>3 months ago) and 8 patients (21%) had under-
gone previous revascularization (>3 months before
the study).The mean LV ejection fraction (LVEF) in
the patient group was 32 ± 10% at rest, estimated
by previous radionuclide ventriculography or gated
99mTc-tetrofosmin SPECT. The patients had on
average 2.5 ± 0.7 stenosed coronary arteries on
angiography. Ten patients had diabetes mellitus,
which was well-regulated by oral hypoglycemics
and/or insulin, necessary for optimal FDG image
quality. Patients with unstable angina and/or heart
failure requiring hospitalization were excluded.
None of the patients had cardiac events during the
study. Assessment of contractile function, LV vol-
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study procedures. CAG: coronary
angiography.
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repeated 6 months after revascularization (see schematic outline; Figure 1).All surgeons
and cardiologists were blinded to the gated FDG PET results.Coronary angiography was
repeated 6 months after revascularization to exclude re-occlusion of the revascularized
coronary arteries or bypass grafts.The study protocol was approved by the local Medical
Ethics committee and all patients gave written informed consent.
Positron emission tomography
Patients had a glucose-enriched breakfast. Ninety minutes prior to FDG injection, acipi-
mox (500 mg) was administered orally to lower the circulating free fatty acids (6).To pre-
vent side-effects of acipimox (eg. skin rash), 250 mg of aspirin was administered orally 5
minutes before acipimox intake. Guided by the plasma glucose levels, patients received
additional insulin as previously described (7). In short, in patients with aplasma glucose
level >9 mmol/L at baseline, 6 units of insulinwere administered subcutaneously. When
plasma glucose levelsremained >9 mmol/L, additional insulin was administered.
PET acquisition was performed on an ECAT-951/31 PET system (Siemens/CTI, Knox-
ville, TN, USA) imaging 31 planes over a total axial length of 10.8 cm (see schematic out-
line;Figure 2).Following the transmission scan (68Ge/68Ga rod sources), 400 MBq of FDG
was injected intravenously, followed by the PET dynamic acquisition procedure.The total
FDG PET acquisition time was 50 minutes, with the last 20 minutes acquired in gated
mode with 16 frames per cardiac cycle. The myocardial count rate was higher than 10
kcps (true coincidents). The length of each gate was optimized for the current RR-inter-
val. The RR-interval was allowed to vary by ± 10%. Data were corrected for attenuation
using the transmission scan and were reconstructed using filtered back-projection (Hann
filter: 0.5 pixels/cycle).
After manual reorientation, 12 short-axis images of FDG were obtained with a plane
thickness from 7 to 9 mm at an in-plane resolution of approximately 7 mm.Myocardial tis-
sue was corrected for spillover of activity from the blood pool in the LV myocardium.The
dynamic PET studies were transformed into static studies and frames of gated FDG PET
were summed and used for further data analysis.
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Figure 2. schematic outline of the gated FDG PET protocol.
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Images were acquired on a 1.5 Tesla MRI system (Vision, Siemens Medical Systems,
Erlangen, Germany) equipped with high performance gradients (maximum gradient
strength = 40 mT/m; maximum slew rate = 200 mT/m/ms).Patients were examined in the
supine position using a flexible body array coil for signal reception.
Scout images depicting the myocardium were acquired in the coronal and sagital imag-
ing planes using a 2-D FLASH ECG-triggered sequence (one slice per heartbeat; TR =
40 – 100 ms, TE = 6 ms, flip angle = 58°, field of view (FOV) = 300 – 350 mm, slice thick-
ness = 8 mm) after which the short-axis plane was determined.The short-axis plane was
defined perpendicular to the LV long-axis from the center of the mitral annulus to the
apex. Slices were acquired at 8 to 10 LV base to apex short-axis locations during
repeated breath-holds (± 15 seconds). Images were reconstructed using 2D-Fourier
reconstruction with in-plane matrix of 128 x 256 (reconstructed voxel size = 17.6 mm3).
The TR was varied depending on the R-R interval of the patient and the number of car-
diac phases to be imaged.
A Sun Sparc workstation (Sun Microsystems, Mountain View, CA, USA) was used for fur-
ther analysis of data.Global LV function, i.e.LVEF, and LV volumes were derived from the
MR images using previously validated automated software (MR Analytical Software Sys-
tem [MASS], Leiden, The Netherlands) (8). An improvement in LVEF ≥5%, and reduction
≥10% in LVEDV and LVESV after revascularization were considered clinically meaningful
(9).
Assessment of regional wall motion was performed visually by an experienced observer
blinded to the clinical data and PET results. Moreover, baseline and follow-up MRI stud-
ies were interpreted in random order. A 17-segment model was used and each segment
was assigned a wall motion score using a 4-point scoring system (1 = normal wall motion,
2 = hypokinesia, 3 = akinesia, 4 = dyskinesia). An improvement in regional wall motion
post-revascularization by 1 grade or more was considered significant. Of note, a change
from dyskinetic to akinetic was not considered improvement in function, but rather is con-
sidered as a mechanical phenomenon (10).
Coronary angiography
Repeat coronary angiography was applied by a femoral approach using the standard
Judkins technique and performed by a cardiologist blinded to all study data.After the pro-
cedure, a trained observer interpreted all angiographic findings independently. A signifi-
cant re-stenosis or new stenosis was defined as >70% stenosis (percent luminal
diameter narrowing).
Gated FDG PET: data analysis and viability criteria 
Data from the gated FDG PET studies were re-orientated to short-axis, horizontal and
vertical long-axis sections. Data of FDG was analyzed quantitatively and displayed in a
17-segment polar map as recently proposed (11), using the quantitative gated SPECT
(QGS) program (version 3; Cedars-SinaiMedical Center, Los Angeles, CA), a commer-
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age (12,13). Average segmental counts were calculated from the 17 segments and nor-
malized to the segment with the highest average counts.
WT was automatically calculated and expressed in a 17-segment polar map as the per-
centage increase in wall thickness from the end-diastolic to the end-systolic phase.
Receiver operating characteristic (ROC) curve analysis was used both for FDG uptake
and WT to determine the optimal cutoff value for prediction of improvement in regional
and global LV function (using MRI as the gold standard) (14,15). The performance of a
variable can be classified using the area under the curve with 0.90-1 = excellent, 0.80-
0.90 = good, 0.70-0.80 = fair, 0.60-0.70 = poor and 0.50-0.60 = test without value.
Statistical analysis
Descriptive results were expressed as mean ± SD.Patient data were compared using the
Student’s t test for (un)paired data when appropriate. Pairwise deletion Mann-Whitney
statistics was used to compare the difference between areas under the curve (deter-
mined by ROC curve analysis) for FDG uptake and WT. Sensitivity and specificity for the
prediction of improvement in regional function were subsequently determined. McNe-
mar’s test was used to compare the sensitivity and specificity of FDG uptake and WT for
prediction of improvement post-revascularization.
Univariate logistic regression analysis was performed to determine which variables best
predicted improvement in LVEF post-revascularization.The relation between the number
of dysfunctional and viable segments and the change in LVEF after revascularization was
determined by linear regression analysis. ROC curve analysis was performed to deter-
mine the optimal number of dysfunctional but viable segments (according to FDG uptake
and WT), allowing discrimination between patients with and without improvement in LVEF
≥ 5% (16). Sensitivity and specificity to predict improvement in LVEF were subsequently
determined. Sensitivity and specificity were also calculated for prediction of LV reverse
remodeling (defined as a reduction ≥10% in LV volumes). McNemar test was used to
compare the sensitivity and specificity between FDG uptake and WT to predict improve-
ment in LVEF and LV reverse remodeling after revascularization. A P-value < 0.05 was
considered significant.
Results
Thirty-eight patients underwent revascularization, in particular 23 patients underwent
CABG and 15 patients underwent PTCA (mean number of target vessels per patient: 2.5
± 0.7). The procedures were uncomplicated. Repeat coronary angiography (to assess
vessel- or graft-patency) was performed in 27 patients demonstrating that 3 bypass grafts
were occluded and 3 lesions after PTCA showed re-stenosis. The patients who did not
undergo repeat coronary angiography did not have recurrent symptoms after revascular-
ization, and grafts/vessels were considered patent.
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from further analysis because of technical reasons. Another 27 (4%) segments allocated
to the vessels/grafts with re-stenosis or occlusion were also excluded.
Data analysis was based on the remaining 617 segments.Of these, 359 (58%) segments
had contractile dysfunction, with 213 segments belonging to the distribution area of
revascularized vessels. These 213 segments were used for the final analysis. Of these
213 revascularized segments, 145 (68%) were hypokinetic and 68 (32%) were a- or dys-
kinetic before revascularization.
Prediction of improvement of regional function
Using ROC analysis, a segmental FDG uptake value of ≥50% was identified as the opti-
mal cutoff value, with an area under the curve of 0.91 ± 0.03.For WT on gated FDG PET,
an optimal cutoff value of 10% WT was identified with an area under the curve of 0.89 ±
0.03.The difference between both areas under the curve was not significant (Figure 3).
Of all 213 dysfunctional segments, 133 (62%) improved in function on the follow-up MRI
(Figure 4). Of these 133 recovered segments, 125 (93%) segments were classified as
viable using the cutoff value of 50% FDG uptake. Of the 80 segments without recovery,
only 12 (15%) were incorrectly identified as viable by FDG uptake. Accordingly, FDG
uptake had a sensitivity of 93% with a specificity of 85% for the prediction of recovery of
regional function post-revascularization. Using the cutoff value of 10% WT, 119 (89%) of
133 segments with functional recovery were considered viable, as compared to only 18
(22%) of the segments without recovery. Hence, the sensitivity and specificity were 89%
(NS vs FDG uptake) and 78% (P <0.05 vs FDG uptake) respectively.
The results of 190 (89%) segments between FDG uptake and WT were concordant,
whereas 23 (11%) segments showed discordance. Out of these 23 segments, 17 (74%)
segments were correct with FDG uptake, and 6 (26%) segments with WT.
Sensitivity and specificity were also assessed for hypokinetic and a-/dyskinetic segments
separately, by using the same cutoff values of FDG uptake and WT. Of the 145 hypoki-
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Figure 3. Recovery of dysfunctional segments after revascularization
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ery of function post-revascularization.The
sensitivity and specificity for FDG uptake
were 94% and 86%, whereas the sensitiv-
ity and specificity for WT were 91% (NS vs
FDG uptake) and 78% (P <0.05 vs FDG
uptake). Of the 68 a-/dyskinetic seg-
ments, 30 (44%) recovered in function
after revascularization.The sensitivity and
specificity for FDG uptake were 91% and
85% as compared to 86% (NS vs FDG
uptake) and 79% (P  <0.05 vs FDG
uptake) for WT.
Prediction of improvement in LVEF
The mean LVEF in the 38 patients im-
proved from 32 ± 10% to 39 ± 12% (P <
0.001).
An improvement in LVEF ≥5% was
observed in 24 (63%) patients. The char-
acteristics of the patients with and without improvement in LVEF are summarized in Table
1. Univariate analysis (including age, gender, previous myocardial infarction, NYHA
class, LVEF, number of stenosed vessels, previous CABG/PTCA, diabetes and number
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Figure 4. ROC curves for the prediction of
improvement in regional function post-revascu-
larization using percentage FDG uptake (area
under curve 0.91 ± 0.03) and wall thickening
(area under curve 0.89 ± 0.03, NS versus %
FDG uptake). The optimal cutoff values were
≥50% for FDG uptake and ≥10% for wall thick-
ening.
Table 1. Characteristics of patients with and without improvement in LVEF after revascularization
Pts with improved  Pts without improved  P-value
LVEF (n = 24) LVEF (n = 14)
Age (yrs) 64 ± 7 67 ± 8 NS
Gender (M/F) 24/6 14/0 NS
Previous infarction 18 (75%) 12 (85%) NS
Diabetes 6 (25%) 3 (21%) NS
Previous PTCA/CABG 7 (29%) 3 (21%) NS
Nr stenosed vessels 2.5 ± 0.7 2.7 ± 0.6 NS
LVEF (%) 31 ± 11 32 ± 8 NS
LVEDV (mL) 141 ± 45 160 ± 65 NS
LVESV (mL) 99 ± 45  110 ± 54 NS
NYHA class pre-revascularization 3.0 ± 1.1 3.2 ± 1.1 NS
Nr FDG viable segs  4.5 ± 2.2 1.5 ± 1.3 <0.001
Nr FDG non-viable segs  1.2 ± 1.8 2.2 ± 2.1 NS
Nr WT viable segs 4.7 ± 2.0 1.5 ± 1.2 <0.001
Nr WT non-viable segs  1.3 ± 1.8 2.1 ± 2.3 NS
CABG:coronary artery bypass grafting;LVEDV:left ventricular end-diastolic volume;LVEF:left ven-
tricular ejection fraction; LVESV: left ventricular end-systolic volume; NYHA: New York Heart Asso-
ciation; PTCA: percutaneous transluminal coronary angioplasty; Segs: segments; WT: wall
thickening.
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that the number of viable segments
according to both FDG uptake or WT were
the only predictors of improvement in
LVEF after revascularization (Table 1). A
correlation was observed between the
number of revascularized, viable seg-
ments on both FDG uptake and WT and
the magnitude of improvement in LVEF,
indicating that the extent of viability
directly determined the magnitude of
improvement in LVEF post-revasculariza-
tion (P <0.001) (Figures 5A and 5B).
ROC curve analysis showed that ≥3
viable segments on FDG uptake or WT
had the highest accuracy to predict
improvement in LVEF, with a comparable
area under the curve (0.87 ± 0.03 versus
0.87 ± 0.02, NS, see Figure 6). This re-
sulted in a sensitivity and specificity of
87% and 85% for FDG uptake and 75% (P
<0.05 vs FDG uptake) and 85% (NS vs
FDG uptake) for WT.
Prediction of LV reverse remodeling
Based on ROC curve analysis, the optimal cutoff level for prediction of LV reverse remod-
eling (reduction in LVEDV or LVESV ≥10%) was considered ≥3 viable segments on both
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Figure 5. scatterplots showing the relation between the number of viable segments with ≥50% FDG
uptake (panel A) and ≥10% wall thickening (panel B) and the change in LVEF after revasculariza-
tion.
Figure 6. ROC curves for the prediction of
improvement in LVEF post-revascularization
improvement (LVEF ≥5%) using the number of
viable segments with preserved (≥50%) FDG
uptake (area under curve 0.87 ± 0.03) and the
number of viable segments with preserved
(≥10%) wall thickening (area under curve 0.87 ±
0.02, NS versus % FDG uptake). The optimal
cutoff values were ≥3 viable segments, both for
FDG uptake and wall thickening.
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and WT demonstrated a significant reduction in LVEDV and LVESV. Conversely, patients
with less than 3 viable segments demonstrated ongoing LV remodeling with a significant
increase in LV volumes (Table 2).FDG uptake had a sensitivity and specificity of 89% and
65% to predict reverse LV remodeling, as compared to 78% (P <0.05 vs FDG uptake) and
70% (NS vs FDG uptake) for WT.
Discussion
The most important findings of this study can be summarized as follows. ROC curve
analysis identified the optimal cutoff values for FDG uptake and WT as 50% tracer uptake
and 10% WT.These cutoff values yielded good sensitivity for the detection of viability of
93% and 89% (NS) respectively with a specificity of 85% and 78% (P <0.05) respectively.
In 74% of the discordant segments, FDG uptake predicted regional recovery correctly in
comparison to WT. For prediction of improvement in LVEF the sensitivities for FDG
uptake and WT were 87% and 75% respectively (P <0.05) with a specificity of 85% both.
For prediction of reverse LV remodeling, the sensitivities were 89% and 78% (P <0.05) for
FDG uptake and WT respectively, with specificities of 65% and 70% (NS).
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Figure 7. Panel A: ROC curves for the prediction of (≥10%) reduction in LVEDV post-revasculariza-
tion using the number of viable segments with preserved (≥50%) FDG uptake (area under curve
0.82 ± 0.07) and the number of viable segments with preserved (≥10%) wall thickening (area under
curve and 0.82 ± 0.07;P = NS versus % FDG uptake).The optimal cutoff values were ≥3 viable seg-
ments, both for FDG uptake and wall thickening.
Panel B: ROC curves for the prediction of (≥10%) reduction in LVESV post-revascularization using
the number of viable segments with preserved (≥50%) FDG uptake (area under curve :0.85 ± 0.06)
and the number of viable segments with preserved (≥10%) wall thickening (area under curve and
0.83 ± 0.06; P = NS versus % FDG uptake). The optimal cutoff values were ≥3 viable segments,
both for FDG uptake and wall thickening.
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Many studies (n=22) have employed FDG PET to evaluate tissue viability and predict
improvement of regional and global function after revascularization (2,17-20).The minor-
ity of these studies (n=4) used the relative FDG uptake value, normalized to the peak of
activity, in order to predict functional recovery after revascularization (2,17,18,20). The
cutoff values for FDG uptake varied from 50% to 65% in these previous FDG PET stud-
ies and were chosen arbitrarily.Two studies actually reported the accuracy to predict out-
come after revascularization. Baer et al. performed FDG PET in 42 patients with LV
dysfunction (LVEF 40 ± 13%) to predict functional recovery, using ≥50% FDG uptake as
threshold value (2).Transesophageal echocardiography was used to assess wall motion
before and 4-6 months after revascularization. Sensitivity was similar, but specificity was
considerably lower compared to our study for the prediction of improvement of regional
function. Schmidt et al. performed FDG PET in 40 patients with LV dysfunction (LVEF 42
± 10%) to predict functional recovery, using ≥50% FDG uptake as threshold value (20).
MRI was used to assess wall motion before and 4-6 months after revascularization. Sen-
sitivity and specificity were 100% and 73% for the prediction of outcome.The current find-
ings are in line with these results, although a higher specificity was noted in the present
study.This may be due to the fact that ROC curve analysis was used to optimize results.
Wall thickening as a marker for functional recovery
A relatively new approach is the use of WT on gated FDG PET for the assessment of
myocardial viability. The initial studies evaluating preserved WT as a marker of viability
were performed with use of MRI. Perrone-Filardi et al. were the first to report on the use
of MRI for assessment of WT to evaluate viability (21).In 25 patients with chronic LV dys-
function (LVEF 28 ± 10%), the authors demonstrated that dysfunctional but viable seg-
ments (according to FDG PET) had preserved WT on MRI. Since the patients did not
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Table 2. Left ventricular remodeling (reverse and ongoing) in viable patients (≥3 viable segments
with preserved FDG uptake or WT) or nonviable patients (<3 viable segments with preserved FDG
uptake or WT).
Viable patients
LVEDV LVEDV mean P LVESV LVESV mean P
Pre Post difference Pre Post difference
FDG≥50% 138±44 117±31 -21±27 <0.05 94±43 69±36 -25±21 <0.02
WT≥10% 138±45 116±38 -21±29 <0.05 95±44 69±36 -25±21 <0.02
Nonviable patients
LVEDV LVEDV mean P LVESV LVESV mean P
Pre Post difference Pre Post difference
FDG≥50% 162±16 184±77 +21±35 <0.02 115±54 133±64 +18±31 <0.02
WT≥10% 167±62 188±72 +21±35 <0.02 117±51 135±61 +18±31 <0.02
LVEDV: left ventricular end-diastolic volume (mL); LVESV: left ventricular end-systolic volume (mL);
WT: wall thickening.
BINNENWERK SLART  25-05-2005  13:06  Pagina 131undergo revascularization, improvement of function could not be studied.
Few studies have performed a comparison between WT derived from gated FDG PET and
MRI (22-24). With the newer software algorithms, WT can now be assessed from gated
SPECT or PET imaging. Comparative studies in normal individuals reported good correla-
tions between gated FDG PET and MRI for the assessment of regional WT (22).Waiter et
al.compared gated FDG PET with MRI for the assessment of WT in a pilot study including
9 patients with ischemic heart disease and reduced LV function (24). Wall thickening on
MRI and PET was assessed visually, using a three point grading scale;agreement between
the 2 techniques was 81%. When MRI was considered the gold standard for WT, gated
FDG PET had a sensitivity and specificity of 79% and 82% to assess preserved WT.
Improvement of function post-revascularization has not been studied using WT on gated
FDG PET. However, several SPECT studies with 99mTc-labeled agents have aimed at pre-
dicting functional recovery post-revascularization based on preserved WT (25-29).Stolfuss
et al. evaluated 19 patients (mean LVEF 35 ± 7%) and reported a sensitivity of 82% with a
specificity of 54% to predict functional recovery using gated 99mTc-tetrofosmin SPECT; the
authors analyzed WT visually, using a semi-quantitative five-point scoring method and
combined the WT results with the perfusion data (27). In the current study, a comparable
sensitivity (89%) and specificity were noted with a higher specificity (78%) was noted. A
potential explanation for the higher specificity observed in the current study may be related
to the superior spatial resolution of PET as compared to SPECT. Also, attenuation correc-
tion as used with PET may allow a superior detection of WT as compared to SPECT.
Which parameter to predict recovery?
In the current study, 2 parameters obtained with FDG PET to assess viability were eval-
uated: percentage FDG uptake and percentage WT. This head-to-head comparison in
patients undergoing revascularization, demonstrated that sensitivity for both approaches
was comparable (93% versus 89%), whereas specificity was higher for percentage FDG
uptake (85% versus 78%, P <0.05). This observation can be related to the fact that WT
may not entirely reflect active contraction, but can also occur as a passive process (teth-
ering) in partially infarcted areas. Indeed, studies using echocardiography have shown
that subendocardial infarction frequently resulted in hypokinesia (not akinesia) which did
not improve in function after revascularization (30).Also, studies using MRI have demon-
strated that special tagging techniques are needed to differentiate active contraction in
hypokinetic segments from passive motion (tethering) (31).
Other studies have frequently compared FDG uptake with regional perfusion in order to
assess regions with perfusion-metabolism mismatch as marker of viability (5,32,33).
These studies generally showed the highest accuracy to predict functional outcome post-
revascularization (19). Regional perfusion was not assessed in the current study, and
therefore this approach could not be directly compared with percentage FDG uptake or
WT. However, the results of our study, using WT in combination with FDG uptake for the
prediction of functional recovery, is comparable to these previous studies using perfu-
sion-metabolism mismatch as marker of viability.
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From a clinical point of view, improvement in LVEF is more important than improvement
in regional LV function prediction (34-36). Accurate identification of patients who may
improve in LVEF is important, since LVEF is an important prognostic parameter (37). In
the present study, 24 patients (63%) showed improvement in LVEF (≥5%) after revascu-
larization. In line with previous studies, the number of viable segments on gated FDG
PET was linearly related to the improvement in LVEF post-revascularization. Moreover,
patients with 3 or more viable segments using either FDG uptake or WT had a high like-
lihood of functional recovery post-revascularization, although sensitivity was somewhat
higher with FDG uptake as compared to WT (85% versus 75%, P <0.05).
Another clinically relevant end-point is prediction of reverse LV remodeling after revascu-
larization. The data in the current study support the hypothesis that patients with viable
myocardium do not only benefit from revascularization in terms of improvement in LVEF,
but also by prevention of ongoing LV remodeling or even reverse remodeling after revas-
cularization. Large trials have demonstrated the prognostic value of LV volumes for long-
term outcome, and therefore identification of patients with a high likelihood of prevention
of ongoing LV remodeling or even reverse remodeling is important (38,39). At least as
important is the observation that patients with nonviable myocardium showed ongoing LV
remodeling after revascularization, with a significant increase in LV volumes. These re-
sults indicate that revascularization per se, does not necessarily stop the remodeling
process, and stress the value of viability assessment to identify patients who may bene-
fit from revascularization. The results in the current study indicate that both percentage
FDG uptake and WT are useful markers to assess viability and predict benefit from
revascularization.
Limitations
Some limitations of this study need attention.First, repeat cardiac catheterization was not
performed in all patients;however, none of the patients without repeat catheterization had
recurrent symptoms. Second, functional follow-up was performed at 6 months after
revascularization; this period may be too short to fully appreciate recovery of function;
previous work demonstrated that recovery of function may occur up to one year after
revascularization (40).
Conclusion
The observations in the present study provide further support for the use of FDG PET to
predict outcome after revascularization. Segments with ≥50% FDG uptake or ≥10% WT
have a high likelihood to improve in function post-revascularization. Patients with ≥3
viable segments according to these criteria have a high likelihood to improve in LVEF and
will not suffer ongoing LV dilatation. Preserved (≥50%) FDG uptake is slightly superior to
preserved (≥10%) WT to predict outcome.
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The aim of this study was to compare left ventricular (LV) volumes and regional wall
motion (RWM) determined by PET with those determined by the reference technique,
cardiovascular MRI.
Methods: LV  end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), and LV
ejection fraction (LVEF) were measured and RWM was scored in 38 patients with chronic
coronary artery disease using both gated FDG PET and MRI. A 9-segment model was
used for PET and MRI to assess RWM.
Results: Good correlations were observed between MRI and gated PET for all parame-
ters (r values ranging from 0.91 to 0.96). With PET, there was a significant but small
underestimation of LVEDV and LVEF. Mean ± SD LVEDV, LVESV, and LVEF for MRI and
gated PET was 131 ± 57 mL, 91 ± 12 mL, 33 ± 12% and 117 ± 56 mL, 85 ± 51 mL, 30 ±
11%, respectively. For regional wall motion, an agreement of 85% was found, with a
kappa statistic of 0.79 (95% confidence intervals 0.70 to 0.89, SE 0.049).
Conclusion: LV volumes, LVEF and region wall motion can be assessed with gated FDG
PET and correlate well with these parameters assessed by MRI.
Key words: gated FDG PET, left ventricular volumes, LVEF, regional wall motion, MRI.
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Left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and
left ventricular end-systolic volume (LVESV) are important prognostic parameters in
patients with chronic coronary artery disease (CAD) and left ventricular (LV) dysfunction
(1). Hence, accurate assessment of LVEF and LV volumes in these patients is important
and several non-invasive techniques are available for this purpose, including 2D echo-
cardiography (2), magnetic resonance imaging (MRI) (3), and radionuclide ventriculogra-
phy (4). Positron emission tomography (PET) is a well-established technique for the
imaging and quantification of myocardial metabolism and perfusion. Metabolic imaging
with 18F-fluorodeoxyglucose (FDG) is considered the gold standard for assessment of
viability (5,6). Electrocardiographically (ECG) gated PET with FDG offers the unique
potential combining LV function and myocardial metabolism assessments in a single PET
examination.Limited data are available on the accuracy of gated PET compared with the
accuracy of MRI for the assessment of LVEF, LV volumes and regional wall motion in
patients with depressed LV function (7-11). Most of these studies were performed with
other techniques, including gated SPECT, left ventriculography, and 2D echocardiogra-
phy, to compare LV function, LV volumes and regional wall motion function with those
determined by gated PET. MRI is considered the gold standard for determining parame-
ters of LV function.The aim of this study was to compare the accuracy of gated PET with
that of MRI (serving as the gold standard) for the assessment of LV function, LV volumes,
and regional wall motion in patients with chronic CAD and depressed LVEF.
Materials and methods
Patients
The inclusion criteria were angiographically proven CAD and impaired LV function docu-
mented on 2D echocardiography or LV angiography by use of an ejection fraction cutoff
value of approximately 45%.Exclusion criteria were unstable angina pectoris or heart fai-
lure requiring hospitalization, cardiac pacemakers or intracranial clips, arrhythmias ma-
king ECG gating impossible, and claustrophobia.
Thirty-eight patients (28 men and 10 women; mean age 66 ± 9 yrs) with clinically dia-
gnosed CAD were evaluated in this study. All patients underwent an ECG gated FDG
PET scan and ECG triggered MRI within one week.
Twenty-eight patients had a previous myocardial infarction (all > 6 months before the
study) and 17 patients exhibited Q waves on the electrocardiogram (8 anterior, 5 inferior,
2 both and 2 lateral) (Table 1).These patients had 2.2 ± 0.7 vessels with a significant ste-
nosis of more than 70% diameter reduction (7 patients had 1-vessel disease, 15 had 2-
vessel disease and 16 had 3-vessel disease).Ten patients had type 1 or 2 diabetes, and
7 had systemic hypertension. Nine patients had undergone previous revascularization.
Twenty-eight patients had angina pectoris (Canadian Cardiovascular Society class 1-4).
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the PET and MRI scans.
PET scanning
All anti-anginal medication and caffeine containing beverages were withdrawn at least 24
h prior to the PET studies. Patients were prepared with a glucose-enriched breakfast,
except diabetic patients. At 90 min before FDG injection, 500 mg of acipimox (a nicotinic
acid derivative) was administered orally. To prevent side-effects of acipimox (eg. skin
rash), 250 mg of aspirin was given just before acipimox intake. An euglycaemic hyperin-
sulinaemic glucose clamp was used in accordance with a standardized protocol as des-
cribed by DeFronzo et al. (12) and Knuuti et al. (13) in patients with insulin-dependent
diabetes mellitus
Gated FDG PET was performed on an ECAT-951/31 PET system (Siemens/CTI) imaging
31 planes over a total axial length of 10.8 cm. After the transmission scan (68Ge/68Ga rod
sources) was performed, 400 MBq of FDG was injected intravenously, followed by the
acquisition procedure.The total FDG acquisition time was 50 min, the last 20 min were in
gated acquisition mode with 16 frames per cardiac cycle.The myocardial count rate was
higher than 10 kcps coincident. All gated FDG PET scans were obtained in phased
mode, that is, the length of each gate was optimized for the current RR-interval.The RR-
interval was allowed to vary by ± 10%. Data were corrected for attenuation with the
transmission scan and were reconstructed with filtered back-projection (Hann filter: 0.5
pixels/cycle).After manual reorientation, 12 short-axis images were obtained with a plane
thickness from 7 to 9 mm at an in-plane resolution of approximately 7 mm.
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Table 1. Patient Characteristics
Parameter Value*
Patients: 38
Male 28
Female 10
Mean ± SD age (y)  66 ± 9
Medical history:
Myocardial infarction 28
Coronary angioplasty  7
Coronary artery bypass graft 2
Diabetes Mellitus 10
Systemic hypertension  7
CAD:
One vessel 7
Two vessels 15
Three vessels  16
Angina pectoris  28
*Reported as number of patients unless indicated otherwise.
Canadian Cardiovascular Society classes 1-4.
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A quantitative gated single photon emission computed tomography (QGS) analysis pro-
gram derived from Germano et al. (14-17) to assess LV volumes, LVEF and RWM was
used to analyze the gated PET data. In brief, QGS segments the myocardium on the
basis of LV short-axis images.Endocardial and epicardial surfaces are determined on the
basis of count profiles that are fitted to asymmetric Gaussian curves. With myocardial
size, shape, and location criteria, surface points can be determined even in regions wit-
hout apparent radioactivity uptake.These calculations are performed for each gate, resul-
ting in a determination of the myocardial surfaces as a function of the cardiac cycle.LVEF
is calculated from the largest and smallest LV volumes, defined as end-diastole and end-
systole (Figure 1). We applied this program to gated PET data without any changes or
pre-processing except for a translation of the data to the required input format.
A 9-segment model, including 1 apical segment, 4 distal segments (anterior, lateral, infe-
rior and septal) and 4 basal segments (anterior, lateral, inferior and septal), was used for
PET.Each segment was assigned a wall motion score of 0 to 2: normal = 0, hypokinetic=
1, and akinetic/dyskinetic= 2.
A summed wall motion score was calculated for each patient as the sum of the individual
scores of the 9 segments.
Also, the 9-segment polar map was used to display LV FDG uptake. Segments were
scored according to a 4-point scoring system:0 = normal (activity 75-100% of maximum),
1=   mild reduction (50-75%), 2 = severe reduction (25-50%), 3 = absent tracer uptake
(activity 0-25%).
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Figure 1. Image from QGS of the end-diastolic (A) and end-systolic (B) phases showing epicardial
and endocardial borders of the left ventricle. SEPT = septal; LAT = lateral.
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All images were acquired with patients in the supine by use of a 1.5 T MRI system (Sie-
mens Vision, Siemens Medical Systems) with a flexible body array coil for signal recep-
tion. Spin-echo scout images were obtained in the coronal and sagital imaging planes,
after which the short-axis plane was determined.The short-axis plane was defined per-
pendicular to the LV long-axis from the center of the mitral annulus to the apex. Slices of
8 mm were acquired at 8 to10 base-to-apex short-axis locations during repeated breath
holds (± 15 s) with a 2D fast low-angle shot ECG triggered sequence with various repe-
tition times (TRs).The field of view was 300 - 350 mm.Images were obtained in 128 x 256
matrices.
During 1 cardiac cycle of a breath hold, a limited number (5 – 10) of raw data lines were
acquired for each TR for the succesive phases of the cardiac cycle.Therefore, the breath
hold should span a number of cardiac cycles to fill the k-space. The TR ranged from 40
to 100 ms with an echo time of 6 ms depending on the R-R interval of the patient and the
number of cardiac phases to be imaged.
MRI data analysis 
A Sparc workstation (Sun Microsystems, Mountain View, CA) was used for further analy-
sis. LV volumes were calculated from the MR images using previously validated automa-
ted software (MR Analytical Software System [MASS], Leiden, The Netherlands) (18).
The details of this procedure have been described previously (18,19).In brief, the borders
of the LV on short axes were outlined automatically, but when endocardial detection was
unreliable, contours were corrected manually  appropriate (Figure 2). The enclosed sur-
face areas were measured automatically. Papillary muscles were regarded as being part
of the LV cavity (19). Endocardial and epicardial borders were traced in all end-diastolic
and end-systolic images; epicardial fat was excluded (19).The window width and window
level settings were determined automatically by scaling to the maximum grey scale.
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Figure 2.Transverse 2-chamber view of the end-diastolic (A) and end-systolic (B) phases of the left
ventricle. Epicardial and endocardial contours are automatically drawn, but incorrect contours can
be manually corrected.
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the assessment of RWM, MRI images were visually interpreted by a single, experienced
observer unaware of the PET results. A 9-segment model was used with the same sco-
ring system as that described above; each segment was assigned a wall motion score by
use of a 3-point scoring system (0 to 2 for normal to akinetic or dyskinetic).
Statistical analysis
Continuous data of EDV, ESV and LVEF values were expressed as mean ± SD and
tested for statistical significance with the 2-tailed student’s test for paired data.The agree-
ment for segmental wall motion was assessed from 3 x 3 tables by use of weighted kappa
statistics. Kappa values of <0.4, between 0.4 and 0.75, and >0.75 were considered to
represent poor, fair to good, and excellent agreement, respectively, based on Fleiss clas-
sification (20). The kappa values are reported with their 95% confidence intervals (CI)
and their SEs.
The agreements among LVESV, LVEDV, LVEF, and summed wall motion scores derived
from the gated PET and MRI data were determined by linear regression (Pearson’s cor-
relation coefficient) and Bland-Altman analysis (21). The absence of a relation between
the summed FDG defect score and the difference between LVEF measured by gated
PET and MRI was evaluated by linear regression analysis (Pearson’s correlation coeffi-
cient). For all tests, a P value of <0.05 was considered significant.
Ethics
All patients gave informed consent for the gated FDG PET and MRI study.The study was
approved by the local research ethics committee.
Results
Non-gated FDG PET data
Twenty-six patients exhibited severe FDG defects (activity 0-25%), with a mean of 2.8 ±
1.6 segments per patient. In addition, 28 patients also exhibited moderate defects (score
1 or 2).
Regional wall motion by MRI and gated PET
Ten LV segments of two MRI studies were dropped from this investigation because of
reduced quality resulting from patient movement.
On MRI, 159 segments exhibited normal wall motion, 118 demonstrated hypokinesia, and
55 akinesia or dyskinesia.On gated PET, 146 segments showed normal wall motion, 137
revealed hypokinesia, and 49 akinesia or dyskinesia. The agreement on a segmental
basis is demonstrated in Table 2. An agreement of 85% was found with a kappa statistics
of 0.79 (95% CI 0.70 to 0.89, SE 0.049), indicating excellent agreement. Importantly, 43
of 55 of the akinetic or dyskinetic segments (78%) on the MRI were identically classified
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kinetic by gated PET. Hence, for the 173 dysfunctional segments on MRI, the exact
agreement was 83% (with a kappa statistics of 0.79, 95% CI 0.68 to 0.90, SE 0.055). An
agreement of 79% was found between FDG PET studies with segments showing ≤ 25%
FDG uptake and akinetic or dyskinetic segments on MRI.
Virtually all disagreements between MRI and gated PET wall motion scores were a 1-
grade difference (49/50;98%).The relation between the summed wall motion scores was
excellent (y =0.83x + 1.20, r =0.92, P <0.001) and is demonstrated in Figure 3. The
agreement on a patient basis (expressed by the percentage of identically scored seg-
ments) varied from 67% to 100%, with a mean agreement of 85 ± 11% per patient;impor-
tantly, the agreement was > 85% in 21 patients.Three basal segments (anterior, lateral,
inferior) and 2 distal segments (lateral and septal) exhibited the highest agreement
(> 85%) (Figure 4).The basal anterior segment and the apex revealed the lowest agree-
ment between the 2 techniques (70%).
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Table 2. Agreement between MRI and gated FDG PET for assessment of Regional Wall Motion
Score (RWMS) 
No. of segments with the following RWMS on gated PET
RWMS on MRI 0 1 2 Total
0 136 22  1  159
1 10  103  5  118
2 0  12  43  55
Total 146 37  49 332   
Agreement was excellent (85%; kappa statistic, 0.79)
y = 0.83x + 1.2
r = 0.92, SEE 1.
 P < 0.001
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Figure 3. Relationship between the summed
wall motion score (WMS) per patient on MRI
and on gated FDG PET.
Figure 4. Agreement of regional wall motion
score (RWMS) per segment on MRI and on gated
FDG PET. Basal segments: 1 =anterior; 2 =lat-
eral; 3 =inferior; 4=septal. Distal segments: 5
=anterior; 6 =lateral; 7 =inferior; 8 =septal; 9 =api-
cal segment. Mean = mean agreement for all 9
segments ± SD.
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The quantitative measurements of LV volumes and LVEF are shown in Table 3. LVESV
measured by MRI ranged from 31 to 202 mL (mean 91 ± 12 mL). The corresponding
values for gated PET (range 24 to 198 mL, mean 85 ± 51 mL, P =0.57) were slightly lower
but not significantly different from MRI. Linear regression revealed a good correlation (y
=0.91x + 2.0, r =0.94, P <0.0001) between LVESV measured by MRI and gated PET
(Figure 5A). The Bland-Altman plot showed a mean difference of 12.5 ± 13.5 mL which
was not significantly different from zero (P =0.57) (Figure 5B).
LVEDV measured by MRI ranged from 61 to 267 mL (mean 131 ± 57 mL). The corres-
ponding values for gated PET were lower: LVEDV ranged from 41 to 242 mL (mean 117
± 56 mL, P <0.01). Linear regression demonstrated a good correlation (y = 0.93x + 22.1,
r = 0.91, P <0.001) between LVEDV measured by MRI and gated PET (figure 6A). The
Bland-Altman plot showed a mean difference of 19.6 ± 18.7 mL, which was significantly
different from 0 (Figure 6B).
LVEF measured by MRI ranged from 14% to 59% (mean 33 ± 12%).The corresponding
values for gated PET were close to MRI but significantly different:LVEF ranged from 13%
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Table 3. Measurements of LV volumes and LVEF by MRI and gated FDG PET
Value determined by:
Measurement MRI  Gated  PET  P
LVESV 91 ± 12 85 ± 51 0.57
Mean (mL) 31-202 24-198
Range (mL) 
LVEDV
Mean (mL) 131 ± 57 117 ± 56 <0.001
Range (mL)  61-267 41-242
LVEF
Mean (%) 33 ± 12 30 ± 11 <0.001
Range 14-59 13-55
y = 
r  = 0.94, SEE 1
P <0.0001
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Figure 5. Relationship between LVESV assessed by MRI and gated FDG PET (A). Bland-Altman
plot for LVESV without a systematic trend (B).
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wed a good correlation (y = 1.0x + 2.5, r = 0.96, P <0.001) between LVEF assessed by
MRI and gated PET (Figure 7A). The Bland-Altman plot for LVEF showed a mean diffe-
rence of 3.4 ± 2.2 %, which was significantly different from 0 (Figure 7B).
Variation in LV volumes and other parameters
The relation between various gated PET parameters and the difference between LV volu-
mes assessed by MRI and gated PET was investigated. The underestimation of the
LVEDV or LVESV by gated PET compared with MRI was not related to the number of aki-
netic and/or dyskinetic segments on gated PET, nor to the total number of segments with
absent FDG uptake (activity, 0-25%).
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Figure 6. Relationship between LVEDV assessed by MRI and gated FDG PET (A). Bland-Altman
plot for LVEDV without a systematic trend (B).
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Figure 7. Relationship between LVEF assessed by MRI and gated FDG PET (A).
Bland-Altman plot for LVEF without a systematic trend (B).
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In this study, good correlations between gated PET and MRI were observed for the para-
meters regional wall motion, LVESV, LVEDV and LVEF.
For regional wall motion, the exact agreement between the 2 techniques was 85%.Virtu-
ally all differences were within 1 grade of regional wall motion. The largest share of dis-
crepancies between the 2 modalities was attributable to 12 segments with hypokinesia
on MRI that were classified as akinetic on gated PET.
The relatively small number of segmental discrepancies may be due to spatial misalign-
ment of segments between the MRI and gated PET images volumes. Although segmen-
tal analysis is important, a more global analysis may also be  relevant as an indication for
intervention. From this point of view, it is important to note that the correlation between
the summed wall motion score obtained with the 2 techniques was very good.When indi-
vidual patients were considered, the mean exact agreement was 85% of all segments per
patient (Figure 4). These data suggest that gated PET provides adequate clinical infor-
mation on regional wall motion in nearly all patients with depressed LVEF.These results
are comparable to those obtained by Vaduganathan et al. (22) who used a similar study
protocol to compare gated SPECT versus MRI.
Few other studies have compared gated PET and MRI for assessment of LV function.
Waiter et al. (8) compared regional myocardial wall thickening of gated PET at rest ver-
sus that on MRI and showed a segmental correlation of 81%. A disadvantage of their
visual method of wall thickening scoring may be over- or underestimation of the regional
LV function when a segment shows a high or low FDG uptake, respectively.
The correlations in our study between LV volumes measurements by gated PET and MRI
were also very good, although both LVESV and LVEDV were lower with gated PET than
with MRI.
Two possible explanations for this finding can be ruled out:No relationship was found bet-
ween the underestimation of LV volumes by gated PET and the extent or severity of FDG
defects, and no relationship was found between the extent or severity of regional wall
motion abnormalities and underestimation of LV volumes.
Underestimation of LV volume measurements with gated PET may be attributable to
automatic algorithms, differences in nature of the images, and variances in how algo-
rithms operate. For example, MRI algorithms consider papillary muscles as being part of
the LV cavity, whereas the gated PET algorithms merges papillary muscles into the myo-
cardial wall, thereby reducing the cavity volume.The finding of underestimation of LVESV
and LVEF is most likely due to the fact that the temporal resolution of gated FDG PET is
lower than that of MRI. Also the used 2D (with septa) imaging on our PET scanner may
result in lower sensitivity than modern instruments in the 3D mode.This 2D system may
produce noisy data, which could contribute to the slight underestimation of cardiac volu-
mes. PET data are reconstructed, and the use of different filter sets will influence LV
volume measurements, as ia also the case with gated SPECT data (23). Patient motion
or respiration motion may also influence the determination of LVEF, but appropriate
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Despite these differences in LV measurement techniques, the correlations between
gated PET and MRI for assessment of LV volumes, LVEF and RWM were high.
Schaefer et al. also evaluated LV function and regional wall motion of gated FDG PET in
comparison with MRI in 30 patients, using also QGS for gated FDG PET quantification
(24).They also found a high correlation between gated FDG PET and MRI for EDV, ESV
and LVEF (r =0.96, r =0.97, and r =0.95, respectively). They found a total agreement of
both techniques in all region wall motion scoring classifications of 76%, a fraction lower
than our finding of 85%.This small difference is may be due to used gates of 8 per car-
diac cycle instead of 16.
Willemsen et al. (17) compared the same QGS program (originally developed for gated
SPECT), suitable for PET systems, with equilibrium radionuclide angiography (ERNA) in
20 patients with CAD.They observed a high correlation between the QGS program and
ERNA in LVEF measurement and a slight underestimation of LVEF (y= -5.9 + 0.90
(ERNA) – EF; r =0.86) by gated PET.
Gated PET probably better estimates LVEF, LVEDV and LVESV as obtained by the stan-
dard, MRI, than does gated SPECT (25).This situation probably results from the higher
spatial resolution of PET than of SPECT, a fact that minimizes the uncertainty in the exact
position of the myocardial wall. In addition, the small LV volume problem, common with
gated SPECT, is less present with gated PET, because of the higher spatial resolution of
PET. The algorithm of Germano et al. is based on detection of the myocardial wall from
short-axis slices, but the exact wall position is subsequently corrected, based on valida-
tion studies by means of segmentation algorithm that has been empirically determined
from SPECT studies (16). As gating of SPECT data has added greatly to the clinical
value of myocardial SPECT, gating of PET data may contribute even more to the value of
PET. LV function estimated by gated PET may be of additional value to the observer-
dependent ultrasound results. Combining regional wall motion with according perfusion-
metabolism match and mismatch patterns can be beneficial for interpretation.Gated PET
results therefore argue in favor of cardiac PET studies in general.
Other PET techniques, including gated blood-pool PET after red blood-cell labeling with
C15O, also provides information about LV volumes and function but do not provide infor-
mation about metabolism (26,27).A major advantage of the gated FDG PET technique is
the integration of the assessment of myocardial metabolism and contractile function. In
combination with PET myocardial perfusion imaging, gated FDG PET permits a complete
LV evaluation, using a single technique for the evaluation of major clinical parameters,
including metabolism, flow reserve and LV function. Obtaining functional information of
the LV requires no additional scanning time or tracer injection. Therefore, successful
assessment of cardiac function by gated FDG PET without the need for other clinical
modalities will reduce significantly the time needed and the costs of prerevascularization
examinations. Also, the single-technique approach inherently has the advantage of a
very good image alignment, which allows the 3D comparison of regional function versus
myocardial perfusion and metabolism.
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Gated FDG PET permits the assessment of LV volumes, LVEF and RWM and all these
parameters correlated well with those determined by MRI. Gated FDG PET can be per-
formed easily following a dynamic FDG acquisition protocol, and the data will facilitate the
integration of the assessment of myocardial metabolism and contractile function by PET
without additional scanning time or patient burden.
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9.1 Summary
Differentiation between viable and non-viable myocardium in patients with coronary
artery disease and left ventricular (LV) dysfunction plays a major role in decision making
for revascularization. New noninvasive techniques may improve the accuracy for the
detection of viable myocardium, but careful evaluation of these new techniques is needed
before clinical use.
SECTION I: General introduction and outline of the thesis. Chapter 1 presents an over-
view about the different conventional and new nuclear imaging techniques and back-
grounds for the detection of myocardial viability.
SECTION II: evaluates the value of attenuation correction in myocardial perfusion scinti-
graphy and viability detection. Chapter 2 describes the value of attenuation correction
(AC) in myocardial perfusion imaging, before and after a 1-year experience period. Non-
uniform attenuation of the emitted radiation may produce severe artefacts, which may
result in fixed defects on SPECT images that can easily be mistaken for myocardial
infarction.The addition of transmission scans, by using line array of gadolinium-153 rods
may help in distinguishing attenuation artefacts from myocardial infarction.In this study of
patients referred for MPI, both non-corrected (NC) and AC images were analysed by
three independent readers shortly after implementation of AC.The same images were re-
analysed 1 year later. Results were compared with gold standards for ischemia and
infarction based on coronary angiography, follow-up, ultrasound and gated blood pool
imaging. We conclude that AC improves interpretation of myocardial perfusion studies.
With AC, specificity is increased and sensitivity is similar as compared with NC images.
However, AC requires experience and is associated with a learning curve.
Chapter 3 evaluates the value of AC of gated 99mTc-tetrofosmin SPECT for the detection
of myocardial viability in comparison with the reference method FDG SPECT. Both the
NC and AC 99mTc-tetrofosmin SPECT images were compared with the FDG images. By
use of AC, the agreement between 99mTc-tetrofosmin and FDG imaging improved from
84% to 90%. Similar observations were made when the analysis was restricted to the
dysfunctional segments. We conclude that addition of AC to gated 99mTc-tetrofosmin
SPECT significantly improved the detection of myocardial viability in patients with chro-
nic coronary artery disease, although as compared with FDG SPECT imaging minimal
underestimation of viability remained.
SECTION III: evaluates the value of DISA SPECT for the detection of myocardial viabi-
lity. In Chapter 4, we investigated whether DISA SPECT yields additional information for
the assessment of myocardial viability in comparison with rest-stress 99mTc-sestamibi.
Nineteen patients with known coronary artery disease and irreversible perfusion defects
on previous rest-stress 99mTc-sestamibi test studies were analyzed. DISA SPECT was
performed using energy windows of 140 (±15%), 170 (±20%) and 511 keV (±15%). Ima-
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and 99mTc-sestamibi images were visually scored for a perfusion-metabolism mismatch
pattern.There was an excellent correlation between the 99mTc-sestamibi uptake detected
in the single and dual isotope acquisition.The average difference between the dual and
single isotope 99mTc-sestamibi uptake was 1.2%, which is very low.Of the 79 regions with
irreversible perfusion defects on previous rest-stress 99mTc-sestamibi, six regions in five
patients showed a perfusion-metabolism mismatch pattern. We conclude that DISA
SPECT does not affect the quality of the 99mTc-sestamibi images. Furthermore, 99mTc-
sestamibi/FDG DISA SPECT may show viability in a small but significant number of
regions with irreversible perfusion defects on rest-stress 99mTc-sestamibi.
The quality of DISA SPECT is excellent, however the agreement for the assessment of
myocardial viability with the reference method positron emission tomography (PET) is
unclear.Therefore, in Chapter 5,58 patients with chronic coronary artery disease and LV
dysfunction were studied with DISA SPECT and PET.Patients underwent a one-day dipy-
ridamole stress 99mTc-sestamibi/FDG DISA SPECT and 13N-ammonia/FDG PET proto-
col. Within 1 week, resting MRI was performed to assess contractile function.
Comparison of PET and DISA SPECT data was performed using both visual and quanti-
tative analysis.The correlation of normalized activities of the flow tracers 99mTc-sestamibi
and 13N-ammonia was good, (r = 0.82;P < 0.001).The correlation between both FDG stu-
dies was also good (r = 0.83; P < 0.001).The agreement for the detection of viability for
all segments between DISA SPECT and PET was 82%; in dysfunctional segments only,
the agreement was also 82%.
When the DISA SPECT data were analyzed visually, the agreement between DISA
SPECT and PET was 83%. Moreover, there was no difference between visual and quan-
titative DISA SPECT analysis for the detection of viability (P < 0.001). We conclude that
this study showed an overall good agreement between  99mTc-sestamibi/18FDG DISA
SPECT and PET for the assessment of myocardial viability in patients with severe left
ventricular dysfunction. Quantitative or visual analysis of the SPECT data did not influ-
ence the agreement with PET, suggesting that visual assessment may be sufficient for
clinical purposes.
Patients with LV dysfunction who have viable myocardium are the patients at highest risk
because of the potential for ischemia but at the same time benefit most from revasculari-
zation, due to functional LV improvement. It is important to identify viable myocardium in
these patients. Unclear is the value of DISA SPECT in comparison with PET for the pre-
diction of LV recovery in patients with LV dysfunction.
Therefore, in Chapter 6, 47 patients with chronic coronary artery disease and LV dysfunc-
tion underwent DISA SPECT (with 99mTc-sestamibi and FDG) and PET (with 13N-ammonia
and FDG) to evaluate the value for the prediction of LV recovery. PET and DISA SPECT
data were analyzed quantitatively. MRI was used to assess LV function (regional function,
LVEF and LV volumes) before and 6 months after revascularization.For prediction of impro-
vement of regional LV function, PET and DISA SPECT had comparable sensitivity (90%
and 89% respectively) and specificity (86% both). For prediction of improvement in LVEF,
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Reverse LV remodeling occurred in viable patients after revascularization, whereas nonvia-
ble patients showed further LV dilatation after revascularization. Accuracy to predict LV
reverse remodeling was similar for DISA SPECT and PET.We conclude that DISA SPECT
and PET have comparable accuracy to predict improvement in (regional and global) LV
function and reverse LV remodeling.
Although DISA SPECT is an accurate method, PET remains a valuable technique for the
assessment of myocardial viability in nuclear medicine institutes equipped with PET
cameras.However PET is a comprehensive, time-consuming technique.Gated FDG PET
might be a novel technique to reduce the acquisition time.Therefore, SECTION IV evalu-
ates the value of gated FDG PET for the assessment of myocardial viability. In Chapter
7, the value of FDG uptake and wall thickening was analyzed by gated FDG PET for the
prediction of recovery of regional and global left ventricular function in 38 patients with
coronary artery disease after revascularization. Patients underwent a gated FDG PET
protocol and an additional MRI within 1 week to assess regional wall motion and global
ventricular function. MRI and coronary angiography were repeated 6 months after revas-
cularization.
Receiver operating characteristic (ROC) curve analysis yielded a cutoff level of ≥50%
where FDG uptake gave the highest sensitivity and specificity (93% and 85%, respecti-
vely) for prediction of LV recovery after revascularization.Using wall thickening (WT) as a
predictor of functional LV recovery, ROC analysis showed ≥10% as the optimal cut off
level for the highest sensitivity and specificity (89% and 78%, respectively).The number
of viable segments with FDG uptake and WT were the strongest predictors for the impro-
vement in LVEF after revascularization. Reverse LV remodeling occurred in viable
patients, whereas nonviable patients showed further LV dilatation after revascularization.
Specificity for the prediction of LV reverse remodeling were similar for FDG uptake and
WT, although sensitivity was higher using FDG ≥50% uptake criterion.
We conclude that segments with ≥50% FDG uptake or ≥10% WT on gated FDG PET
have a high likelihood to improve in function post-revascularization. Patients with ≥3 via-
ble segments according to these criteria have a high likelihood to improve in LVEF and
will not suffer ongoing LV dilatation. Preserved (≥50%) FDG uptake is slightly superior to
preserved (≥10%) WT to predict outcome.
Gated FDG PET can be used for the assessment of LV volumes, LV ejection fraction
(LVEF) and wall motion. Importantly is the accuracy of gated FDG PET for the assess-
ment of these parameters.However, comparative studies with the reference method MRI
are scarce.Therefore, the aim of the study in Chapter 8 was to compare left ventricular
(LV) volumesand regional wall motion determined by gated FDG PET with those determ-
ined by the reference technique MRI. LV end-diastolic volume (LVEDV), LV end-systolic
volume (LVESV), and LVEF were measured and regional wall motion was scored in 38
patients with chronic coronary artery disease by both gated FDG PET and MRI. Good
correlations were observed between MRI and gated PET forall parameters (r values ran-
ging from 0.91 to 0.96). With PET, there was a significant but small underestimation of
Summary, future perspectives and conclusions | 153
BINNENWERK SLART  25-05-2005  13:06  Pagina 153LVEDV andLVEF. LVEDV, LVESV, and LVEF for MRI were 131± 57 mL, 91 ± 12 mL, and
33% ± 12%, respectively,and those for gated PET were 117 ± 56 mL, 85 ±51 mL, and
30% ± 11%, respectively. For regional wallmotion, an agreement of 85% was found, with
a kappa-statistic of 0.79. We conclude that LV volumes, LVEF, and regional wall motion
can beassessed with gated FDG PET and correlated well with theseparameters asses-
sed by MRI.
9.2 Future perspectives
9.2.1 General
The number of patients with chronic ischemic heart disease will increase, (partially) due
to increasing life expectancy in the Western world.This will further increase the demand
on health care. Identification of viable yet jeopardized myocardium helps in selecting
patients for whom LV dysfunction, secondary to chronic ischemic heart disease, may
improve after revascularization.Therefore, reasonably priced, accurate and patient frien-
dly imaging techniques are needed to fulfil these tasks.
Many nuclear medicine-, radiological techniques and different radiopharmaceuticals are
used for the assessment of myocardial viability and LV function, as described in the intro-
duction chapter.
9.2.2 SPECT
Conventional rest-stress gated myocardial perfusion SPECT is a widely used technique
for the assessment of myocardial ischemia and LV function, with a good accuracy to
assess coronary artery disease.Furthermore, myocardial perfusion scintigraphy is a tho-
roughly validated technique in comparison with other imaging techniques and has the
highest classification for clinical indication according to the international classification
system.The addition of gating to SPECT substantially increases the accuracy of the test
and has now become the standard.Attenuation correction also increases the accuracy of
myocardial perfusion scintigraphy for the detection of ischemia and viability, as confirmed
in this thesis, but is less used. Gated myocardial perfusion SPECT also allows the
assessment of myocardial viability. Preserved wall thickening and wall motion on gated
SPECT indicates viable myocardium. As tracers, 201Thallium and 99mTc-labeled perfusion
tracers (99mTc-sestamibi and 99mTc-tetrofosmin) can be used to assess viability.Preserved
uptake of these tracers may indicate viability in regions with contractile dysfunction. In
rare equivocal cases other techniques complement SPECT.
Although perfusion imaging gives a reasonable impression of viability, imaging using the
metabolic tracer FDG is the best method to detect preserved viability. FDG is a tracer for
PET imaging, but is also possible with conventional gamma cameras nowadays by using
extra-high energy collimators.The current findings in our study clearly establish the use
of FDG imaging with SPECT. In the head-to-head comparison between PET and DISA
SPECT in patients undergoing revascularization, both techniques yielded a similar accu-
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niques were equally good in predicting reverse LV remodeling after revascularization in
patients with viable myocardium. Therefore, this study provides evidence that DISA
SPECT is equivalent to PET, and serves as a good alternative to PET for the assessment
of myocardial viability in patients considered for revascularization. However, DISA
SPECT is not widely implemented on nuclear departments presently, attributable to:
1. The lack of clinical evidence of cardiac DISA SPECT for the detection of myocardial
viability in comparison with the conventional rest-stress myocardial perfusion scinti-
graphy. Our study, however indicates that DISA SPECT is a good alternative for the
assessment of myocardial viability and this technique should be implemented clini-
cally and considered for reimbursement. Patients with a LV-dysfunction based on a
myocardial infarction or ischemia, should be referred to DISA SPECT for the detection
of ischemia and preserved viability.
2. The availability of FDG. Due to better distribution of PET cameras, the use of FDG
becomes more practical. Furthermore, the wide availability of SPECT systems will
easily lead to the implementation of DISA SPECT imaging in nuclear medicine depart-
ments.
3. The opinion that myocardial perfusion SPECT is sufficient for the detection of myo-
cardial viability. In specific cases FDG is of additional value for the detection of pre-
served viability.
9.2.3 PET
FDG and additional myocardial perfusion imaging with PET is believed to be one of the
most accurate methods for the detection of myocardial viability by demonstrating high
sensitivity and specificity values.Unlike SPECT, PET can be performed in a static as well
as in a dynamic imaging mode. Dynamic acquisition allows absolute quantification of
myocardial metabolism and perfusion, by using tracer kinetic models. Static PET acqui-
sition is based on the regional activity distribution, divided by the peak of activity. The
accuracy of static and dynamic PET for the detection of myocardial viability is compara-
ble.
PET may be an attractive technique for the detection of myocardial ischemia and viability
in patients suspected of endothelial dysfunction or multiple coronary vessel disease,
because of the benefits of absolute quantification of myocardial perfusion, flow reserve
and metabolism.
Finally, gated FDG PET is an attractive PET technique, because this technique is less
time-consuming and reveals an accurate assessment of myocardial viability and LV func-
tion, as demonstrated in this thesis.
9.2.4 MRI and echocardiography
Magnetic resonance imaging and echocardiography are other potent diagnostic tools for
myocardial viability assessment.MRI and echocardiography can detect myocardial viabi-
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(with the contrast media gadolinium) seems to be a reliable marker of scar tissue as com-
pared with 201Thallium or FDG. Another area of interest with MRI is the assessment of
myocardial ischemia using gadolinium and vasodilators like adenosine or dipyridamole.
However, MRI and echocardiography are also accompanied by several disadvantages:
the reproducibility of echocardiography is moderate, because this depends on the expe-
rience of the echocardiographist; dobutamine stress MRI is a relative unattractive proto-
col for patients, attributable to the length of the procedure and the unpleasant side-effects
of dobutamine while laying in the narrow gantry of the MRI; contrast agents are non-spe-
cific and cellular processes are not visualized in the way nuclear medicine techniques do;
the clinical experience with MRI is limited compared with nuclear imaging techniques;the
limitation of MRI and the presence of pacemakers and defibrillators.This last issue may
be of particular importance in patients with heart failure, who will frequently have under-
gone implantation of these devices.
9.2.5 Computed tomography (CT)
CT is not generally used for the assessment of myocardial viability. However, CT may be
additional as an AC device in myocardial perfusion scintigraphy.The high photon flux pro-
duced by CT generates better correction than the lower flux methods incorporating radio-
active sources, such as the array of gadolinium-153 rods, as used in our studies.With the
introduction of PET-CT or SPECT-CT systems, CT may be applied as a new attenuation
correction tool.
Another potential application of these systems is the possibility of obtaining coronary cal-
cium scores at the same imaging session as the SPECT scan for the assessment of
coronary risk. The clinical value of coronary calcium scoring is at this time still an open
question in clinical practice and its applicability and significance needs to be explored.
An intriguing possibility is the potential value of CT coronary angiography performed
together with SPECT rest-stress perfusion imaging.Multislice CT (MSCT) scanners have
been found to have sufficient resolution to image coronary arteries with invasive coronary
angiography.There are limitations in visualizing lesions in the smallest distal vessels, and
in the presence of heavy calcifications.The latter limitation can be overcome with the aid
of the SPECT perfusion results.
It is conceivable that patients with known or suspected disease could be studied with
sequential stress-rest perfusion imaging, CT angiography, calcium scoring, ventriculo-
graphy, and FDG metabolism, allowing acquisitions of superimposed images of both
coronary anatomy, perfusion, wall motion, and viability. This complete set of spatially
mapped information could add precision and ease to decision-making for interventions
planning. This proposition still needs to be evaluated in clinical studies, because the
experience of PET- or SPECT-CT is lacking at present.
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Cardiac imaging techniques in nuclear medicine play an important role for the noninva-
sive evaluation of myocardial viability in patients with coronary artery disease. FDG is a
very accurate tracer for the assessment of myocardial metabolism. DISA SPECT is an
important technique to detect myocardial viability. With the new developments in AC,
gated FDG PET and combined cameras (PET- or SPECT-CT), the accuracy for the detec-
tion of myocardial ischemia and viability will be further improved with fewer different tech-
niques. The improved infrastructure of PET (and PET-CT) scanners in combination with
the availability of FDG have set the stage for more widespread use of PET(-CT) and pro-
bably for DISA SPECT for indications shown to be of benefit.Patients with LV-dysfunction
based on a myocardial infarction or ischemia should be referred to DISA SPECT for
detection of ischemia and preserved viability. The potential clinical success of nuclear
cardiology for the assessment of myocardial viability will contribute to optimal patient
selection for coronary revascularization, which is advantageous for patient and society.
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10.1 Samenvatting
Patiënten met kransslagaderlijden en een verminderde linker hartkamer functie (= linker
ventrikel (LV) functie) van het hart kunnen zeer gebaat zijn bij een dotterbehandeling of
een hartomleiding. De LV functie en de prognose van de patiënt kunnen aanzienlijk ver-
beteren na deze behandelingen. Wel is het erg belangrijk dat voorafgaande aan de
ingreep nauwkeurig vastgesteld wordt hoeveel levensvatbaar, (herstelbaar (vitaal) en
niet-levensvatbaar (niet-vitaal = hartinfarcering)) hartspierweefsel aanwezig is. Het is
alleen zinvol gebleken patiënten met voldoende vitaal hartspierweefsel te dotteren of te
opereren. Bij onvoldoende vitaal hartspierweefsel is het meestal beter de patiënt met
medicijnen te behandelen.
Nieuwe nucleair geneeskundige technieken kunnen mogelijk de nauwkeurigheid voor het
aantonen van vitaal hartspierweefsel verhogen, echter goede evaluatie van deze nieuwe
technieken is noodzakelijk voordat deze klinisch toegepast kunnen worden.
DEEL I: Algemene introductie en doelomschrijving van dit proefschrift. Hoofdstuk 1
geeft een overzicht van de verschillende conventionele en nieuwe nucleaire afbeel-
dingstechnieken en hun achtergronden voor het detecteren van vitaal hartspierweefsel.
DEEL II: evalueert de toegevoegde waarde van verzwakkingscorrectie bij de myocard-
perfusiescintigrafie en de detectie van vitaliteit in het hart. Hoofdstuk 2 beschrijft de toe-
gevoegde waarde van de verzwakkingscorrectie als nieuwe techniek bij de
myocardperfusiescintigrafie, zonder en met 1 jaar klinische ervaring met verzwakkings-
correctie.
Het achterwege laten van verzwakkingscorrectie kan leiden tot artefacten in het myo-
cardperfusiescintigram (uitgevoerd met single positron emission computed tomography
(SPECT)). Deze artefacten zijn zogenaamde irreversibele defecten op de SPECT scan
die verward kunnen worden met een hartinfarct. Een verzwakkingsartefact wordt veroor-
zaakt door zich over het hart projecterend weefsel (bijvoorbeeld een borst) dat de
gamma-straling absorbeert. Met behulp van verzwakkingscorrectie kunnen er zoge-
naamde transmissiescans vervaardigd worden. Met deze transmissiescans, waarbij
gebruik gemaakt wordt van radioactieve lijnbronnen (gadolinium-153), kan er onder-
scheid worden gemaakt tussen verzwakkingsartefacten en hartinfarcering.In onze studie
werden de zowel niet-verzwakkingsgecorrigeerde als verzwakkingsgecorrigeerde hart-
studies door 3 verschillende nucleair geneeskundigen beoordeeld op het moment dat het
verzwakkingscorrectie systeem net geïntroduceerd was op de afdeling nucleaire genees-
kunde. Dezelfde hartstudies werden 1 jaar later opnieuw door dezelfde nucleair genees-
kundigen beoordeeld. De resultaten van de beoordelingen werden vergeleken met het
coronair angiogram, de klinische bevindingen, echocardiografie en de MUGA van de
patiënten.Wij concluderen dat verzwakkingscorrectie de interpretatie van myocardperfu-
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onderzoek toe, maar de sensitiviteit blijft onveranderd hoog in vergelijking met het niet-
verzwakkingsgecorrigeerde hartonderzoek. Uit het onderzoek blijkt verder dat er sprake
is van een leercurve in de interpretatie van verzwakkingsgecorrigeerde hartonderzoe-
ken.
Hoofdstuk 3 evalueert de waarde van verzwakkingsgecorrigeerde gated 99mTc-tetrofos-
min SPECT voor het detecteren van vitaliteit in het hart in vergelijking met de referentie
methode FDG SPECT. 99mTc-tetrofosmin SPECT afbeeldingen, met en zonder verzwak-
kingscorrectie, werden vergeleken met de FDG SPECT afbeeldingen. Na verzwakkings-
correctie nam de overeenkomst tussen gated 99mTc-tetrofosmin SPECT en FDG SPECT
toe van 84% naar 90%. Overeenkomstige bevindingen werden gezien wanneer alleen
die delen van de LV met verminderde wandbewegingen werden geanalyseerd. Wij con-
cluderen dat toevoeging van verzwakkingscorrectie aan gated 99mTc-tetrofosmin SPECT
de detectie van vitaliteit in het hart bij patiënten met kransslagaderlijden duidelijk verbe-
tert. Echter een kleine onderschatting ten op zichte van de FDG SPECT blijft bestaan.
DEEL III: evalueert de waarde van dual isotope simulataneous acquisition (DISA) SPECT
voor het detecteren van vitaal hartspierweefsel. Het voordeel van DISA SPECT is dat 2
verschillende isotopen gelijktijdig afgebeeld kunnen worden, waarbij een 99mTc-gelabelde
tracer de perfusie en FDG het metabolisme in het hart afbeeldt.Dit is mogelijk doordat de
fotonenergie van 99mTc en 18F van elkaar verschillen. Door vervolgens verschillende ener-
gievensters op de gammacamera te gebruiken kunnen de 2 isotopen van elkaar onder-
scheiden worden.DISA SPECT draagt bij tot een kortere duur van het onderzoek en geeft
tevens een identieke geometrische registratie van de 2 verschillende isotopen.
In Hoofdstuk 4 hebben we onderzocht of de scankwaliteit van 99mTc-sestamibi door de
FDG van DISA SPECT wordt beïnvloed.Tevens werd gekeken of DISA SPECT een toe-
gevoegde waarde heeft voor het detecteren van vitaliteit in het hart in vergelijking met de
conventionele rust-stress 99mTc-sestamibi scan. In dit onderzoek werden 19 patiënten
met kransslagaderlijden en irreversibele perfusiedefecten eerst met een voorafgaande
rust-stress 99mTc-sestamibi scan in kaart gebracht. DISA SPECT werd uitgevoerd met
energie vensters van 140 (±15%), 170 (±20%) en 511 keV (±15%). Planaire 140 keV
afbeeldingen werden gecorrigeerd voor strooistraling door middel van een subtractie
venster van 170 keV.FDG en 99mTc-sestamibi afbeeldingen van de DISA SPECT werden
visueel beoordeeld met betrekking tot perfusie-metabolisme mismatch. Er bleek een uit-
stekende correlatie te zijn tussen 99mTc-sestamibi opname op de conventionele rust scan
en die op de DISA SPECT scan.Van de 79 segmenten in de linker ventrikel met een irre-
versibel perfusiedefect op de conventionele rust-stress 99mTc-sestamibi, waren er 6 seg-
menten in 5 patiënten met een perfusie-metabolisme mismatch, passend bij restvitaliteit.
Wij concluderen dat de DISA SPECT techniek de kwaliteit van de 99mTc-sestamibi afbeel-
dingen niet beïnvloedt. Bovendien toont 99mTc-sestamibi/FDG DISA SPECT rest-vitaliteit
aan in een klein, maar significant aantal segmenten van de linker ventrikel.
De kwaliteit van DISA SPECT is uitstekend, maar onduidelijk is wat de klinische waarde
van DISA SPECT is in het detecteren van vitaliteit in het hart in vergelijking met de posi-
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daard om vitaliteit in het hart op te sporen.
Daarom werden in de volgende studie, in Hoofdstuk 5, achtenvijftig patiënten met krans-
slagaderlijden en slechte LV functie (LV ejectie fractie 33 ± 12%) bestudeerd. De patiën-
ten ondergingen op dezelfde dag een dipyridamol (persantin) stress 99mTc-sestamibi/FDG
DISA SPECT scan en 13N-ammonia/FDG PET scan.Binnen 1 week werd er bij deze pati-
ënten een rust MRI verricht om de contractiele functie van de linker ventrikel vast te leg-
gen. De PET en DISA SPECT gegevens werden zowel visueel als kwantitatief
geanalyseerd. De kwantitatieve correlatie tussen de perfusietracers 99mTc-sestamibi and
13N-ammonia was goed, (r = 0.82;P < 0.001), evenals de correlatie tussen beide FDG stu-
dies (r = 0.83; P < 0.001). De overeenkomst tussen DISA SPECT en PET op segment
niveau voor het detecteren van vitaliteit in de linker ventrikel was 82%; wanneer alleen
naar dysfunctionele segmenten gekeken werd, was de overeenkomst eveneens 82%.
Wanneer de DISA SPECT gegevens visueel geanalyseerd werden, was de overeen-
komst tussen DISA SPECT en PET 83%.Opvallend was, dat er geen verschil was tussen
de visuele and kwantitatieve DISA SPECT analyse (P < 0.001). Deze studie toont een
goede overeenkomst aan tussen 99mTc-sestamibi/FDG DISA SPECT en PET voor het
detecteren van vitaliteit in het hart bij patiënten met een ernstige LV dysfunctie. Kwantita-
tieve of visuele analyse van de DISA SPECT scan tonen een goede overeenkomst met
PET, hetgeen aangeeft dat visuele beoordeling volstaat in de klinische praktijk.
Patiënten met een ernstige LV dysfunctie als gevolg van ischemisch, doch vitaal hart-
spierweefsel, hebben een verhoogde kans op een fatale hartaandoening.Deze patiënten
zijn gebaat bij een revascularisatie van de kransslagaderen, omdat er een grote kans
bestaat dat de LV functie hierna zal verbeteren.
Daarom ondergingen zevenenveertig patiënten met kransslagaderlijden en LV dysfunc-
tie zowel een DISA SPECT (met 99mTc-sestamibi en FDG) als een PET (met 13N-ammo-
nia en FDG) onderzoek, zoals beschreven in Hoofstuk 6. De gegevens van de PET en
de DISA SPECT studie werden kwantitatief geanalyseerd. De MRI werd gebruikt om de
LV  functie (regionale functie, LVEF en LV volumes) zowel voor als 6 maanden na de
revascularisatie te bepalen. PET en DISA SPECT hadden een vergelijkbare sensitiviteit,
respectievelijk 90% en 89%, en specificiteit (beide 86%) voor het voorspellen van het ver-
beteren van de regionale LV functie. De sensitiviteit voor het voorspellen van LVEF ver-
betering was voor DISA SPECT 83% en voor PET 86% (specificiteit 100% voor beide
technieken). Afname van het LV volume na de revascularisatie, zogenaamde “reverse
remodeling”, kwam voor bij patiënten met aangetoonde vitaliteit in het hart. Echter bij
patiënten zonder aangetoonde vitaliteit nam het volume van de linker ventrikel verder toe
(“ongoing remodeling”). DISA SPECT en PET hadden een vergelijkbare voorspellende
waarde voor een afname of toename van de LV volume na revascularisatie. Wij conclu-
deren dat DISA SPECT en PET even goed voorspellen of de (regionale and globale) LV
functie en het LV volume zullen verbeteren na revascularisatie.
Alhoewel DISA SPECT een goede methode is, blijft PET alsnog een waardevolle tech-
niek voor het aantonen van vitaliteit in het hart. Echter PET is een vrij langdurig onder-
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in DEEL IV de waarde van gated FDG PET voor het detecteren van vitaliteit in het hart.
In Hoofdstuk 7 wordt de mate van FDG opname in de LV en de mate van wandverdik-
king van de LV gebruikt om te kunnen voorspellen of de regionale en globale LV functie
bij 38 patiënten met kransslagaderlijden na revascularisatie zullen herstellen. De patiën-
ten ondergingen binnen 1 week zowel een gated FDG PET scan als een MRI om de
regionale en globale LV functie vast te leggen.De MRI en het coronair angiogram werden
6 maanden na revascularisatie herhaald.
Een FDG opname van 50% of meer gaf de hoogste sensitiviteit en specificiteit (respec-
tievelijk 93% en 85%) in het voorspellen van LV functie verbetering na revascularisatie.
Een wandverdikking van 10% of meer gaf de hoogste sensitiviteit en specificiteit (89% en
78%, respectievelijk) ter voorspelling van de LV verbetering na revascularisatie.Van alle
verschillende parameters hadden het aantal vitale hartsegmenten voor zowel de FDG
opname als de wandverdikking de beste voorspellende waarde voor een verbetering in
LVEF na revascularisatie. Afname in LV volume trad op bij patiënten met voldoende vita-
liteit in het hart. Daarentegen trad bij patiënten met onvoldoende vitaliteit in het hart een
toename (=verslechtering) op van het LV volume.De specificiteit van de FDG opname en
wandverdikking was gelijk voor het voorspellen van LV volume verbetering. De sensiti-
viteit van de FDG opname was echter beter dan de wandverdikking.
We concluderen dat LV segmenten met 50% of meer FDG opname of een wandverdik-
king van 10% of meer een goede kans op herstel hebben na revascularisatie. Patiënten
met 3 of meer vitale hartsegmenten, gebaseerd op de bekende FDG- en wandverdik-
kingscriteria, hebben na revascularisatie een goede kans op herstel van de LVEF zonder
verdere LV dilatatie. De FDG opname bleek in het algemeen wel een iets betere voor-
speller voor het herstel van LV functie en volume dan de wandverdikking.
Gated FDG PET kan ook gebruikt worden voor het kwantificeren van het volume, de
ejectie fractie en de wandbewegingen van de linker ventrikel.Hierbij is van belang om de
nauwkeurigheid van gated FDG PET voor deze verschillende parameters vast te leggen.
Echter, vergelijkende studies met de MRI (gouden standaard) zijn schaars. Het doel van
Hoofdstuk 8 was om de nauwkeurigheid van gated FDG PET in vergelijking met de MRI
vast te stellen. Bij 38 patiënten met kransslagaderlijden werd het LV eind-diastolisch
volume (LVEDV), LV eind-systolisch volume (LVESV) en de LVEF bepaald met gated
FDG PET en de MRI.Tevens werd bij deze patiëntengroep de wandbewegingen beoor-
deeld.Voor alle parameters waren de correlaties tussen MRI en gated FGD PET hoog (r
–waarden varieerden van 0.91 tot 0.96). Met PET was er wel een kleine onderschatting
van de LVEDV enLVEF.De gemiddelde LVEDV, LVESV en LVEF bepaald met MRI waren
respectievelijk 131± 57 ml, 91 ± 12 ml en 33% ± 12%, en voor gated FDG PET was dit
respectievelijk 117 ± 56 ml, 85 ±51 ml en 30% ± 11%. De overeenkomst in beoordeling
van de regionale wandbewegingen tussen gated FDG PET en MRI was 85%, met een
kappa van 0.79.Wij concluderen dat met gated FDG PET de LV volumes, de LVEF en de
regionale wandbewegingen goed te bepalen zijn en dat deze parameters goed correle-
ren met de MRI bevindingen.
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10.2.1 Algemeen
Door de verbeterde levensverwachting zal het aantal patiënten met een chronische,
ischemische (op basis van zuurstoftekort) hartaandoening stijgen. Hierdoor zal de druk
op de gezondheidszorg, om beeldvorming van deze hartaandoeningen te verrichten, toe-
nemen. Het vaststellen van vitaal hartspierweefeI is van belang om te kunnen voorspel-
len of de LV functie van hartpatiënten zal herstellen na revascularisatie. Daarom is het
noodzakelijk dat er betaalbare, nauwkeurige en patiëntvriendelijke afbeeldingsappara-
tuur beschikbaar is om hieraan te kunnen voldoen. Nucleair geneeskundige technieken
spelen hierbij een belangrijke rol.
Op dit moment zijn er verschillende nucleair geneeskundige technieken en radiofarmaca
in gebruik ter bepaling van vitaliteit in een dysfunctioneel hart, zoals beschreven in de
introductie.
10.2.2 SPECT 
De reguliere rust-stress gated myocard perfusie SPECT is een veelgebruikte en goede
techniek voor het bepalen van ischemie en de LV functie.De myocardperfusiescintigrafie
SPECT is een goed gevalideerde techniek in vergelijking met andere afbeeldingstech-
nieken. De myocardperfusiescintigrafie SPECT staat hoog geclassificeerd als klinische
indicatie. Door de recente toevoeging van gating aan de SPECT techniek is de nauw-
keurigheid van myocardperfusiescintigrafie verder substantieel toegenomen. Verzwak-
kingscorrectie heeft er eveneens toe geleid dat de nauwkeurigheid van de
myocardperfusiescintigrafie voor het detecteren van ischemie en vitaliteit in het hart is
verbeterd, zoals in dit proefschrift is bevestigd. Gated SPECT verbetert ook de detectie
van vitaliteit in de linker ventrikel.Wandverdikking en wandbeweging op de gated SPECT
duidt op vitaal hartspierweefsel. De tracers 201Thallium and 99mTc-gelabelde perfusietra-
cers (99mTc-sestambi en 99mTc-tetrofosmin) kunnen gebruikt worden om vitaliteit in de lin-
ker ventrikel aan te tonen.Voldoende opname van deze tracers in gebieden van de linker
ventrikel met verminderde wandbeweging duidt op vitaal hartspierweefsel. In specifieke
gevallen zijn andere technieken aanvullend om rest-vitaliteit in het hart aan te tonen.
Ofschoon de myocardperfusiescintigrafie een goede indruk geeft van vitaliteit in de linker
ventrikel, blijft beeldvorming met FDG een van de beste methoden om vitaliteit aan te
tonen. FDG wordt gewoonlijk als tracer bij de PET beeldvorming gebruikt. Echter FDG
beeldvorming is tegenwoordig ook mogelijk op de conventionele gamma-camera (FDG
SPECT), waarbij gebruikt gemaakt wordt van extra hoge energie (EHE) collimatoren. Dit
maakt het mogelijk om FDG op grotere schaal voor de cardiologische beeldvorming te
gebruiken. De bevindingen van ons onderzoek bevestigen dat goede FDG beeldvorming
mogelijk is op een conventionele gammacamera. Uit ons onderzoek komt naar voren dat
PET en DISA SPECT een vergelijkbare voorspellende waarde hebben m.b.t.verbetering
van de regionale en globale LV functie bij patiënten na revacularisatie. De DISA SPECT
techniek lijkt hiermee een goed alternatief te zijn voor PET. Op dit moment is de DISA
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lingen en daar is een aantal verklaringen voor te geven:
1. Het tot nu toe ontbreken van een goede klinische evaluatie van DISA SPECT voor het
detecteren van vitaliteit in het hart. Onze studie geeft nu duidelijk aan dat DISA
SPECT een betrouwbare techniek is voor het detecteren van vitaliteit in het hart. De
weg is nu vrij om DISA SPECT te implementeren als klinisch diagnosticum. Een
belangrijke doelgroep zijn met name patiënten met een LV dysfunctie veroorzaakt
door een infarct of ischemie.
2. De beperkte beschikbaarheid van FDG. Inmiddels is het aantal PET camera’s sterk
uitgebreid en is bovendien FDG eenvoudiger verkrijgbaar.Gecombineerd met de zeer
uitgebreide aanwezigheid van conventionele gamma-camera’s op de diverse nucleair
geneeskundige afdelingen moet het mogelijk zijn DISA SPECT systemen in te voe-
ren.
3. De misvatting dat myocardperfusiescintigrafie alleen, voldoende is voor het bepalen
van vitaliteit in het hart. FDG heeft een toegevoegde waarde om rest-vitaliteit in het
hart vast te stellen, zoals ook in ons onderzoek naar voren komt.
10.2.3 PET
FDG in combinatie met een perfusietracer wordt gezien als een van de nauwkeurigste
methoden voor het detecteren van vitaliteit in het hart. De PET scan kan zowel statisch
als dynamisch verricht worden.Het voordeel van de dynamische PET scan is, dat de per-
fusie en het metabolisme van het hartspierweefsel gekwantificeerd kunnen worden met
behulp van kinetische tracer modellen.De statische PET scan is gebaseerd op een semi-
kwantitatieve analyse, waarbij de activiteit in de verschillende regio’s van de linker ventri-
kel vergeleken wordt met de regio met de hoogste activiteit (ratio bepaling). De
nauwkeurigheid van de statische en de dynamische PET scan voor het detecteren van
hartvitaliteit liggen overigens dicht bij elkaar.
Wanneer conventionele SPECT technieken geen uitsluitsel bieden, kan PET een aan-
vullende techniek zijn voor het detecteren van ischemie en vitaliteit in het hart.Met name
bij patienten met verdenking op endotheeldysfunctie of meertaks/hoofdstamlijden van de
kransslagaderen is de kwantificatie van de perfusie, de perfusiereserve en het metabo-
lisme zinvol.
De PET scan uitgevoerd met een rust-, stress-perfusie- en FDG onderdeel is voor de
patient een vrij langdurige procedure. Dit probleem kan omzeild worden door gebruik te
maken van gated FDG PET. Gated FDG PET wordt zonder een perfusietracer uitge-
voerd, maar kan wel op een betrouwbare manier vitaliteit aantonen in een dysfunctionele
linker ventrikel, zoals bevestigd in dit proefschrift.
10.2.4 MRI en echocardiografie
Magnetische resonantie beeldvorming en echocardiografie zijn andere potentiële tech-
nieken om vitaliteit in het hart vast te stellen. MRI en echocardiografie kunnen met dobu-
tamine stress de reserve-contractiliteit van de linker ventrikel vaststellen.Verder kan met
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De betrouwbaarheid van deze methode komt goed overeen met die van 201Tl of FDG.Een
andere toepassing van de MRI is het vaststellen van ischemie in het hart met behulp van
de contrastvloeistof gadolinium in combinatie met de vasodilatoren adenosine of dipyri-
damole.
Er zijn echter ook beperkingen aan de MRI en de echocardiografie: de reproduceerbaar-
heid van de echocardiografie is vrij matig, omdat de kwaliteit van het echo-onderzoek
sterk afhankelijk is van de ervaring van de onderzoeker; het dobutamine stress MRI
onderzoek is een relatief patiënt onvriendelijk onderzoek, vanwege de duur van het
onderzoek, de mogelijke bijwerkingen van dobutamine en het liggen in een kleine ruimte;
gadolinium is relatief aspecifiek en geeft niet de cellulaire processen weer zoals de
nucleair geneeskundige tracers; de beperkte klinische ervaring met MRI in vergelijking
met de nucleair geneeskundige technieken; de contra-indicatie bij patiënten met een
pacemaker of defibrillator.Dit laatste punt is met name van belang bij patiënten met hart-
falen, die steeds vaker met pacemakers of defibrillatoren uitgerust worden.
10.2.5 Computed tomography (CT)
De CT is vrij recent in de cardiologische beeldvorming geïntroduceerd en staat hiermee
nog aan het begin van de ontwikkeling. De CT wordt in het algemeen niet gebruikt voor
het aantonen van vitaliteit van het hart. De CT kan wel aanvullend zijn als een verzwak-
kingscorrectiesysteem met betrekking tot de myocardperfusiescintigrafie. De hoge foto-
nenstroom die door de CT geproduceerd wordt, geeft een betere verzwakkingscorrectie
dan de lage fotonenstroom bij de geïncorporeerde radioactieve lijnbronnen, zoals de
gadolinium-152 lijnbronnen in onze studie.Met de introductie van de geïntegreerde PET-
CT of SPECT-CT kan de CT eenvoudig worden toegepast als een verzwakkingscorrec-
tiesysteem.
Met deze geïntegreerde camerasystemen is het eveneens mogelijk om een calciums-
core van de kransslagaderen te berekenen. De calciumscore is mogelijk een interes-
sante diagnosticum voor risicostratificatie van kransslagaderlijden.
Een andere mogelijkheid van SPECT-CT is het gelijktijdig afbeelden van de kransslaga-
ders middels angiografie en myocardperfusiescintigrafie. Multislice CT (MSCT) scans
beschikken over voldoende resolutie om met behulp van contrastvloeistof kransslagade-
ren af te beelden. Er zijn wel beperkingen in het in beeld brengen van de kleinste vaat-
structuren, met name bij ernstige verkalkingen. In dit geval kunnen de SPECT
bevindingen een uitkomst bieden.
Het is denkbaar dat patiënten met kransslagaderlijden of de verdenking hierop, geanaly-
seerd kunnen worden op één camera, met de mogelijkheid om gelijktijdig stress-rust per-
fusie, angiografie, calciumscore, ventriculografie en FDG metabolisme te bepalen. Alle
belangrijke gegevens worden dan tijdens 1 cameraprocedure vastgelegd. Dit complete
overzicht van gegevens kan gebruikt worden voor snelle en accurate besluitvorming met
betrekking tot eventuele revascularisatie.
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Nucleaire geneeskunde speelt een belangrijke rol binnen de niet-invasieve cardiologi-
sche beeldvorming voor het visualiseren van vitaliteit in het hart bij patiënten met krans-
slagaderlijden. FDG heeft zich hierin bewezen als een nauwkeurige tracer voor het
bepalen van vitaliteit in het hart. DISA SPECT is een belangrijke aanvullende techniek
voor het detecteren van vitaliteit in het hart. Met de nieuwe ontwikkelingen, zoals ver-
zwakkingscorrectie, DISA SPECT, gated FDG PET en gecombineerde camerasystemen
(PET-CT en SPECT-CT), neemt de nauwkeurigheid voor het bepalen van ischemie en
vitaliteit in het hart toe.Door de verbeterde beschikbaarheid van PET (en PET-CT) came-
ra’s en FDG nemen de mogelijkheden voor cardiologische beeldvorming met FDG toe,
dit geldt met name voor DISA SPECT. Het klinisch succes van de nucleaire cardiologie
ligt in het nauwkeurig bepalen van ischemie en vitaliteit in het hart, hetgeen zal leiden tot
een optimale patiënten selectie voor revascularisatie.
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ging 2001;28 (8):S553. European Association of Nuclear Medicine, Aug 2001, Napoli,
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Riemer Harmand Johan Anne Slart werd geboren in Emmercompascuum op 10 april
1969. Hij volgde zijn middelbare schoolopleiding te Emmen. In 1987 begon hij met de
studie chemische technologie aan de Hogere Technische School te Groningen. In 1988
werd de overstap gemaakt naar de studie geneeskunde aan de Rijksuniversiteit te
Groningen.Tijdens de studie geneeskunde werkte hij mee aan het onderzoek “Morpho-
metric analysis of the corneal endothelium with three different specular microscopes” op
de afdeling Oogheelkunde onder leiding van Prof. Dr. G. van Rij en Dr. M. Landesz.
De officiële wetenschappelijke stage getiteld “An animal model of pain produced by
systemic administration of an immunotherapeutic anti-ganglioside antibody” werd ver-
richt in San Diego, Californië (VS) onder leiding van Prof. Dr. T.L.Yaksh en Dr. L.S. Sor-
kin. Na het afronden van de co-schappen in het Medisch Spectrum Twente te Enschede
behaalde hij in 1997 het artsexamen. Na 2 maanden gewerkt te hebben bij de GG & GD
startte hij met de opleiding nucleaire geneeskunde (opleider: dr. D.A. Piers). Tijdens het
laatste jaar van de opleiding begon hij met het promotieonderzoek onder leiding van pro-
motores Prof. Dr. D.J. van Veldhuisen, Prof. Dr. E.E. van der Wall en co-promotores Dr.
P.L.Jager en Dr.J.J.Bax.In september 2001 rondde hij de opleiding tot nucleair genees-
kundige af en werd vervolgens staflid, werkzaam op de afdeling Nucleaire Geneeskunde
en Moleculaire Beeldvorming in het Universitair Medisch Centrum Groningen met cardi-
ologie als aandachtsgebied.
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